Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Acquired Immunodeficiency Syndrome
The potential contribution of decision aids to screening programmes.
Acquired Immunodeficiency Syndrome
[Significance of the PSA-concentration for the detection of prostate cancer]
Acute Coronary Syndrome
Editorial Comment on: Is There a Relationship Between Acute Coronary Syndrome and Prostate Specific Antigen Level?
Acute Coronary Syndrome
Is there a relationship between acute coronary syndrome and prostate specific antigen level?
Acute Kidney Injury
Evidence for intrarenal kallikrein storage during chromate-induced acute renal failure in rat.
Acute Kidney Injury
Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences.
Adenocarcinoma
A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature.
Adenocarcinoma
A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy.
Adenocarcinoma
A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.
Adenocarcinoma
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia.
Adenocarcinoma
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Adenocarcinoma
Adenocarcinoma of urinary bladder: A report of two patients.
Adenocarcinoma
Anejaculation as an atypical presentation of prostate cancer: a case report.
Adenocarcinoma
Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.
Adenocarcinoma
Bullous pemphigoid associated with prostate adenocarcinoma.
Adenocarcinoma
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature.
Adenocarcinoma
Carcinosarcoma of the prostate. Report of 21 cases.
Adenocarcinoma
Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.
Adenocarcinoma
Challenges in diagnosis and treatment of a cervical spinal cord injury patient with melanoma, adenocarcinoma, and hepatic and osteolytic metastases: need to implement strategies for prevention and early detection of cancer in spinal cord injury patients.
Adenocarcinoma
Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL.
Adenocarcinoma
Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Adenocarcinoma
Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma.
Adenocarcinoma
Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Adenocarcinoma
Diagnosis and Conservative Management of Ureteral Orifice Injury During Robotic Prostatectomy for a Large Prostate with a Prominent Median Lobe.
Adenocarcinoma
Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
Adenocarcinoma
DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers.
Adenocarcinoma
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Adenocarcinoma
Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen.
Adenocarcinoma
Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study.
Adenocarcinoma
Early outcomes of active surveillance for localized prostate cancer.
Adenocarcinoma
Eosinophilic pneumonia and thoracic metastases as an initial manifestation of prostatic carcinoma.
Adenocarcinoma
Female para-urethral adenocarcinoma: histological and immunohistochemical study.
Adenocarcinoma
Gleason Score Correlation Between Prostate Needle Biopsy and Radical Prostatectomy Materials.
Adenocarcinoma
Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue.
Adenocarcinoma
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Adenocarcinoma
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Adenocarcinoma
Hydronephrosis associated with ureteral metastasis of prostate cancer: A rare case report.
Adenocarcinoma
Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
Adenocarcinoma
Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.
Adenocarcinoma
Incorrect biochemistry complicates prostate cancer management.
Adenocarcinoma
Interstitial microwave thermal therapy for prostate cancer: method of treatment and results of a phase I/II trial.
Adenocarcinoma
Invasive carcinoma of prostate presenting as rectal carcinoma.
Adenocarcinoma
Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling?
Adenocarcinoma
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Adenocarcinoma
Laparoscopic repair of external iliac-artery transection during laparoscopic radical prostatectomy.
Adenocarcinoma
Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate.
Adenocarcinoma
Malignant anterior urethral strictures: a rare complication of transurethral resection of malignant prostate.
Adenocarcinoma
Metastasis of Occult Prostatic Carcinoma to the Sphenoid Sinus: Report of a Rare Case and a Review of the Literature.
Adenocarcinoma
Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
Adenocarcinoma
Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level.
Adenocarcinoma
Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma.
Adenocarcinoma
MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma.
Adenocarcinoma
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
Adenocarcinoma
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID.
Adenocarcinoma
Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma.
Adenocarcinoma
Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate and Incidence of Biochemical Recurrence.
Adenocarcinoma
New cancer markers.
Adenocarcinoma
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Adenocarcinoma
Outcome based staging for clinically localized adenocarcinoma of the prostate.
Adenocarcinoma
Paget's disease primarily involving the scrotum.
Adenocarcinoma
Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy.
Adenocarcinoma
Periprostatic subendothelial intravascular granulomatosis: a mimic of high-grade intravascular prostatic adenocarcinoma.
Adenocarcinoma
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Adenocarcinoma
Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy.
Adenocarcinoma
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Adenocarcinoma
Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Adenocarcinoma
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Adenocarcinoma
Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Adenocarcinoma
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Adenocarcinoma
Prostate Cancer Presenting as Huge Mediastinal and Retroperitoneal Masses: Case Report and Review of the Literature.
Adenocarcinoma
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Adenocarcinoma
Prostate specific antigen after irradiation for prostatic carcinoma.
Adenocarcinoma
Prostate specific antigen and prostate specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts.
Adenocarcinoma
Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Adenocarcinoma
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Adenocarcinoma
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Adenocarcinoma
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Adenocarcinoma
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Adenocarcinoma
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
Adenocarcinoma
Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Adenocarcinoma
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Adenocarcinoma
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Adenocarcinoma
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Adenocarcinoma
Prostatic ductal adenocarcinoma showing Bcl-2 expression.
Adenocarcinoma
Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.
Adenocarcinoma
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Adenocarcinoma
Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
Adenocarcinoma
Re: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.
Adenocarcinoma
Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.
Adenocarcinoma
Re: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Adenocarcinoma
Rectal Hem-o-Lok clip migration after robot-assisted laparoscopic radical prostatectomy.
Adenocarcinoma
Recurrent prostate cancer despite undetectable prostate specific antigen.
Adenocarcinoma
Review article Salvage surgery for locally recurrent prostate cancer after radiation therapy.
Adenocarcinoma
Serum prostate specific antigen levels are not elevated in most of the patients with advanced pancreatic adenocarcinoma.
Adenocarcinoma
Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
Adenocarcinoma
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Adenocarcinoma
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
Adenocarcinoma
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
Adenocarcinoma
The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate.
Adenocarcinoma
The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
Adenocarcinoma
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Adenocarcinoma
The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Adenocarcinoma
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Adenocarcinoma
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
Adenocarcinoma
The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma.
Adenocarcinoma
Unusual metastatic patterns of prostate adenocarcinoma.
Adenocarcinoma
Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
Adenocarcinoma
Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
Adenocarcinoma
Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy.
Adenocarcinoma
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Adenocarcinoma
[A case of brain metastasis associated with prostate cancer]
Adenocarcinoma
[A case of clear cell adenocarcinoma of the female urethra]
Adenocarcinoma
[A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy].
Adenocarcinoma
[A Case of Neuroendcrine Carcinoma of the Prostate Diagnosed by Prostate Re-Biopsy during Hormonal Treatment and Effectively Treated by Multidisciplinary Therapy].
Adenocarcinoma
[A case of prostate cancer with invasion to the middle ureter]
Adenocarcinoma
[A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases]
Adenocarcinoma
[A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel].
Adenocarcinoma
[An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?]
Adenocarcinoma
[Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels]
Adenocarcinoma
[Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].
Adenocarcinoma
[Preliminary data on our laparoscopy experience in urinary pathology]
Adenocarcinoma
[Primary adenocarcinoma of the male urethra].
Adenocarcinoma
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
Adenocarcinoma
[Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements]
Adenocarcinoma
[Signet ring cell carcinoma of the prostate successfully treated with endocrine therapy: a case report]
Adenocarcinoma
[Small cell carcinoma of the prostate: a case report]
Adenocarcinoma
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]
Adenocarcinoma of Lung
Expression of the prostate specific antigen gene by lung tissue.
Adenocarcinoma, Clear Cell
[A case of clear cell adenocarcinoma of the female urethra]
Adenocarcinoma, Mucinous
[Mucinous adenocarcinoma of the prostate: a case report and review of 32 cases on immunohistochemical study of both PSA and CEA]
Adenocarcinoma, Mucinous
[Two cases of mucinous adenocarcinoma of the prostate]
Adenocarcinoma, Papillary
[A case of ductal adenocarcinoma of prostate associated with retroperitoneal multiple cysts].
Adenoma
A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Adenoma
Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?
Adenoma
Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Adenoma
Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma.
Adenoma
Regional distribution of tissue kallikrein in the human brain.
Adenoma
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Adenoma, Villous
Villous adenoma of the urachus: a case with prostate specific antigen immunoreactivity.
Aggressive Periodontitis
[Role of salivary kallikrein in the pathogenesis of periodontosis]
Alkalosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Alopecia
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Alveolitis, Extrinsic Allergic
Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice.
Alzheimer Disease
A top 5 list for French general practice.
Alzheimer Disease
Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline.
Alzheimer Disease
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Alzheimer Disease
Regional distribution of tissue kallikrein in the human brain.
Alzheimer Disease
The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons.
Anemia
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Anemia
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Anemia, Sickle Cell
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease.
Aneurysm
Serine proteases and cardiac function.
Aortic Aneurysm, Abdominal
A single nucleotide polymorphism in exon 3 of the kallikrein 1 gene is associated with large but not small abdominal aortic aneurysm.
Arthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Arthritis
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Arthritis, Psoriatic
Determination of tissue kallikrein and alpha 1-antitrypsin-tissue kallikrein complexes in synovial fluid of patients with rheumatoid, osteo and psoriatic arthritis.
Arthritis, Psoriatic
Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report.
Arthritis, Rheumatoid
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Expression and characterization of human tissue kallikrein variants.
Arthritis, Rheumatoid
Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils.
Arthritis, Rheumatoid
Inhibitor regulation of tissue kallikrein activity in the synovial fluid of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Kallikreins and kininogens in saliva and plasma of patients presenting with rheumatoid arthritis.
Arthritis, Rheumatoid
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Arthritis, Rheumatoid
Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes.
Asthma
Bivalent antibody pliers inhibit ?-tryptase by an allosteric mechanism dependent on the IgG hinge.
Asthma
Bivalent inhibition of human beta-tryptase.
Asthma
Dual functionality of ?-tryptase protomers as both proteases and cofactors in the active tetramer.
Asthma
Expression and characterization of human tissue kallikrein variants.
Asthma
Kinin receptors on epithelial cells and smooth muscle of the trachea.
Asthma
Leukocytic cell sources of airway tissue kallikrein.
Asthma
Localization of immunoreactive tissue kallikrein in human trachea.
Asthma
Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree.
Atherosclerosis
Induction of tissue kallikrein in human carotid atheroma does not lead to kallikrein-kinins pathway activation.
Atherosclerosis
Patient selection and counseling before prostatic arterial embolization.
Autoimmune Diseases
Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.
Autoimmune Pancreatitis
IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease?
Azoospermia
Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases.
Bacterial Infections
Characterization and expression analysis of a trypsin-like serine protease from planarian Dugesia japonica.
Bacteriuria
[Granulomatous Prostatitis : Three Cases Report].
Bartter Syndrome
[The pathophysiological significance of increased renal kallikrein excretion in Bartter's syndrome (author's transl)]
Bone Resorption
The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.
Brain Infarction
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Brain Injuries
Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.
Brain Injuries, Traumatic
Determination of serum tissue kallikrein levels after traumatic brain injury.
Brain Ischemia
Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.
Brain Ischemia
Experimental therapy with tissue kallikrein against cerebral ischemia.
Brain Ischemia
Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB.
Brain Ischemia
Tissue kallikrein promotes survival and ??catenin degradation in SH?SY5Y cells under nutrient stress conditions via autophagy.
Brain Ischemia
Tissue kallikrein protects SH-SY5Y neuronal cells against oxygen and glucose deprivation-induced injury through bradykinin B2 receptor-dependent regulation of autophagy induction.
Brain Ischemia
Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.
Brain Neoplasms
Brain metastasis from prostate small cell carcinoma: not to be neglected.
Breast Cyst
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.
Breast Cyst
Prostate specific antigen in the female body: its role in breast cancer prognosis.
Breast Cyst
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease.
Breast Cyst
Prostate specific antigen--a new constituent of breast cyst fluid.
Breast Cyst
Prostatic acid phosphatase in breast cyst fluid.
Breast Diseases
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Breast Neoplasms
Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B? receptor in breast cancer cells.
Breast Neoplasms
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
Breast Neoplasms
Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer.
Breast Neoplasms
Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing.
Breast Neoplasms
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids.
Breast Neoplasms
Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines.
Breast Neoplasms
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary.
Breast Neoplasms
Effect of cathepsin D and prostate specific antigen on latent transforming growth factor-beta in breast cancer cell lines.
Breast Neoplasms
Ethical issues for cancer screening.
Breast Neoplasms
Ethical issues for cancer screenings. Five countries--four types of cancer.
Breast Neoplasms
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.
Breast Neoplasms
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Breast Neoplasms
Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
Breast Neoplasms
Expression of prostate specific antigen in male breast cancer.
Breast Neoplasms
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Breast Neoplasms
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Breast Neoplasms
IGFs and human cancer: implications regarding the risk of growth hormone therapy.
Breast Neoplasms
Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells.
Breast Neoplasms
Immunohistochemical analysis of prostate specific antigen in breast cancer.
Breast Neoplasms
Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines.
Breast Neoplasms
Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis.
Breast Neoplasms
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Breast Neoplasms
Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells.
Breast Neoplasms
Modeling the overdetection of screen-identified cancers in population-based cancer screening with the Coxian phase-type Markov process.
Breast Neoplasms
New cancer markers.
Breast Neoplasms
Online, Interactive Option Grid Patient Decision Aids and their Effect on User Preferences.
Breast Neoplasms
Oral testosterone replacement in Korean patients with PADAM.
Breast Neoplasms
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Breast Neoplasms
Prevalence of the use of cancer related self-tests by members of the public: a community survey.
Breast Neoplasms
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Breast Neoplasms
Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study.
Breast Neoplasms
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Breast Neoplasms
Prostate specific antigen in the female body: its role in breast cancer prognosis.
Breast Neoplasms
Prostate specific antigen in women with breast cancer: is it amenable to routine immunohistochemical detection?
Breast Neoplasms
Prostate specific antigen production by breast tumors after induction with oral contraceptives.
Breast Neoplasms
PS3-42: Health Literacy and Cancer Prevention: It's Not What You Say It's What They Hear.
Breast Neoplasms
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Breast Neoplasms
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
Breast Neoplasms
Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
Breast Neoplasms
Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.
Breast Neoplasms
Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
Breast Neoplasms
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
Breast Neoplasms
Unrealistic optimism and the Health Belief Model.
Breast Neoplasms
Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.
Breast Neoplasms
Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry.
Breast Neoplasms, Male
Expression of prostate specific antigen in male breast cancer.
Bronchitis
A top 5 list for French general practice.
Bronchitis
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Carcinoid Tumor
Flushing in the carcinoid syndrome and plasma kallikrein.
Carcinoid Tumor
Grossly elevated serum prostatic acid phosphatase in a patient with carcinoid.
Carcinoid Tumor
Prostate-specific acid phosphatase in carcinoid tumors.
Carcinoma
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
Carcinoma
A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy.
Carcinoma
A neurocomputational model for prostate carcinoma detection.
Carcinoma
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
Carcinoma
A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor.
Carcinoma
A novel protease homolog differentially expressed in breast and ovarian cancer.
Carcinoma
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Carcinoma
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
Carcinoma
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
Carcinoma
A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
Carcinoma
Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Carcinoma
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.
Carcinoma
Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
Carcinoma
Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
Carcinoma
An evaluation of prostate specific antigen in prostatic cancer.
Carcinoma
An unusual case of metastatic small intestinal tumor due to prostate cancer.
Carcinoma
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Carcinoma
Androgen effect on prostate specific antigen secretion.
Carcinoma
Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.
Carcinoma
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
Carcinoma
Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
Carcinoma
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
Carcinoma
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review.
Carcinoma
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Carcinoma
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
Carcinoma
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Carcinoma
Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
Carcinoma
Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Carcinoma
Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?
Carcinoma
Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Carcinoma
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Carcinoma
Cerebellar metastases from prostatic carcinoma.
Carcinoma
Changes in beta-2 microglobulin expression in prostate cancer.
Carcinoma
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Carcinoma
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide.
Carcinoma
Chest radiography in patients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis.
Carcinoma
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Carcinoma
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Carcinoma
Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Carcinoma
Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma.
Carcinoma
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Carcinoma
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Carcinoma
Comparative analysis of whole saliva proteomes for the screening of biomarkers for oral lichen planus.
Carcinoma
Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Carcinoma
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Carcinoma
Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
Carcinoma
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Carcinoma
Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Carcinoma
Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Carcinoma
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
Carcinoma
Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau.
Carcinoma
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Carcinoma
Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
Carcinoma
Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans.
Carcinoma
Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
Carcinoma
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Carcinoma
Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Carcinoma
Current prognostic factors for prostate carcinoma.
Carcinoma
Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience.
Carcinoma
Dedifferentiated Epithelial-Myoepithelial Carcinoma of the Parotid Gland With Aberrant Expression of Prostate Specific Antigen: A Case Report.
Carcinoma
Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
Carcinoma
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
Carcinoma
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
Carcinoma
Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics.
Carcinoma
Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.
Carcinoma
Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Carcinoma
Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Carcinoma
Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Carcinoma
Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
Carcinoma
Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Carcinoma
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Carcinoma
Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Carcinoma
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Carcinoma
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Carcinoma
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Carcinoma
Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells.
Carcinoma
Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council.
Carcinoma
Elevated prostate specific antigen (PSA) levels a risk factor for pathological hip fracture in metastatic prostatic carcinoma.
Carcinoma
Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?
Carcinoma
Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
Carcinoma
Establishment of human prostate carcinoma skeletal metastasis models.
Carcinoma
Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma.
Carcinoma
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Carcinoma
Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma.
Carcinoma
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Carcinoma
Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases.
Carcinoma
Exploration on Gleason score variation trend of patients with prostate carcinoma from 1996 to 2019: a retrospective single center study.
Carcinoma
Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues.
Carcinoma
Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate.
Carcinoma
Expression of tissue kallikrein in human kidney.
Carcinoma
Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.
Carcinoma
False positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Carcinoma
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Carcinoma
From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Carcinoma
Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Carcinoma
Gleason Score Correlation Between Prostate Needle Biopsy and Radical Prostatectomy Materials.
Carcinoma
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
Carcinoma
Gonadotropin-releasing hormone/human chorionic gonadotropin beta based recombinant antibodies and vaccines.
Carcinoma
Hepatocellular carcinoma metastatic to the gingiva as a first manifestation of hepatocellular carcinoma.
Carcinoma
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Carcinoma
Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment.
Carcinoma
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Carcinoma
Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate.
Carcinoma
Imaging of prostate carcinoma.
Carcinoma
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Carcinoma
Immunohistologic diagnosis of 2 cases of metastatic prostate cancer to breast.
Carcinoma
Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites.
Carcinoma
Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.
Carcinoma
Increased expression of protease M in ovarian tumors.
Carcinoma
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.
Carcinoma
Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score ?3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy: A Radical Prostatectomy Correlated Series.
Carcinoma
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Carcinoma
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.
Carcinoma
Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma.
Carcinoma
Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen.
Carcinoma
Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Carcinoma
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
Carcinoma
Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Carcinoma
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Carcinoma
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
Carcinoma
Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
Carcinoma
Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Carcinoma
Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Carcinoma
Mechanisms by which Interleukin-6 Regulates Prostate Specific Antigen Gene Expression in Prostate LNCaP Carcinoma Cells.
Carcinoma
Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum.
Carcinoma
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Carcinoma
Migrations in clinical and pathological stage of prostatic carcinoma in patients undergoing radical prostatectomy in the period between 1993 and 2003.
Carcinoma
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Carcinoma
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
Carcinoma
Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma.
Carcinoma
Molecular cloning, purification and in situ localization of human colon kallikrein.
Carcinoma
Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population.
Carcinoma
New cancer markers.
Carcinoma
Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity.
Carcinoma
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Carcinoma
Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
Carcinoma
Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens.
Carcinoma
Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies.
Carcinoma
Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: A case report.
Carcinoma
Pathologic classification of prostate carcinoma: the impact of margin status.
Carcinoma
Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score = 7.
Carcinoma
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Carcinoma
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Carcinoma
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
Carcinoma
Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Carcinoma
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Carcinoma
Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer.
Carcinoma
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Carcinoma
Predicting the pathology results of radical prostatectomy from preoperative information: a validation study.
Carcinoma
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Carcinoma
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
Carcinoma
Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Carcinoma
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Carcinoma
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Carcinoma
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
Carcinoma
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Carcinoma
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations.
Carcinoma
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Carcinoma
Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Carcinoma
Prostate biopsy in patients after proctectomy.
Carcinoma
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Carcinoma
Prostate cancer screening in the Tyrol, Austria: experience and results.
Carcinoma
Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City.
Carcinoma
Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
Carcinoma
Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Carcinoma
Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
Carcinoma
Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma.
Carcinoma
Prostate specific antigen after irradiation for prostatic carcinoma.
Carcinoma
Prostate specific antigen and local recurrence after radical prostatectomy.
Carcinoma
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
Carcinoma
Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma.
Carcinoma
Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
Carcinoma
Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Carcinoma
Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
Carcinoma
Prostate specific antigen density in patients with histologically proven prostate carcinoma.
Carcinoma
Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Carcinoma
Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.
Carcinoma
Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Carcinoma
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Carcinoma
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.
Carcinoma
Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Carcinoma
Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
Carcinoma
Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.
Carcinoma
Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy.
Carcinoma
Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.
Carcinoma
Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma.
Carcinoma
Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
Carcinoma
Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma.
Carcinoma
Prostatic acid phosphatase in breast cyst fluid.
Carcinoma
Prostatic Inflammation Detected in Initial Biopsy Specimens and Urinary Pyuria are Predictors of Negative Repeat Prostate Biopsy.
Carcinoma
Pulmonary embolus as a first presentation of occult metastatic prostate cancer.
Carcinoma
Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Carcinoma
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
Carcinoma
Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis.
Carcinoma
Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Carcinoma
Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
Carcinoma
Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Carcinoma
Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Carcinoma
Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma.
Carcinoma
Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.
Carcinoma
Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma.
Carcinoma
Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate.
Carcinoma
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Carcinoma
Role of colour Doppler imaging in detecting prostate cancer.
Carcinoma
Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate.
Carcinoma
Role of screening in detection of clinically localized prostate cancer.
Carcinoma
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Carcinoma
Screening for cancer. Is it useful?
Carcinoma
Screening for carcinoma of the prostate with prostate specific antigen.
Carcinoma
Screening for prostatic carcinoma with prostate specific antigen.
Carcinoma
Screening for prostatic carcinoma with prostate specific antigen: results of the second year.
Carcinoma
Screening for prostatic carcinoma.
Carcinoma
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.
Carcinoma
Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
Carcinoma
Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
Carcinoma
Serum ceruloplasmin as a marker in prostate cancer.
Carcinoma
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Carcinoma
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Carcinoma
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Carcinoma
Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Carcinoma
Structure-guided design of peptidic ligand for human prostate specific antigen.
Carcinoma
The age of the urologist affects the postoperative care of prostate carcinoma patients.
Carcinoma
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
Carcinoma
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
Carcinoma
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
Carcinoma
The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
Carcinoma
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
Carcinoma
The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
Carcinoma
The effect of prostate volume on the yield of needle biopsy.
Carcinoma
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
Carcinoma
The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Carcinoma
The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful!
Carcinoma
The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Carcinoma
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Carcinoma
The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
Carcinoma
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
Carcinoma
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Carcinoma
The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma.
Carcinoma
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
Carcinoma
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Carcinoma
The new human tissue kallikrein gene family: structure, function, and association to disease.
Carcinoma
The outcome of elevated prostate specific antigen and transrectal ultrasound guided prostatic biopsy in detecting carcinoma of the prostate: initial experience in Sri Lanka.
Carcinoma
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Carcinoma
The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy.
Carcinoma
The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma.
Carcinoma
The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate.
Carcinoma
The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
Carcinoma
The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
Carcinoma
The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule.
Carcinoma
The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
Carcinoma
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Carcinoma
The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
Carcinoma
The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Carcinoma
The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view.
Carcinoma
The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Carcinoma
Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma.
Carcinoma
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Carcinoma
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Carcinoma
Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.
Carcinoma
Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate.
Carcinoma
Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Carcinoma
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Carcinoma
Unusual Uptake of Prostate Specific Tracer (68)Ga-PSMA-HBED-CC in a Benign Thyroid Nodule.
Carcinoma
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Carcinoma
Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy.
Carcinoma
Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.
Carcinoma
Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Carcinoma
Utility of Seriated Sections in Prostate Biopsies.
Carcinoma
Values of prostate specific antigen in patients with operable prostate carcinoma.
Carcinoma
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.
Carcinoma
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Carcinoma
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma
Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
Carcinoma
Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma.
Carcinoma
[A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma]
Carcinoma
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
Carcinoma
[Adenocarcinoma of the prostate]
Carcinoma
[Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival]
Carcinoma
[Changes in tumor markers following cryosurgery of prostate carcinoma]
Carcinoma
[Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma]
Carcinoma
[Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen]
Carcinoma
[Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]
Carcinoma
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
Carcinoma
[Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]
Carcinoma
[Early detection of prostate carcinoma. What diagnosis is of value when?]
Carcinoma
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
Carcinoma
[Obstructive jaundice in prostate neoplasm. Case report]
Carcinoma
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]
Carcinoma
[Primary squamous cell carcinoma of the prostate: a case report]
Carcinoma
[Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma]
Carcinoma
[Proper use of prostate specific antigen]
Carcinoma
[Prostate biopsy: assessment of current indications and techniques]
Carcinoma
[Prostate specific antigen (PSA) in the diagnosis and treatment of prostate carcinoma: advances and controversies]
Carcinoma
[Prostate-specific antigen as a tumor marker of prostate carcinoma]
Carcinoma
[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma]
Carcinoma
[Prostatic carcinoma. Screening--when and what?]
Carcinoma
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
Carcinoma
[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer]
Carcinoma
[Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency]
Carcinoma
[Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course]
Carcinoma
[The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate]
Carcinoma
[The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy]
Carcinoma
[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method]
Carcinoma
[The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma]
Carcinoma
[Ultrasonography of the prostate]
Carcinoma
[Value of PSA in the staging of prostatic cancer]
Carcinoma
[Will determination of prostate specific antigen density improve the diagnosis of prostatic carcinoma?]
Carcinoma in Situ
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
Carcinoma, Bronchogenic
Screening for cancer. Is it useful?
Carcinoma, Ductal
Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Carcinoma, Ductal
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Carcinoma, Hepatocellular
A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells.
Carcinoma, Hepatocellular
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Carcinoma, Intraductal, Noninfiltrating
Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Carcinoma, Intraductal, Noninfiltrating
Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
Carcinoma, Intraductal, Noninfiltrating
The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure.
Carcinoma, Ovarian Epithelial
New cancer markers.
Carcinoma, Ovarian Epithelial
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Carcinoma, Renal Cell
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.
Carcinoma, Renal Cell
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Carcinoma, Renal Cell
False positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Carcinoma, Renal Cell
Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Carcinoma, Renal Cell
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma, Small Cell
Changes in beta-2 microglobulin expression in prostate cancer.
Carcinoma, Small Cell
New cancer markers.
Carcinoma, Squamous Cell
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Carcinoma, Squamous Cell
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Carcinoma, Squamous Cell
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Carcinoma, Squamous Cell
The biosynthesis of prostate-specific antigen in non prostatic cell lines.
Carcinoma, Squamous Cell
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]
Carcinoma, Transitional Cell
Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience.
Carcinoma, Transitional Cell
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
Cardiomegaly
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.
Cardiomegaly
Gene therapy for hypertension: a review of potential targets.
Cardiomegaly
Protective actions of human tissue kallikrein gene in transgenic rat hearts.
Cardiomegaly
Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene.
Cardiomegaly
Serine proteases and cardiac function.
Cardiomegaly
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
Cardiomyopathies
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Cardiovascular Abnormalities
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.
Cardiovascular Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Cardiovascular Diseases
Factors that may affect the measurement of prostate specific antigen levels in patients with cardiovascular disease. Letter to the Editor.
Cardiovascular Diseases
Perceived discrimination and use of preventive health services.
Cardiovascular Diseases
Serine proteases and cardiac function.
Carotid Artery Diseases
Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis.
Cerebral Hemorrhage
[Association of single nucleotide polymorphisms of kallikrein 1 gene with cerebral hemorrhage in Changsha Han Chinese]
Cerebral Infarction
Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction.
Cerebral Infarction
Experimental therapy with tissue kallikrein against cerebral ischemia.
Cerebral Infarction
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Cerebral Infarction
Influences of urinary kallidinogenase on neuronal apoptosis in cerebral infarction rats through Nrf2/ARE oxidative stress pathway.
Cerebral Infarction
Remodeling of motor cortex function in acute cerebral infarction patients following human urinary kallidinogenase: A functional magnetic resonance imaging evaluation after 6 months.
Cerebral Infarction
Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.
Cerebrovascular Disorders
Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases.
Choroidal Neovascularization
Tissue kallikrein attenuates choroidal neovascularization via cleavage of vascular endothelial growth factor.
Colitis
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Colitis, Ulcerative
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Colitis, Ulcerative
Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Colitis, Ulcerative
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Colonic Neoplasms
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Colonic Neoplasms
Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
Colorectal Neoplasms
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Colorectal Neoplasms
PS3-42: Health Literacy and Cancer Prevention: It's Not What You Say It's What They Hear.
Colorectal Neoplasms
Screening for cancer. Is it useful?
Colorectal Neoplasms
Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role.
Colorectal Neoplasms, Hereditary Nonpolyposis
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Confusion
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Connective Tissue Diseases
Anionic salivary proteins associated with connective tissue disorders: sialated tissue kallikreins.
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Coronary Artery Disease
Association between angiographically assessed coronary artery disease and serum levels of prostate specific antigen.
Coronary Artery Disease
Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease.
Coronary Artery Disease
Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.
Coronary Artery Disease
Prevalence and associated factors for dipstick microscopic hematuria in men.
Coronary Artery Disease
Relation of plasma tissue kallikrein levels to presence and severity of coronary artery disease in a chinese population.
Coronary Artery Disease
Tissue kallikrein is related to the severity of coronary artery disease.
Coronary Disease
[Improving drug therapy in circulatory insufficiency: the role of renal kallikrein-kinin system]
Cough
Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States.
Cough
Mechanism of irritant-induced cough: studies with a kinin antagonist and a kallikrein inhibitor.
COVID-19
Prostate specific antigen in COVID-19 patients.
Cranial Nerve Diseases
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Crohn Disease
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Crohn Disease
Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Crohn Disease
Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Crohn Disease
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Crohn Disease
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Cystic Fibrosis
Comparative studies on salivary kallikrein from cystic fibrosis patients and controls.
Cystitis
Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis.
Cysts
Histopathological study of the müllerian duct remnant: clarification of disease categories and terminology.
Dengue
A propeptide-independent protease from Tannerella sp.6_1_58FAA_CT1 displays trypsin-like specificity.
Dengue
Steady-state cleavage kinetics for dengue virus type 2 ns2b-ns3(pro) serine protease with synthetic peptides.
Dermatitis, Atopic
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients.
Dextrocardia
Incidental Finding of Dextrocardia with Situs Inversus in a 59-Year-Old Man.
Diabetes Complications
Protease profiling of different biofluids in type 1 diabetes mellitus.
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Diabetes Mellitus
Anorectal application of 5% lidocaine cream reduces pain prior to periprostatic nerve block during transrectal ultrasound guided prostate biopsy: Randomized, prospective controlled study.
Diabetes Mellitus
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Diabetes Mellitus
Human tissue kallikrein: a new bullet for the treatment of ischemia.
Diabetes Mellitus
Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Diabetes Mellitus
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Diabetes Mellitus
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Diabetes Mellitus
Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control.
Diabetes Mellitus
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Diabetes Mellitus, Experimental
Renal kallikrein in human and experimental diabetes mellitus.
Diabetes Mellitus, Type 1
Human Tissue Kallikrein 1 Improves Erectile Dysfunction of Streptozotocin-Induced Diabetic Rats by Inhibition of Excessive Oxidative Stress and Activation of the PI3K/AKT/eNOS Pathway.
Diabetes Mellitus, Type 1
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Diabetes Mellitus, Type 1
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Diabetes Mellitus, Type 1
Protease profiling of different biofluids in type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Diabetes Mellitus, Type 2
Increased tissue kallikrein levels in type 2 diabetes.
Diabetes Mellitus, Type 2
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Diabetes Mellitus, Type 2
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Diabetes Mellitus, Type 2
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.
Diabetes, Gestational
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Diabetic Angiopathies
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Diabetic Cardiomyopathies
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.
Diabetic Nephropathies
Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.
Diabetic Nephropathies
Kallikrein protects against microalbuminuria in experimental type I diabetes.
Diabetic Nephropathies
Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.
Diabetic Nephropathies
[Renal kallikrein in diabetic nephropathy]
Diabetic Retinopathy
Levels of human tissue kallikrein in the vitreous fluid of patients with severe proliferative diabetic retinopathy.
Diabetic Retinopathy
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Diabetic Retinopathy
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Disorders of Sex Development
Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
Disseminated Intravascular Coagulation
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Diverticulitis
Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Diverticulum
Patient selection and counseling before prostatic arterial embolization.
Drug-Related Side Effects and Adverse Reactions
Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial.
Dwarfism, Pituitary
Prostate biopsy free system for laparoscopic radical prostatectomy in a pituitary dwarfism: a case report.
Dyspnea
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
End Stage Liver Disease
[Influence of renal and hepatic function in the serum concentration of prostate specific antigen]
Endotoxemia
Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis.
Enterocolitis
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Epilepsy
Evaluation of inflammatory kinin-forming components in experimental epilepsy in rats.
Epilepsy
Kallikrein 1 is overexpressed by astrocytes in the hippocampus of patients with refractory temporal lobe epilepsy, associated with hippocampal sclerosis.
Epilepsy, Temporal Lobe
Kallikrein 1 is overexpressed by astrocytes in the hippocampus of patients with refractory temporal lobe epilepsy, associated with hippocampal sclerosis.
Epiretinal Membrane
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Erectile Dysfunction
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
Erectile Dysfunction
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
Erectile Dysfunction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Erectile Dysfunction
Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
Erectile Dysfunction
Development and initial evaluation of a novel urology curriculum for medical students.
Erectile Dysfunction
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Erectile Dysfunction
Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's heath and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality?
Erectile Dysfunction
Human tissue kallikrein 1 ameliorates erectile function via modulation of macroautophagy in aged transgenic rats.
Erectile Dysfunction
Human Tissue Kallikrein 1 Improves Erectile Dysfunction of Streptozotocin-Induced Diabetic Rats by Inhibition of Excessive Oxidative Stress and Activation of the PI3K/AKT/eNOS Pathway.
Erectile Dysfunction
Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
Erectile Dysfunction
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Erectile Dysfunction
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Erectile Dysfunction
Preserved Erectile Function in the Aged Transgenic Rat Harboring Human Tissue Kallikrein 1.
Erectile Dysfunction
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Erectile Dysfunction
Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1.
Erectile Dysfunction
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
Erectile Dysfunction
The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
Erectile Dysfunction
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Erectile Dysfunction
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Escherichia coli Infections
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Escherichia coli Infections
Re: Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Esophageal Squamous Cell Carcinoma
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Essential Hypertension
A coding polymorphism of the kallikrein 1 gene is associated with essential hypertension: a tagging SNP-based association study in a Chinese Han population.
Essential Hypertension
Acute effect of furosemide on renal kallikrein and prostaglandin systems in mild to moderate essential hypertension.
Essential Hypertension
An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: comparisons with human hypertensive nephropathy.
Essential Hypertension
Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study.
Essential Hypertension
Comparative hypertensionology-renal dopaminergic activity in experimental hypertensive rats.
Essential Hypertension
Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
Essential Hypertension
DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene.
Essential Hypertension
Effect of upright tilting on kinins as compared to renin activity in the renal venous blood from patients with essential hypertension.
Essential Hypertension
Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension.
Essential Hypertension
Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension.
Essential Hypertension
Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension.
Essential Hypertension
Gender differences of human tissue kallikrein and an erythrocyte kallikrein-like enzyme in essential hypertension.
Essential Hypertension
Impaired renal kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
Essential Hypertension
Is the renal kallikrein system relevant to sodium sensitivity in patients with essential hypertension.
Essential Hypertension
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension.
Essential Hypertension
Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system.
Essential Hypertension
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Essential Hypertension
Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension.
Essential Hypertension
Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-aldosterone system.
Essential Hypertension
Salivary kallikrein excretion in hypertension.
Essential Hypertension
The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension.
Essential Hypertension
Urinary excretions of kininase I and kininase II activities in essential hypertension. A sensitive and simple method for its kinin-destroying capacity.
Extranodal Extension
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Extranodal Extension
A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
Extranodal Extension
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor.
Extranodal Extension
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Extranodal Extension
Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
Extranodal Extension
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Extranodal Extension
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
Extranodal Extension
Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival.
Extranodal Extension
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Extranodal Extension
E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
Extranodal Extension
Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy.
Extranodal Extension
Factors affecting surgical margin positivity in robotic assisted radical prostatectomy.
Extranodal Extension
Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
Extranodal Extension
Is year of radical prostatectomy a predictor of outcome in prostate cancer?
Extranodal Extension
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Extranodal Extension
Nerve advancement with end-to-end reconstruction after partial neurovascular bundle resection:a feasibility study.
Extranodal Extension
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
Extranodal Extension
Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy.
Extranodal Extension
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Extranodal Extension
Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy.
Extranodal Extension
Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
Extranodal Extension
Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Extranodal Extension
Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database.
Extranodal Extension
The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.
Extranodal Extension
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
Extranodal Extension
The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail: pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072.
Extranodal Extension
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.
Fibrocystic Breast Disease
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease.
Fibrocystic Breast Disease
Prostate specific antigen- PSA in women with menstrual disturbances and fibrocystic mastopathy.
Fowlpox
A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in Patients with Prostate Cancer.
Gastritis
Correlation of kinin generating activity with Helicobacter pylori-associated gastric infection.
Gastritis
[Role of tissue kallikrein in chronic gastritis]
Gastritis, Atrophic
Significance of tissue kallikrein in chronic atrophic gastritis.
Gastroesophageal Reflux
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Gastrointestinal Neoplasms
Increasing the sensitivity of enzyme-linked immunosorbent assay using multiplexed electrokinetic concentrator.
Gastrointestinal Stromal Tumors
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.
Glaucoma
Impact of a patient incentive program on receipt of preventive care.
Glioma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Glioma
Phase I study of phenylacetate administered twice daily to patients with cancer.
Glomerulonephritis
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
Glomerulonephritis
[Components of kallikrein-kinin system in the urine of patients with glomerulonephritis]
Glucose Intolerance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Gonorrhea
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Granuloma
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Granuloma
Iatrogenic granulomas of the prostate and the urinary bladder.
Granuloma
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Gynecomastia
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Gynecomastia
The relationship between pubertal gynecomastia, prostate specific antigen, free androgen index, SHBG and sex steroids.
Hamartoma
Isolated metastasis to a pulmonary hamartoma.
Hand-Foot Syndrome
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Heart Diseases
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Heart Diseases
Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
Heart Diseases
Online, Interactive Option Grid Patient Decision Aids and their Effect on User Preferences.
Heart Diseases
Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Heart Diseases
Update on the safety of testosterone therapy in cardiac disease.
Heart Failure
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Heart Failure
Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.
Heart Failure
Serine proteases and cardiac function.
Heart Failure, Systolic
The amidase activity of human tissue kallikrein is significantly lower in the urine of patients with systolic heart failure.
Hematuria
Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
Hematuria
Deficits in urological knowledge among medical students and primary care providers: potential for impact on urological care.
Hematuria
Ductal prostatic adenocarcinoma: magnetic resonance imaging documenting the effect of hormone-radiotherapy.
Hematuria
Holmium Laser Enucleation vs Bipolar Plasmakinetic Enucleation of a Large Volume Benign Prostatic Hyperplasia: A Randomized Controlled Trial.
Hematuria
Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin.
Hematuria
Urological knowledge among primary health care physicians in Saudi Arabia.
Hemianopsia
[A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer].
Hemospermia
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Hemospermia
Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin.
Hepatitis
Impact of Laboratory Test Use Strategies in a Turkish Hospital.
Hepatitis
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Hepatitis C
Analysis of interaction between RNA aptamer and protein using nucleotide analogs.
Hepatitis C
Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
Hepatitis C
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Hepatitis C
Understanding preventive health screening services use in persons with serious mental illness: how does integrated behavioral health primary care compare?
Hepatitis, Chronic
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Hepatitis, Chronic
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Herpes Zoster
A delayed sperm penetration of cumulus layers by disruption of acrosin gene in rats.
HIV Infections
Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women.
Hyperaldosteronism
Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse.
Hyperaldosteronism
Direct hypotensive action of intravascular bradykinin in man.
Hyperandrogenism
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
Hyperandrogenism
Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight.
Hyperglycemia
Effects of aprotinin on the kallikrein-kinin system in type I diabetes (insulitis).
Hyperinsulinism
Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.
Hyperinsulinism
Changes of glandular kallikrein activity in human plasma following glucose ingestion.
Hyperinsulinism
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Hyperkalemia
Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans.
Hypersensitivity
Change in tissue kallikrein level in nasal wash after the administration of oxatomide in patients with nasal allergy.
Hypersensitivity
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis.
Hypersensitivity
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Hypersensitivity
[Kinins and kallikrein in nasal secretion after antigen challenge in patients with allergic rhinitis]
Hypertension
A missing link between a high salt intake and blood pressure increase.
Hypertension
A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.
Hypertension
Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats.
Hypertension
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.
Hypertension
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypertension
An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: comparisons with human hypertensive nephropathy.
Hypertension
Association of the tissue kallikrein gene promoter with ESRD and hypertension.
Hypertension
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.
Hypertension
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.
Hypertension
Cation excretion and kallikrein secretion by the rat parotid gland in various hypertensive models.
Hypertension
Cellular and functional aspects of the renal kallikrein system in health and disease.
Hypertension
Changes in urinary tissue kallikrein excretion in black African women with hypertensive disorders of pregnancy.
Hypertension
Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients.
Hypertension
Cosegregation of blood pressure with a kallikrein gene family polymorphism.
Hypertension
Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
Hypertension
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.
Hypertension
Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats.
Hypertension
Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases.
Hypertension
Expression of the renal kallikrein gene in mineralocorticoid-treated and genetically hypertensive rats.
Hypertension
Gender differences of human tissue kallikrein and an erythrocyte kallikrein-like enzyme in essential hypertension.
Hypertension
Gene therapy for hypertension: a review of potential targets.
Hypertension
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats.
Hypertension
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Hypertension
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats.
Hypertension
Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats.
Hypertension
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Hypertension
Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension.
Hypertension
Immunoreactive glandular kallikrein in plasma during alterations of urinary kallikrein excretion.
Hypertension
Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Hypertension
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Hypertension
Independent, marked associations of alleles of the insulin receptor and dipeptidyl carboxypeptidase-I genes with essential hypertension.
Hypertension
Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats.
Hypertension
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
Hypertension
Kallikrein genes: cloning in man and expression in rat renal hypertension.
Hypertension
Kallikrein-kinin in stroke, cardiovascular and renal disease.
Hypertension
Kallikrein-kinin system in severe experimental hypertension.
Hypertension
KLK1 A1789G gene polymorphism and the risk of coronary artery stenosis in the Chinese population.
Hypertension
Lack of oral kallikrein in lowering systemic blood pressure in primary hypertension.
Hypertension
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension.
Hypertension
Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria.
Hypertension
Modulation of renin-angiotensin and kallikrein gene expression in experimental hypertension.
Hypertension
New experimental evidence for a role of tissue kallikrein in hypertension.
Hypertension
Prevalence and associated factors for dipstick microscopic hematuria in men.
Hypertension
Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats.
Hypertension
Protective effect of cicletanine on hypertension-induced decreases in the renal kallikrein-kinin and prostaglandin systems in stroke-prone spontaneously hypertensive rats.
Hypertension
Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension.
Hypertension
Purification of human tissue prokallikrein excreted from insect cells by liquid chromatography.
Hypertension
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Hypertension
Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure.
Hypertension
Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension.
Hypertension
Renal functional reserve in obesity hypertension.
Hypertension
Renal kallikrein activity in rats developing spontaneous hypertension.
Hypertension
Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.
Hypertension
Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.
Hypertension
Renal kallikrein in human and experimental diabetes mellitus.
Hypertension
Renal kallikrein system, volemia, and renal hypertension.
Hypertension
Renal phenotype of low kallikrein rats.
Hypertension
Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes.
Hypertension
Salivary kallikrein excretion in hypertension.
Hypertension
Serine proteases and cardiac function.
Hypertension
Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.
Hypertension
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Hypertension
Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats.
Hypertension
The "silver-haired" general medical services patient. Clinical activity of the non-means tested over-70's during their first six months.
Hypertension
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.
Hypertension
The renal kallikrein-kinin system in renoparenchymal hypertension.
Hypertension
The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension.
Hypertension
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.
Hypertension
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
Hypertension
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Hypertension
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
Hypertension
Urinary and renal kallikrein in hypertensive fawn-hooded (FH/Wjd) rats.
Hypertension
[Changes in the activity of renal intracortical kallikrein during induction of Goldblatt arterial hypertension of the 2 kidney--1 clip type in the rat]
Hypertension
[Kallikrein (urine) in pregnancy-induced hypertension]
Hypertension, Pregnancy-Induced
Tissue kallikrein and kininogen levels in fetoplacental tissues from normotensive pregnant women and women with pregnancy-induced hypertension.
Hypertension, Renal
Renal kallikrein activity and urinary kallikrein excretion in rats with experimental renal hypertension.
Hypertension, Renal
Renal kallikrein system, volemia, and renal hypertension.
Hypertension, Renal
Renal tissue kallikrein, plasma renin and plasma aldosterone in renal hypertension.
Hypertension, Renovascular
Cation excretion and kallikrein secretion by the rat parotid gland in various hypertensive models.
Hypertension, Renovascular
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats.
Hypertension, Renovascular
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
Hypertension, Renovascular
[Renal kallikrein: variations in relation to sodium intake and experimental renovascular hypertension (author's transl)]
Hypertrophy, Left Ventricular
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypogonadism
Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism.
Hypogonadism
Oral testosterone replacement in Korean patients with PADAM.
Hypogonadism
Testosterone replacement therapy in male hypogonadism.
Hypogonadism
The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men.
Hypogonadism
[A case of progressive prostatic carcinoma in a patient with acquired hypogonadism.]
Hypoparathyroidism
FAM111A induces nuclear dysfunction in disease and viral restriction.
Hypotension
High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice.
Hypotension
High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model.
Hypotension
Human tissue kallikrein induces hypotension in transgenic mice.
Hypotension
Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein.
Hypotension
Kallikrein, kininogen and kinins in control of blood pressure.
Hypotension
Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Inappropriate ADH Syndrome
Increased renal kallikrein excretion in SIADH after vincristine therapy.
Infarction, Middle Cerebral Artery
Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.
Infarction, Middle Cerebral Artery
Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.
Infarction, Middle Cerebral Artery
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Infarction, Middle Cerebral Artery
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
Infarction, Middle Cerebral Artery
The Long-Term Outcome Comparison of Different Time-Delayed Kallikrein Treatments in a Mouse Cerebral Ischemic Model.
Infections
Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery.
Infections
Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe.
Infections
Correlation of kinin generating activity with Helicobacter pylori-associated gastric infection.
Infections
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Infections
Experimental Rhinovirus Infection Increases Human Tissue Kallikrein Activation in Allergic Subjects.
Infections
Involvement of proteases in porcine reproductive and respiratory syndrome virus uncoating upon internalization in primary macrophages.
Infections
Patient selection and counseling before prostatic arterial embolization.
Infections
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Infections
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Infections
Prostate specific antigen in urinary tract infection.
Infections
Re: Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Infections
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Infections
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Infections
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration.
Infections
Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection.
Infections
Upregulation of a Trypsin-Like Serine Protease Gene in Antheraea pernyi (Lepidoptera: Saturniidae) Strains Exposed to Different Pathogens.
Infections
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Infertility
Successful fertility treatment with gonadotrophin therapy for male hypogonadotrophic hypogonadism.
Infertility, Male
Genetic association study of a single nucleotide polymorphism of kallikrein-related peptidase 2 with male infertility.
Infertility, Male
Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility.
Infertility, Male
Successful fertility treatment with gonadotrophin therapy for male hypogonadotrophic hypogonadism.
Inflammatory Bowel Diseases
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Inflammatory Bowel Diseases
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Influenza, Human
A top 5 list for French general practice.
Influenza, Human
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Influenza, Human
Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Influenza, Human
Quantification of antigen by digital domain analysis of integrated nanogap biosensors.
Influenza, Human
The "silver-haired" general medical services patient. Clinical activity of the non-means tested over-70's during their first six months.
Influenza, Human
Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection.
Influenza, Human
Understanding preventive health screening services use in persons with serious mental illness: how does integrated behavioral health primary care compare?
Influenza, Human
When a usual source of care and usual provider matter: adult prevention and screening services.
Insulin Resistance
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
Insulin Resistance
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Insulin Resistance
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Insulin Resistance
Tissue kallikrein deficiency, insulin resistance and diabetes in mouse and man.
Insulin Resistance
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.
Intracranial Aneurysm
Effect of HUK on the outcome of ruptured intracranial aneurysm.
Ischemic Stroke
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Ischemic Stroke
Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis.
Ischemic Stroke
Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: A systematic review.
Ischemic Stroke
Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.
Ischemic Stroke
Experimental therapy with tissue kallikrein against cerebral ischemia.
Ischemic Stroke
High Level of Serum Tissue Kallikrein Is Associated with Favorable Outcome in Acute Ischemic Stroke Patients.
Ischemic Stroke
Human tissue kallikrein in the treatment of acute ischemic stroke.
Ischemic Stroke
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Ischemic Stroke
Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery.
Ischemic Stroke
Human urinary kallidinogenase in acute ischemic stroke: A single-arm, multicenter, phase IV study (RESK study).
Ischemic Stroke
Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial.
Ischemic Stroke
Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke.
Ischemic Stroke
Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension.
Ischemic Stroke
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Ischemic Stroke
Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients.
Ischemic Stroke
Remote limb ischemic postconditioning promotes motor function recovery in a rat model of ischemic stroke via the up-regulation of endogenous tissue kallikrein.
Ischemic Stroke
The Pyk2/MCU Pathway in the Rat Middle Cerebral Artery Occlusion Model of Ischemic Stroke.
Ischemic Stroke
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.
Ischemic Stroke
Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases.
Ischemic Stroke
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Ischemic Stroke
Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-?B and activating Nrf2 signaling pathway in rats.
Ischemic Stroke
Treatment of Human Urinary Kallidinogenase Combined with Maixuekang Capsule Promotes Good Functional Outcome in Ischemic Stroke.
Kidney Failure, Chronic
Association of the tissue kallikrein gene promoter with ESRD and hypertension.
Kidney Failure, Chronic
Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats.
Kidney Failure, Chronic
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
Kidney Failure, Chronic
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Kidney Failure, Chronic
Patient selection and counseling before prostatic arterial embolization.
Kidney Failure, Chronic
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Kidney Failure, Chronic
Prostate cancer in renal transplant recipients.
Kidney Failure, Chronic
Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease.
Kidney Failure, Chronic
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
Kidney Failure, Chronic
Role of renal kallikrein in the increased fractional sodium excretion in the rat remnant kidney model of chronic renal failure.
Kidney Failure, Chronic
Role of renal kallikrein in the regulation of blood pressure in the rat remnant kidney model of chronic renal failure.
Kidney Failure, Chronic
Serum tumor markers in hemodialysis patients.
Kidney Failure, Chronic
[Influence of renal and hepatic function in the serum concentration of prostate specific antigen]
Kidney Failure, Chronic
[Tumour markers in chronic kidney disease.]
Leiomyosarcoma
Prostate Leiomyosarcoma: A Rare Misleading Tumor.
Leukemia
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
Leukemia
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
Liver Cirrhosis
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Liver Cirrhosis
[Excretion of renal kallikrein in liver cirrhosis]
Liver Cirrhosis, Alcoholic
Renal kallikrein excretion in alcoholic cirrhosis. Relationship to other vasoactive systems.
Liver Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Liver Diseases
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Liver Neoplasms
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.
Lung Neoplasms
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Lung Neoplasms
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lung Neoplasms
Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer.
Lung Neoplasms
KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.
Lung Neoplasms
Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA.
Lupus Erythematosus, Systemic
Kallikreins and lupus nephritis.
Lupus Nephritis
Kallikreins and lupus nephritis.
Lupus Nephritis
Kinin system in lupus nephritis.
Lymphadenopathy
Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual?
Lymphatic Metastasis
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Lymphatic Metastasis
Contemporary appraisal of radical perineal prostatectomy.
Lymphatic Metastasis
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Lymphatic Metastasis
Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.
Lymphatic Metastasis
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Lymphatic Metastasis
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Lymphatic Metastasis
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Lymphatic Metastasis
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Lymphatic Metastasis
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
Lymphatic Metastasis
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
Lymphatic Metastasis
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Lymphatic Metastasis
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Lymphatic Metastasis
Increased SPC24 in prostatic diseases and diagnostic value of SPC24 and its interacting partners in prostate cancer.
Lymphatic Metastasis
Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
Lymphatic Metastasis
Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
Lymphatic Metastasis
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Lymphatic Metastasis
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
Lymphatic Metastasis
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Lymphatic Metastasis
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Lymphatic Metastasis
Positron emission tomography in urological oncology.
Lymphatic Metastasis
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Lymphatic Metastasis
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Lymphatic Metastasis
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Lymphatic Metastasis
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Lymphatic Metastasis
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Lymphatic Metastasis
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Lymphatic Metastasis
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Lymphatic Metastasis
Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis.
Lymphatic Metastasis
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Lymphatic Metastasis
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Lymphatic Metastasis
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
Lymphatic Metastasis
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
Lymphatic Metastasis
Treatment of the positive surgical margin following radical prostatectomy.
Lymphatic Metastasis
[Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients].
Lymphatic Metastasis
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
Lymphatic Metastasis
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Lymphocytosis
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Lymphoma
Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.
Lymphoma
Kallikrein-kinin system in patients with neoplastic diseases.
Lymphoma
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
Malnutrition
Role of bradykinin B2 receptors in neonatal kidney growth.
Meckel Diverticulum
Incidental possible diagnosis by 18F-fluorocholine PET/CT of Meckel's diverticulum and potential pitfalls.
Melanoma
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Melanoma
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Melanoma
Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas.
Meningioma
Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma.
Metabolic Syndrome
The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Microphthalmos
Autosomal-Recessive Posterior Microphthalmos Is Caused by Mutations in PRSS56, a Gene Encoding a Trypsin-Like Serine Protease.
Mouth Neoplasms
Dielectrophoretic label-free immunoassay for rare-analyte quantification in biological samples.
Myocardial Infarction
Acute myocardial infarction without cardiogenic shock does not affect serum prostate specific antigen levels: A case control study.
Myocardial Infarction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Myocardial Infarction
Analyses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction.
Myocardial Infarction
New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration.
Myocardial Infarction
Prostate specific antigen levels after acute myocardial infarction.
Myocardial Infarction
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.
Myocardial Infarction
Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.
Myocardial Infarction
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.
Myocardial Infarction
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.
Myocardial Infarction
Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity.
Myocardial Infarction
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway.
Myocardial Infarction
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis.
Myocardial Ischemia
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.
Myocardial Ischemia
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Myocardial Ischemia
Tissue kallikrein is required for the cardioprotective effect of Cyclosporin A in myocardial ischemia in the mouse.
Nasopharyngitis
A top 5 list for French general practice.
Neoplasm Metastasis
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
Neoplasm Metastasis
(99m)Tc-MDP uptake in SPECT/CT by a bladder hernia simulating inguinal metastasis: A case report.
Neoplasm Metastasis
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Neoplasm Metastasis
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Neoplasm Metastasis
A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
Neoplasm Metastasis
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Neoplasm Metastasis
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.
Neoplasm Metastasis
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Neoplasm Metastasis
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
Neoplasm Metastasis
A pilot study of intermittent androgen deprivation in advanced prostate cancer.
Neoplasm Metastasis
A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up.
Neoplasm Metastasis
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Neoplasm Metastasis
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Neoplasm Metastasis
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Neoplasm Metastasis
Assay for prostate specific antigen (PSA): problems and possible solutions.
Neoplasm Metastasis
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Neoplasm Metastasis
Autoantibodies to prostasomes as new markers for prostate cancer.
Neoplasm Metastasis
Bicalutamide: in early-stage prostate cancer.
Neoplasm Metastasis
Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Neoplasm Metastasis
Can radiotherapy salvage isolated local recurrence following radical prostatectomy?
Neoplasm Metastasis
Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted?
Neoplasm Metastasis
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.
Neoplasm Metastasis
Cancer control following anatomical radical prostatectomy: an interim report.
Neoplasm Metastasis
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Neoplasm Metastasis
Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.
Neoplasm Metastasis
Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy.
Neoplasm Metastasis
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Neoplasm Metastasis
Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts.
Neoplasm Metastasis
Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Neoplasm Metastasis
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Neoplasm Metastasis
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Neoplasm Metastasis
Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Neoplasm Metastasis
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Neoplasm Metastasis
Contemporary appraisal of radical perineal prostatectomy.
Neoplasm Metastasis
Correlation between bone metabolic markers and bone scan in prostatic cancer.
Neoplasm Metastasis
Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Neoplasm Metastasis
Current treatment of non-metastatic castration-refractory prostate cancer.
Neoplasm Metastasis
Cytogenetics and Molecular Genetics of Prostate Cancer: A Comprehensive Update.
Neoplasm Metastasis
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Neoplasm Metastasis
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
Neoplasm Metastasis
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.
Neoplasm Metastasis
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Neoplasm Metastasis
Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound.
Neoplasm Metastasis
Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
Neoplasm Metastasis
Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.
Neoplasm Metastasis
Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
Neoplasm Metastasis
Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy.
Neoplasm Metastasis
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Neoplasm Metastasis
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level.
Neoplasm Metastasis
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Neoplasm Metastasis
Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.
Neoplasm Metastasis
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Neoplasm Metastasis
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Neoplasm Metastasis
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Neoplasm Metastasis
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Neoplasm Metastasis
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Neoplasm Metastasis
Establishment of human prostate carcinoma skeletal metastasis models.
Neoplasm Metastasis
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.
Neoplasm Metastasis
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Neoplasm Metastasis
Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms.
Neoplasm Metastasis
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Neoplasm Metastasis
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Neoplasm Metastasis
Expression of Telomere Repeat Binding Factor 1 and TRF2 in Prostate Cancer and Correlation with Clinical Parameters.
Neoplasm Metastasis
Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer.
Neoplasm Metastasis
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
Neoplasm Metastasis
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Neoplasm Metastasis
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
Neoplasm Metastasis
HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer.
Neoplasm Metastasis
High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey.
Neoplasm Metastasis
High dose rate brachytherapy for prostate cancer.
Neoplasm Metastasis
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Neoplasm Metastasis
Historical prostate cancer screening and treatment outcomes from a single institution.
Neoplasm Metastasis
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Neoplasm Metastasis
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Neoplasm Metastasis
Imaging of prostate cancer.
Neoplasm Metastasis
Imaging of prostate carcinoma.
Neoplasm Metastasis
Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
Neoplasm Metastasis
Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Neoplasm Metastasis
Increased SPC24 in prostatic diseases and diagnostic value of SPC24 and its interacting partners in prostate cancer.
Neoplasm Metastasis
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Neoplasm Metastasis
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Neoplasm Metastasis
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Neoplasm Metastasis
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Neoplasm Metastasis
Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model.
Neoplasm Metastasis
Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Neoplasm Metastasis
Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review.
Neoplasm Metastasis
Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
Neoplasm Metastasis
Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Neoplasm Metastasis
Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
Neoplasm Metastasis
Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
Neoplasm Metastasis
Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen.
Neoplasm Metastasis
Laparoscopic port-site metastasis as the manifestation of neuroendocrine prostate cancer: Case report and literature review.
Neoplasm Metastasis
Late recurrence of adenoid cystic carcinoma of the prostate.
Neoplasm Metastasis
Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
Neoplasm Metastasis
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Neoplasm Metastasis
Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis.
Neoplasm Metastasis
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
Neoplasm Metastasis
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
Neoplasm Metastasis
Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.
Neoplasm Metastasis
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Neoplasm Metastasis
Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Neoplasm Metastasis
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Neoplasm Metastasis
Metastasis on Bone Scan With Low Prostate Specific Antigen (? 20 ng/ml) and Gleason's Score (<8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines?
Neoplasm Metastasis
Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Neoplasm Metastasis
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Neoplasm Metastasis
Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
Neoplasm Metastasis
Morphometric and clinical studies on 68 consecutive radical prostatectomies.
Neoplasm Metastasis
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID.
Neoplasm Metastasis
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
Neoplasm Metastasis
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Neoplasm Metastasis
Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy.
Neoplasm Metastasis
Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: A case report.
Neoplasm Metastasis
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Neoplasm Metastasis
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Neoplasm Metastasis
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Neoplasm Metastasis
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Neoplasm Metastasis
Piflufolastat F 18: Diagnostic First Approval.
Neoplasm Metastasis
Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
Neoplasm Metastasis
Positron emission tomography in urological oncology.
Neoplasm Metastasis
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Neoplasm Metastasis
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Neoplasm Metastasis
Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
Neoplasm Metastasis
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.
Neoplasm Metastasis
Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation.
Neoplasm Metastasis
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Neoplasm Metastasis
Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
Neoplasm Metastasis
Prevalence of lymph node metastasis in radical prostatectomy; a retrospective and multicenter study in iran.
Neoplasm Metastasis
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Neoplasm Metastasis
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Neoplasm Metastasis
Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment.
Neoplasm Metastasis
Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Neoplasm Metastasis
Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy.
Neoplasm Metastasis
Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
Neoplasm Metastasis
Prostate specific antigen after irradiation for prostatic carcinoma.
Neoplasm Metastasis
Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Neoplasm Metastasis
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Neoplasm Metastasis
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Neoplasm Metastasis
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Neoplasm Metastasis
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
Neoplasm Metastasis
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Neoplasm Metastasis
Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting (18)F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy.
Neoplasm Metastasis
Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.
Neoplasm Metastasis
Prostatic metastases in the nose and paranasal sinuses.
Neoplasm Metastasis
Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Neoplasm Metastasis
Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Neoplasm Metastasis
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Neoplasm Metastasis
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Neoplasm Metastasis
Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.
Neoplasm Metastasis
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Neoplasm Metastasis
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Neoplasm Metastasis
Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Neoplasm Metastasis
Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study.
Neoplasm Metastasis
Receptor gene messenger RNA expression in metastatic lesions of prostate cancer.
Neoplasm Metastasis
Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis.
Neoplasm Metastasis
Risk of prostate carcinoma death in patients with lymph node metastasis.
Neoplasm Metastasis
Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Neoplasm Metastasis
Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation.
Neoplasm Metastasis
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Neoplasm Metastasis
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Neoplasm Metastasis
Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
Neoplasm Metastasis
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Neoplasm Metastasis
Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Neoplasm Metastasis
Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.
Neoplasm Metastasis
Small cell metastatic prostate cancer with ectopic adrenocorticotropic hormone hypersecretion.
Neoplasm Metastasis
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
Neoplasm Metastasis
Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma.
Neoplasm Metastasis
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Neoplasm Metastasis
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Neoplasm Metastasis
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Neoplasm Metastasis
Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy.
Neoplasm Metastasis
Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer.
Neoplasm Metastasis
Surgical approaches to local failure after definitive therapy.
Neoplasm Metastasis
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
Neoplasm Metastasis
The Benefit of a Surgical Resection of a Solitary Pulmonary Metastasis of Prostate Cancer after Radical Prostatectomy.
Neoplasm Metastasis
The Effect of Radium-223 Therapy in Agent Orange-Related Prostate Carcinoma.
Neoplasm Metastasis
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Neoplasm Metastasis
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
Neoplasm Metastasis
The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate.
Neoplasm Metastasis
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
Neoplasm Metastasis
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
Neoplasm Metastasis
The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Neoplasm Metastasis
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
Neoplasm Metastasis
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
Neoplasm Metastasis
The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.
Neoplasm Metastasis
The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
Neoplasm Metastasis
The utility of bone remodeling markers in the diagnosis, evolution and treatment response evaluation in bone metastases.
Neoplasm Metastasis
The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
Neoplasm Metastasis
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Neoplasm Metastasis
Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.
Neoplasm Metastasis
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Neoplasm Metastasis
Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome.
Neoplasm Metastasis
Treatment of the positive surgical margin following radical prostatectomy.
Neoplasm Metastasis
Tumor fraction in cell-free DNA as a biomarker in prostate cancer.
Neoplasm Metastasis
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Neoplasm Metastasis
Unresolving / progressive skin lesions in cancer patients: be aware of carcinoma cutis.
Neoplasm Metastasis
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Neoplasm Metastasis
Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy.
Neoplasm Metastasis
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Neoplasm Metastasis
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Neoplasm Metastasis
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Neoplasm Metastasis
[A Case of de novo Neuroendocrine Prostate Cancer].
Neoplasm Metastasis
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
Neoplasm Metastasis
[A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases]
Neoplasm Metastasis
[A case of solitary endobronchial metastasis of prostatic cancer]
Neoplasm Metastasis
[Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival]
Neoplasm Metastasis
[CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].
Neoplasm Metastasis
[Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature]
Neoplasm Metastasis
[Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]
Neoplasm Metastasis
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
Neoplasm Metastasis
[Diagnostic imaging of the prostate cancer].
Neoplasm Metastasis
[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]
Neoplasm Metastasis
[Ganglion curage in prostate cancer]
Neoplasm Metastasis
[Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients].
Neoplasm Metastasis
[Is it possible to do without bone gammagraphy in the staging of prostatic cancer?]
Neoplasm Metastasis
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
Neoplasm Metastasis
[Local recurrence after radical prostatectomy and salvage radiotherapy]
Neoplasm Metastasis
[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
Neoplasm Metastasis
[Ophthalmoplegia in a patient with prostate cancer and bone metastases]
Neoplasm Metastasis
[Predictive factors for bone metastases of prostate cancer].
Neoplasm Metastasis
[Prostate cancer recurrence after radical prostatectomy and salvage radiotherapy]
Neoplasm Metastasis
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Neoplasm Metastasis
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
Neoplasm Metastasis
[Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]
Neoplasm Metastasis
[Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
Neoplasm Metastasis
[When should bone scanning be carried out in prostatic cancer?]
Neoplasm Micrometastasis
Novel imaging in advanced prostate cancer.
Neoplasm Micrometastasis
Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients.
Neoplasm Micrometastasis
The application of the RT-PCR method for the staging of the prostate cancer progression.
Neoplasm, Residual
A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy.
Neoplasm, Residual
Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Neoplasm, Residual
Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography.
Neoplasm, Residual
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Neoplasm, Residual
Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen.
Neoplasm, Residual
Impact of margin size on the incidence of local residual tumor after laparoscopic radical prostatectomy.
Neoplasm, Residual
LncRNA SNHG9 is a prognostic biomarker and correlated with immune infiltrates in prostate cancer.
Neoplasm, Residual
Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
Neoplasm, Residual
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Neoplasm, Residual
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Neoplasm, Residual
The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate.
Neoplasm, Residual
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Neoplasms
"Robotic fatigue?" - The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy.
Neoplasms
'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases.
Neoplasms
25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.
Neoplasms
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?
Neoplasms
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
Neoplasms
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Neoplasms
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Neoplasms
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Neoplasms
A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.
Neoplasms
A case of Sister Mary Joseph's nodule from prostatic cancer.
Neoplasms
A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects.
Neoplasms
A cell kinetics model for prostate cancer and its application to clinical data and individual patients.
Neoplasms
A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.
Neoplasms
A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer.
Neoplasms
A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
Neoplasms
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
Neoplasms
A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
Neoplasms
A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy.
Neoplasms
A critical comparison of techniques for MRI-targeted biopsy of the prostate.
Neoplasms
A guideline to clinical utility of prostate specific antigen.
Neoplasms
A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.
Neoplasms
A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy.
Neoplasms
A Modified Partin Table to Better Predict Extracapsular Extension in Clinically Localized Prostate Cancer.
Neoplasms
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.
Neoplasms
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
Neoplasms
A nanoplasmonic biosensor for label-free multiplex detection of cancer biomarkers.
Neoplasms
A new human prostate carcinoma cell line, 22Rv1.
Neoplasms
A new serially transplantable human prostatic cancer (HONDA) in nude mice.
Neoplasms
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
Neoplasms
A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results.
Neoplasms
A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores.
Neoplasms
A novel immunosensor for the monitoring of PSA using binding of biotinylated antibody to the prostate specific antigen based on nano-ink modified flexible paper substrate: efficient method for diagnosis of cancer using biosensing technology.
Neoplasms
A novel label-free colorimetric aptasensor for sensitive determination of PSA biomarker using gold nanoparticles and a cationic polymer in human serum.
Neoplasms
A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor.
Neoplasms
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
Neoplasms
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
Neoplasms
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
Neoplasms
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
Neoplasms
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.
Neoplasms
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
Neoplasms
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
Neoplasms
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
Neoplasms
A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup.
Neoplasms
A review of the role of established tumour markers.
Neoplasms
A Review on the Clinical Utility of PSA in Cancer Prostate.
Neoplasms
A simple computer program for calculating PSA recurrence in prostate cancer patients.
Neoplasms
A survival model for fractionated radiotherapy with an application to prostate cancer.
Neoplasms
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Neoplasms
A systematic review of brachytherapy. Is it an effective and safe treatment for localised prostate cancer?
Neoplasms
A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
Neoplasms
A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies.
Neoplasms
A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
Neoplasms
Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
Neoplasms
Active surveillance for low-risk prostate cancer.
Neoplasms
Active surveillance: towards a new paradigm in the management of early prostate cancer.
Neoplasms
Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
Neoplasms
Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
Neoplasms
Adenosquamous carcinoma of the prostate.
Neoplasms
Adjuvant radiotherapy for high-risk patients following radical prostatectomy.
Neoplasms
Adverse prognostic significance of capsular incision with radical retropubic prostatectomy.
Neoplasms
African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
Neoplasms
African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
Neoplasms
African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Neoplasms
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Neoplasms
Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations.
Neoplasms
Aligned carbon nanotubes on quartz substrate for liquid gated biosensing.
Neoplasms
American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen.
Neoplasms
Amplified binding-induced homogeneous assay through catalytic cycling of analyte for ultrasensitive protein detection.
Neoplasms
An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
Neoplasms
An aptamer based resonance light scattering assay of prostate specific antigen.
Neoplasms
An enhanced LSPR fiber-optic nanoprobe for ultrasensitive detection of protein biomarkers.
Neoplasms
An enhanced prognostic system for clinically localized carcinoma of the prostate.
Neoplasms
An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital.
Neoplasms
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Neoplasms
An improved method for computerized tomography-planned transperineal 125iodine prostate implants.
Neoplasms
An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.
Neoplasms
Analysis of tumor spillage during radical prostatectomy using RT-PCR of prostate specific antigen.
Neoplasms
Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results.
Neoplasms
Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Neoplasms
Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Neoplasms
Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Neoplasms
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Neoplasms
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
Neoplasms
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Neoplasms
Antigen Specific T-Cell Responses Against Tumor Antigens are Controlled by Regulatory T Cells in Patients With Prostate Cancer.
Neoplasms
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures.
Neoplasms
Are multiple markers the future of prostate cancer diagnostics?
Neoplasms
Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology.
Neoplasms
Artificial neural network model to predict biochemical failure after radical prostatectomy.
Neoplasms
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Neoplasms
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Neoplasms
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
Neoplasms
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Neoplasms
Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
Neoplasms
Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
Neoplasms
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Neoplasms
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
Neoplasms
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.
Neoplasms
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Neoplasms
Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men.
Neoplasms
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
Neoplasms
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Neoplasms
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review.
Neoplasms
Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
Neoplasms
Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Neoplasms
Baseline staging of newly diagnosed prostate cancer: a summary of the literature.
Neoplasms
Bayesian neural networks for bivariate binary data: an application to prostate cancer study.
Neoplasms
Beyond PSA: The Role of Prostate Health Index (phi).
Neoplasms
Bilateral cancer in prostate biopsy associates with the presence of extracapsular disease and positive surgical margins in low risk patients: a consideration for bilateral nerve sparing radical prostatectomy decision.
Neoplasms
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Neoplasms
Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer.
Neoplasms
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
Neoplasms
Biological, psychological and behavioral, and social variables influencing colorectal cancer screening in African Americans.
Neoplasms
Biomarkers identified for prostate cancer patients through genome-scale screening.
Neoplasms
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Neoplasms
Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer.
Neoplasms
Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations.
Neoplasms
Can 68Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study.
Neoplasms
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
Neoplasms
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
Neoplasms
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
Neoplasms
Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?
Neoplasms
Cancer diagnosis with prostate specific antigen greater than 10 ng./ml. and negative peripheral zone prostate biopsy.
Neoplasms
Cancer incidence among triazine herbicide manufacturing workers.
Neoplasms
Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study.
Neoplasms
Cancer screening in Queensland men.
Neoplasms
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Neoplasms
Carbon Nanotubes Multifunctionalized by Rolling Circle Amplification and Their Application for Highly Sensitive Detection of Cancer Markers.
Neoplasms
Catheter-less robotic radical prostatectomy using a custom-made synchronous anastomotic splint and vesical urinary diversion device: report of the initial series and perioperative outcomes.
Neoplasms
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Neoplasms
Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
Neoplasms
Cerebellar metastases from prostatic carcinoma.
Neoplasms
Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
Neoplasms
Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Neoplasms
Characteristics of patients with familial versus sporadic prostate cancer.
Neoplasms
Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project.
Neoplasms
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Neoplasms
Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Neoplasms
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Neoplasms
Chemoprevention of prostate cancer with nutrients and supplements.
Neoplasms
Chemoprevention of prostate cancer.
Neoplasms
Chemoprevention of prostate cancer: agents and study designs.
Neoplasms
Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model.
Neoplasms
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
Neoplasms
Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.
Neoplasms
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
Neoplasms
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Neoplasms
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Neoplasms
Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts.
Neoplasms
Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Neoplasms
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Neoplasms
Clinical and Biochemical Influence of Prostatic Stones.
Neoplasms
Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer.
Neoplasms
Clinical safety of a viral vector based prostate cancer vaccine strategy.
Neoplasms
Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men.
Neoplasms
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.
Neoplasms
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Neoplasms
Clinical use of prostate specific antigen in patients with prostate cancer.
Neoplasms
Clinical use of tumor markers in oncology.
Neoplasms
Clinical usefulness of percentage of free serum prostate specific antigen.
Neoplasms
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
Neoplasms
Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.
Neoplasms
Clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies.
Neoplasms
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Neoplasms
Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.
Neoplasms
Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding.
Neoplasms
Colorimetric platform for visual detection of cancer biomarker based on intrinsic peroxidase activity of graphene oxide.
Neoplasms
Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Neoplasms
Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate.
Neoplasms
Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer.
Neoplasms
Combining diagnostic test results to increase accuracy.
Neoplasms
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Neoplasms
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Neoplasms
Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Neoplasms
Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Neoplasms
Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Neoplasms
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Neoplasms
Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.
Neoplasms
Comparing Revo-i and da Vinci in Retzius-sparing robot-assisted radical prostatectomy: a preliminary propensity score analysis of outcomes.
Neoplasms
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
Neoplasms
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Neoplasms
Comparison of methods for calculating prostate specific antigen velocity.
Neoplasms
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
Neoplasms
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Neoplasms
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
Neoplasms
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Neoplasms
Contemporary impact of transrectal ultrasound lesions for prostate cancer detection.
Neoplasms
Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination.
Neoplasms
Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Neoplasms
Contemporary trends in low risk prostate cancer: risk assessment and treatment.
Neoplasms
Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
Neoplasms
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Neoplasms
Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
Neoplasms
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Neoplasms
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Neoplasms
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
Neoplasms
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).
Neoplasms
Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
Neoplasms
CuO-induced signal amplification strategy for multiplexed photoelectrochemical immunosensing using CdS sensitized ZnO nanotubes arrays as photoactive material and AuPd alloy nanoparticles as electron sink.
Neoplasms
Current status of tissue kallikrein inhibitors: importance in cancer.
Neoplasms
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Neoplasms
Decrease in prostate specific antigen secretion correlated with docetaxel-induced growth inhibition and apoptosis in human prostate tumor cells.
Neoplasms
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
Neoplasms
Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
Neoplasms
Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.
Neoplasms
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Neoplasms
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Neoplasms
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
Neoplasms
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
Neoplasms
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
Neoplasms
Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins.
Neoplasms
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Neoplasms
Detection of cancer biomarkers by piezoelectric biosensor using PZT ceramic resonator as the transducer.
Neoplasms
Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor.
Neoplasms
Detection of cancer by tumor markers in the blood: a view to the future.
Neoplasms
Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers.
Neoplasms
Determination of prostate volume with transrectal ultrasound for cancer screening. Part I. Comparison with prostate specific antigen assays.
Neoplasms
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
Neoplasms
Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.
Neoplasms
Development of Novel Piezoelectric Biosensor Using PZT Ceramic Resonator for Detection of Cancer Markers.
Neoplasms
Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Neoplasms
Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL.
Neoplasms
Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies.
Neoplasms
Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4.
Neoplasms
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Neoplasms
Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Neoplasms
Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy.
Neoplasms
Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Neoplasms
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Neoplasms
Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology.
Neoplasms
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Neoplasms
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Neoplasms
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Neoplasms
Disproportionate presentation of high risk prostate cancer in a safety net health system.
Neoplasms
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.
Neoplasms
DNA Repair System and Prostate Cancer Progression: The Role of NBS1 Polymorphism (rs1805794).
Neoplasms
Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer?
Neoplasms
Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?
Neoplasms
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Neoplasms
Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis.
Neoplasms
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
Neoplasms
Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?
Neoplasms
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Neoplasms
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Neoplasms
Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.
Neoplasms
Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?
Neoplasms
Does the Prentice criterion validate surrogate endpoints?
Neoplasms
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Neoplasms
Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
Neoplasms
Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.
Neoplasms
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Neoplasms
Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen.
Neoplasms
Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Neoplasms
Dumbbell-like Au-Fe3O4 nanoparticles as label for the preparation of electrochemical immunosensors.
Neoplasms
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.
Neoplasms
Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.
Neoplasms
Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.
Neoplasms
Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea.
Neoplasms
Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy.
Neoplasms
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Neoplasms
Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice.
Neoplasms
Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer.
Neoplasms
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.
Neoplasms
Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.
Neoplasms
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Neoplasms
Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
Neoplasms
Effectiveness of screening for prostate cancer.
Neoplasms
Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Neoplasms
Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells.
Neoplasms
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
Neoplasms
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Neoplasms
Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council.
Neoplasms
Electrochemical immunosensors for cancer biomarker with signal amplification based on ferrocene functionalized iron oxide nanoparticles.
Neoplasms
Electrochemical red-ox therapy of prostate cancer in nude mice.
Neoplasms
Electrochemiluminescence immunosensor for tumor markers based on biological barcode mode with conductive nanospheres.
Neoplasms
Electrochemiluminescent immunosensor for detection of protein cancer biomarkers using carbon nanotube forests and [Ru-(bpy)(3)](2+)-doped silica nanoparticles.
Neoplasms
Elevated glandular kallikrein in estrogen-induced pituitary tumors.
Neoplasms
Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India.
Neoplasms
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Neoplasms
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
Neoplasms
Emerging impact of quercetin in the treatment of prostate cancer.
Neoplasms
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.
Neoplasms
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.
Neoplasms
Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Neoplasms
Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
Neoplasms
Establishing a prediction model for prostate cancer bone metastasis.
Neoplasms
Establishment of human prostate carcinoma skeletal metastasis models.
Neoplasms
Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.
Neoplasms
Evaluating diagnostic strategy of older patients with unexplained unintentional body weight loss: A hospital-based study.
Neoplasms
Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma.
Neoplasms
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
Neoplasms
Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Neoplasms
Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen.
Neoplasms
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Neoplasms
Evaluation of prostate specific antigen as a tumor marker in cancer prostate.
Neoplasms
Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma.
Neoplasms
Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Neoplasms
Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
Neoplasms
Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases.
Neoplasms
Ex vivo ?H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity.
Neoplasms
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
Neoplasms
Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.
Neoplasms
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Neoplasms
Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center.
Neoplasms
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Neoplasms
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Neoplasms
Expression of ARHGAP10 correlates with prognosis of prostate cancer.
Neoplasms
Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Neoplasms
Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes.
Neoplasms
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Neoplasms
Expression of prostate specific antigen in male breast cancer.
Neoplasms
Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Neoplasms
Expression of the multidrug resistance gene in human prostate cancer.
Neoplasms
Expression of the prostate specific antigen gene by lung tissue.
Neoplasms
Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer.
Neoplasms
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.
Neoplasms
Extended pelvic lymphadenectomy in patients with clinically localised prostate cancer: A prospective observational study.
Neoplasms
Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.
Neoplasms
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Neoplasms
Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology.
Neoplasms
Extraperitoneal endoscopic pelvic lymph node dissection: a review of 125 patients.
Neoplasms
Extraprostatic production of prostate specific antigen is under hormonal control.
Neoplasms
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Neoplasms
Factors predicting prostatic biopsy Gleason sum under grading.
Neoplasms
Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence.
Neoplasms
Failure of open radioactive 125iodine implantation to control localized prostate cancer: a study of 41 patients.
Neoplasms
False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Neoplasms
Family history and the risk of prostatic carcinoma in a high risk group of urological patients.
Neoplasms
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.
Neoplasms
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin.
Neoplasms
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Neoplasms
Finasteride-its impact on sexual function and prostate cancer.
Neoplasms
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Neoplasms
Focal prostate cryoablation: initial results show cancer control and potency preservation.
Neoplasms
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
Neoplasms
Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
Neoplasms
FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
Neoplasms
Functional Organotypic Cultures of Prostate Tissues: A Relevant Preclinical Model that Preserves Hypoxia Sensitivity and Calcium Signaling.
Neoplasms
Functionalized MoS2 Nanosheet-Based Field-Effect Biosensor for Label-Free Sensitive Detection of Cancer Marker Proteins in Solution.
Neoplasms
Gel pad array chip for high throughput and multi-analyte microbead-based immunoassays.
Neoplasms
Gene expression correlates of clinical prostate cancer behavior.
Neoplasms
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Neoplasms
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Neoplasms
Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Neoplasms
Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.
Neoplasms
Giant dumbbell-shaped prostatic cystadenoma presenting as pelvic and scrotal mass.
Neoplasms
Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin.
Neoplasms
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
Neoplasms
Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy.
Neoplasms
GPs views and understanding of PSA testing, screening and early detection; survey.
Neoplasms
Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium.
Neoplasms
Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.
Neoplasms
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.
Neoplasms
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Neoplasms
Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Neoplasms
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Neoplasms
HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Neoplasms
Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.
Neoplasms
Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis.
Neoplasms
High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey.
Neoplasms
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Neoplasms
High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
Neoplasms
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
Neoplasms
High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.
Neoplasms
Higher frequency of familial clustering of prostate cancer in French-Canadian men.
Neoplasms
Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases.
Neoplasms
Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.
Neoplasms
Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment.
Neoplasms
Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Neoplasms
Historical prostate cancer screening and treatment outcomes from a single institution.
Neoplasms
Hormone therapy of prostatic bone metastases.
Neoplasms
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Neoplasms
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Neoplasms
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Neoplasms
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Neoplasms
Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Neoplasms
Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer.
Neoplasms
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells.
Neoplasms
Human tissue kallikrein gene family: applications in cancer.
Neoplasms
Human tissue kallikreins and testicular cancer.
Neoplasms
Human tissue kallikreins: a family of new cancer biomarkers.
Neoplasms
Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.
Neoplasms
Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study.
Neoplasms
Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate specific antigen.
Neoplasms
Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring.
Neoplasms
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Neoplasms
Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation.
Neoplasms
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Neoplasms
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
Neoplasms
Imaging and Management of Prostate Cancer.
Neoplasms
Imaging of prostate carcinoma.
Neoplasms
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation.
Neoplasms
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Neoplasms
Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer.
Neoplasms
Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells.
Neoplasms
Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Neoplasms
Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations.
Neoplasms
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.
Neoplasms
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Neoplasms
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Neoplasms
Immunosensor for the detection of cancer biomarker based on percolated graphene thin film.
Neoplasms
Impact of increased number of biopsies on the nature of prostate cancer identified.
Neoplasms
Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study.
Neoplasms
Impact of organ confined prostate cancer treatment on quality of life.
Neoplasms
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
Neoplasms
Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases.
Neoplasms
Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates.
Neoplasms
Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores.
Neoplasms
Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy.
Neoplasms
Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy.
Neoplasms
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Neoplasms
Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy.
Neoplasms
Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles.
Neoplasms
Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy.
Neoplasms
In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.
Neoplasms
Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
Neoplasms
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.
Neoplasms
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.
Neoplasms
Increased expression of protease M in ovarian tumors.
Neoplasms
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Neoplasms
Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease.
Neoplasms
Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.
Neoplasms
Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Neoplasms
Indications for laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Neoplasms
Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis.
Neoplasms
Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Neoplasms
Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
Neoplasms
Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer.
Neoplasms
Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas.
Neoplasms
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Neoplasms
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Neoplasms
Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Neoplasms
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors.
Neoplasms
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
Neoplasms
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Neoplasms
Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression.
Neoplasms
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Neoplasms
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Neoplasms
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Neoplasms
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.
Neoplasms
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Neoplasms
Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: a Key Feature Towards Prodrug-Nanomedicine Design.
Neoplasms
Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set.
Neoplasms
Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer.
Neoplasms
Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
Neoplasms
Is disease flare a problem?
Neoplasms
Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Neoplasms
Is race a positive predictor of cancer on repeat prostate biopsy?
Neoplasms
Is routine digital rectal examination required for the followup of prostate cancer?
Neoplasms
Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Neoplasms
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Neoplasms
Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3.
Neoplasms
Kallikrein-kinin system in patients with neoplastic diseases.
Neoplasms
Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
Neoplasms
Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.
Neoplasms
Kappa statistics in the screening of malignancy of prostate.
Neoplasms
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Neoplasms
Kinin receptors are expressed in human astrocytic tumour cells.
Neoplasms
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Neoplasms
Knowledge of prostate cancer screening among native African urban population in Nigeria.
Neoplasms
Laparoscopic pelvic lymph node dissection.
Neoplasms
Laparoscopic radical prostatectomy with a remote controlled robot.
Neoplasms
Laparoscopic Radical Prostatectomy with a Remote Controlled Robot.
Neoplasms
Laparoscopic radical prostatectomy.
Neoplasms
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
Neoplasms
Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Neoplasms
Lesion Targeted CT-Guided Transgluteal Prostate Biopsy in Combination With Prebiopsy MRI in Patients Without Rectal Access.
Neoplasms
Levels of glandular kallikrein in whole saliva obtained from patients with solid tumors remote from the oral cavity.
Neoplasms
Life events, cortisol and levels of prostate specific antigen: A story of synergism.
Neoplasms
Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database.
Neoplasms
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
Neoplasms
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Neoplasms
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Neoplasms
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer In Vivo.
Neoplasms
Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.
Neoplasms
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis.
Neoplasms
Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.
Neoplasms
Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis.
Neoplasms
Long-Term Combined Androgen Blockade Alone for Localized Prostate Cancer.
Neoplasms
Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
Neoplasms
Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Neoplasms
Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
Neoplasms
Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.
Neoplasms
Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
Neoplasms
Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.
Neoplasms
Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods.
Neoplasms
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Neoplasms
Macrocystic ductal adenocarcinoma of prostate: A rare gross appearance of prostate cancer.
Neoplasms
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
Neoplasms
Magnetic resonance imaging of clinically localized prostatic cancer.
Neoplasms
Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007.
Neoplasms
Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
Neoplasms
Management of high risk metastatic prostate cancer: the case for novel therapies.
Neoplasms
Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy?
Neoplasms
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
Neoplasms
Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Neoplasms
Mass screening for prostate cancer in Korea: a population based study.
Neoplasms
Matriptase and its putative role in cancer.
Neoplasms
Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies.
Neoplasms
Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Neoplasms
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Neoplasms
Metal-organic gel enhanced fluorescence anisotropy for sensitive detection of prostate specific antigen.
Neoplasms
Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum.
Neoplasms
Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters.
Neoplasms
Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.
Neoplasms
MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
Neoplasms
Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis.
Neoplasms
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Neoplasms
Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer.
Neoplasms
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Neoplasms
Molecular pathology of prostate cancer.
Neoplasms
Monocyte tissue factor levels in cancer patients.
Neoplasms
Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression.
Neoplasms
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Neoplasms
Morphometric and clinical studies on 68 consecutive radical prostatectomies.
Neoplasms
mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
Neoplasms
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Neoplasms
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
Neoplasms
Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Neoplasms
Multiplex detection platform for tumor markers and glucose in serum based on a microfluidic microparticle array.
Neoplasms
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less.
Neoplasms
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Neoplasms
N-cadherin switching occurs in high Gleason grade prostate cancer.
Neoplasms
Nanoporous gold film based immunosensor for label-free detection of cancer biomarker.
Neoplasms
National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer.
Neoplasms
Natural course of localized prostate cancer. a personal view with a review of published papers.
Neoplasms
Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
Neoplasms
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Neoplasms
Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue.
Neoplasms
Nerve-sparing radical prostatectomy: evaluation of results after 250 patients.
Neoplasms
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Neoplasms
No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Neoplasms
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Neoplasms
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.
Neoplasms
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Neoplasms
Occult prostate adenocarcinoma with pulmonary metastasis: diagnosis by fine needle aspiration biopsy of the lung and immunohistochemistry.
Neoplasms
On-a-chip Biosensing Based on All-Dielectric Nanoresonators.
Neoplasms
Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
Neoplasms
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Neoplasms
One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen.
Neoplasms
Oral administration of naturally occurring chitosan based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.
Neoplasms
Oral testosterone replacement in Korean patients with PADAM.
Neoplasms
Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens.
Neoplasms
Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
Neoplasms
Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Neoplasms
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Neoplasms
Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
Neoplasms
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Neoplasms
p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer.
Neoplasms
PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Neoplasms
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores.
Neoplasms
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
Neoplasms
Paper-based electrochemical immunoassay for rapid, inexpensive cancer biomarker protein detection.
Neoplasms
Papillary adenocarcinoma of the male urethra. Case report and review of the literature.
Neoplasms
Papillary cystoadenocarcinoma of the prostate.
Neoplasms
Parenchymal brain metastases from adenocarcinoma of prostate.
Neoplasms
Participation of older patients with prostate cancer in Medicare eligible trials.
Neoplasms
Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Neoplasms
Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
Neoplasms
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology.
Neoplasms
Pathological features of localized prostate cancer in China: a contemporary analysis of radical prostatectomy specimens.
Neoplasms
Pathological outcomes in men with prostate cancer who are eligible for active surveillance.
Neoplasms
Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Neoplasms
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Neoplasms
Patient selection and counseling before prostatic arterial embolization.
Neoplasms
Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.
Neoplasms
Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Neoplasms
Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy.
Neoplasms
Patterns of Local Failure following Radiation Therapy for Prostate Cancer.
Neoplasms
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Neoplasms
PEG-based autonomous capillary system with integrated microbead array for immunoassay.
Neoplasms
Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
Neoplasms
Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Neoplasms
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Neoplasms
Percent free PSA as an additional measure in a prostate cancer screen.
Neoplasms
Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
Neoplasms
Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Neoplasms
Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
Neoplasms
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
Neoplasms
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
Neoplasms
Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy.
Neoplasms
Personalized approach to prostate cancer prognosis.
Neoplasms
Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
Neoplasms
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
Neoplasms
Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
Neoplasms
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Neoplasms
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Neoplasms
Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance.
Neoplasms
Phyllodes tumor of the prostate: long-term followup study of 23 cases.
Neoplasms
Phyllodes tumor of the seminal vesicle: case report and literature review.
Neoplasms
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Neoplasms
Plasma sialic acid in patients with prostate cancer.
Neoplasms
Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Neoplasms
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
Neoplasms
Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
Neoplasms
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression.
Neoplasms
POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES.
Neoplasms
Practice trends in the diagnosis and management of prostate cancer in the United States.
Neoplasms
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Neoplasms
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Neoplasms
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Neoplasms
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy.
Neoplasms
Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.
Neoplasms
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Neoplasms
Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings.
Neoplasms
Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Neoplasms
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Neoplasms
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.
Neoplasms
Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Neoplasms
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Neoplasms
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.
Neoplasms
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Neoplasms
Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
Neoplasms
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Neoplasms
Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
Neoplasms
Prediction of pathological stages before prostatectomy in prostate cancer patients: Analysis of 12 systematic prostate needle biopsy specimens.
Neoplasms
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Neoplasms
Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Neoplasms
Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Neoplasms
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Neoplasms
Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Neoplasms
Predictors of prostate cancer after initial negative systematic 12 core biopsy.
Neoplasms
Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
Neoplasms
Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Neoplasms
Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study.
Neoplasms
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Neoplasms
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
Neoplasms
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer.
Neoplasms
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
Neoplasms
Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Neoplasms
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Neoplasms
Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Neoplasms
Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
Neoplasms
Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Neoplasms
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
Neoplasms
Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.
Neoplasms
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
Neoplasms
Prevalence of abnormal levels of serum tumour markers in elderly people.
Neoplasms
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Neoplasms
Prevalence of the use of cancer related self-tests by members of the public: a community survey.
Neoplasms
Primary Cribriform Carcinoma of the Eyelid With Neuroendocrine Features: A Case Report.
Neoplasms
Primary signet ring cell adenocarcinoma of the prostate treated by radical prostatectomy after preoperative androgen deprivation.
Neoplasms
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Neoplasms
Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Neoplasms
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Neoplasms
Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection.
Neoplasms
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Neoplasms
Prognostic factors in prostate cancer.
Neoplasms
Prognostic Impact of Subclassification of Radical Prostatectomy Positive Margins by Linear Extent and Gleason Grade.
Neoplasms
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Neoplasms
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Neoplasms
Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Neoplasms
Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.
Neoplasms
Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.
Neoplasms
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Neoplasms
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Neoplasms
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Neoplasms
Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey.
Neoplasms
Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group.
Neoplasms
Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.
Neoplasms
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
Neoplasms
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Neoplasms
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
Neoplasms
Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Neoplasms
Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Neoplasms
Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
Neoplasms
Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
Neoplasms
Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Neoplasms
Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.
Neoplasms
Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy.
Neoplasms
Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.
Neoplasms
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Neoplasms
Prostate cancer - Active surveillance as a management option.
Neoplasms
Prostate Cancer - What's New?
Neoplasms
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Neoplasms
Prostate cancer and microfluids.
Neoplasms
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Neoplasms
Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml.
Neoplasms
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
Neoplasms
Prostate cancer detection in veterans with a history of Agent Orange exposure.
Neoplasms
Prostate cancer detection is also relevant in low prostate specific antigen ranges.
Neoplasms
Prostate cancer diagnosed by the 5 region biopsy method is significant disease.
Neoplasms
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
Neoplasms
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Neoplasms
Prostate cancer in men using testosterone supplementation.
Neoplasms
Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
Neoplasms
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Neoplasms
Prostate cancer prevention and finasteride.
Neoplasms
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Neoplasms
Prostate cancer screening in New Zealand: lessons from the past to shape the future in the light of changing evidence.
Neoplasms
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Neoplasms
Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension.
Neoplasms
Prostate cancer volume at biopsy predicts clinically significant upgrading.
Neoplasms
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
Neoplasms
Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens.
Neoplasms
Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging.
Neoplasms
Prostate cancer: who to screen, and what the results mean.
Neoplasms
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Neoplasms
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
Neoplasms
Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
Neoplasms
Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy.
Neoplasms
Prostate imaging features that indicate benign or malignant pathology on biopsy.
Neoplasms
Prostate size does not predict high grade cancer.
Neoplasms
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Neoplasms
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
Neoplasms
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.
Neoplasms
Prostate specific antigen as tumor marker: relationship with histologic grading.
Neoplasms
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Neoplasms
Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Neoplasms
Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Neoplasms
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Neoplasms
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Neoplasms
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Neoplasms
Prostate specific antigen density in patients with histologically proven prostate carcinoma.
Neoplasms
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Neoplasms
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Neoplasms
Prostate specific antigen for early detection of prostate cancer: longitudinal study.
Neoplasms
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Neoplasms
Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
Neoplasms
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Neoplasms
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.
Neoplasms
Prostate specific antigen in the diagnosis and staging of prostate cancer.
Neoplasms
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Neoplasms
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Neoplasms
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Neoplasms
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Neoplasms
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Neoplasms
Prostate specific antigen kinetics in the management of prostate cancer.
Neoplasms
Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
Neoplasms
Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men.
Neoplasms
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Neoplasms
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Neoplasms
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Neoplasms
Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.
Neoplasms
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Neoplasms
Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Neoplasms
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Neoplasms
Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence.
Neoplasms
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Neoplasms
Prostate-specific antigen: its clinical use and application in screening for prostate cancer.
Neoplasms
Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and cancer detection.
Neoplasms
Prostatic cystic epithelial-stromal tumors: a report of 2 new cases.
Neoplasms
Prostatic intraepithelial neoplasia and prostate cancer.
Neoplasms
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
Neoplasms
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer.
Neoplasms
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
Neoplasms
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
Neoplasms
PSA and other tissue kallikreins for prostate cancer detection.
Neoplasms
PSA density (PSAD). Role in patient evaluation and management.
Neoplasms
PSA relapse prostate cancer: the importance of tailored therapy.
Neoplasms
PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Neoplasms
PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Neoplasms
Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence.
Neoplasms
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Neoplasms
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Neoplasms
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
Neoplasms
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.
Neoplasms
Quantitative, label-free detection of five protein biomarkers using multiplexed arrays of silicon photonic microring resonators.
Neoplasms
Race is not a predictor of prostate cancer detection on repeat prostate biopsy.
Neoplasms
Racial differences in a prostate cancer screening study.
Neoplasms
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
Neoplasms
Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
Neoplasms
Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view.
Neoplasms
Radical perineal prostatectomy: a model for evaluating local response of prostate therapy.
Neoplasms
Radical perineal prostatectomy: oncological outcome during a 20-year period.
Neoplasms
Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Neoplasms
Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Neoplasms
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
Neoplasms
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Neoplasms
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
Neoplasms
Radical prostatectomy in men less than 50 years old.
Neoplasms
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.
Neoplasms
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Neoplasms
Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
Neoplasms
Rapid chemiluminescent sandwich enzyme immunoassay capable of consecutively quantifying multiple tumor markers in a sample.
Neoplasms
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
Neoplasms
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Neoplasms
Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
Neoplasms
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.
Neoplasms
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Neoplasms
Re: Short Term Outcomes of Prostate Biopsy in Men Tested for Cancer by Prostate Specific Antigen: Prospective Evaluation Within ProtecT Study.
Neoplasms
Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors.
Neoplasms
Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
Neoplasms
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness.
Neoplasms
Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1'-S-1'-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors.
Neoplasms
Reconnoitring the status of prostate specific antigen and its role in women.
Neoplasms
Rectal Invasion by Prostatic Adenocarcinoma That Was Initially Diagnosed in a Rectal Polyp on Colonoscopy.
Neoplasms
Recurrent prostate cancer despite undetectable prostate specific antigen.
Neoplasms
Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.
Neoplasms
Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Neoplasms
Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.
Neoplasms
Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy.
Neoplasms
Repeat prostate-specific antigen test before prostate biopsy: a 20% decrease in prostate specific antigen values is associated with a reduced risk of cancer and particularly of high-grade cancer.
Neoplasms
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.
Neoplasms
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Neoplasms
Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.
Neoplasms
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Neoplasms
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Neoplasms
Results of compliance with prostate cancer screening guidelines.
Neoplasms
Rh2 synergistically enhances Paclitaxel or mitoxantrone in prostate cancer models.
Neoplasms
Rising prostate specific antigen after radical prostatectomy: a case based review.
Neoplasms
Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test.
Neoplasms
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Neoplasms
Risk of suicide in men with low-risk prostate cancer.
Neoplasms
Robust, Highly Visible, and Facile Bioconjugation Colloidal Crystal Beads for Bioassay.
Neoplasms
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.
Neoplasms
Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.
Neoplasms
Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer.
Neoplasms
Rolling circle amplification integrated with suspension bead array for ultrasensitive multiplex immunodetection of tumor markers.
Neoplasms
Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice.
Neoplasms
Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer.
Neoplasms
Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
Neoplasms
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
Neoplasms
Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours.
Neoplasms
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Neoplasms
Screening and early detection for prostate cancer.
Neoplasms
Screening for cancer. Is it useful?
Neoplasms
Screening for carcinoma of the prostate: a GP based study.
Neoplasms
Screening for familial and hereditary prostate cancer.
Neoplasms
Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.
Neoplasms
Screening for occult nodal metastasis in localized carcinoma of the prostate.
Neoplasms
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Neoplasms
Screening of prostate cancer in males with prostatism.
Neoplasms
Secondary signet ring cell carcinoma of prostate.
Neoplasms
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.
Neoplasms
Selenium: epidemiology and basic science.
Neoplasms
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Neoplasms
Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction.
Neoplasms
Sensitive electrochemical immunosensor for cancer biomarker with signal enhancement based on nitrodopamine-functionalized iron oxide nanoparticles.
Neoplasms
Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Neoplasms
Serial analysis of gene expression (SAGE) in the rat limbal and central corneal epithelium.
Neoplasms
Serial biopsy results in prostate cancer screening study.
Neoplasms
Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
Neoplasms
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
Neoplasms
Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens.
Neoplasms
Serum ceruloplasmin as a marker in prostate cancer.
Neoplasms
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Neoplasms
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Neoplasms
Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study.
Neoplasms
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Neoplasms
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Neoplasms
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Neoplasms
Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones.
Neoplasms
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Neoplasms
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Neoplasms
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
Neoplasms
Serum tumor markers in hemodialysis patients.
Neoplasms
Serum tumor markers in patients on dialysis and kidney transplantation.
Neoplasms
Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Neoplasms
Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens.
Neoplasms
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
Neoplasms
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial.
Neoplasms
Signet-ring carcinoma of the prostate.
Neoplasms
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Neoplasms
Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens.
Neoplasms
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
Neoplasms
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.
Neoplasms
Simultaneous Detection of Multiple Tumor Markers in Blood by Functional Liquid Crystal Sensors Assisted with Target-Induced Dissociation of Aptamer.
Neoplasms
Single Molecule Upconversion-Linked Immunosorbent Assay with Extended Dynamic Range for the Sensitive Detection of Diagnostic Biomarkers.
Neoplasms
Single port robotic radical prostatectomy: a systematic review.
Neoplasms
Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review.
Neoplasms
Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.
Neoplasms
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study.
Neoplasms
Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups.
Neoplasms
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Neoplasms
Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study.
Neoplasms
Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy.
Neoplasms
Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate.
Neoplasms
Staging laparoscopic pelvic lymph node dissection: comparison of results with open pelvic lymphadenectomy.
Neoplasms
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
Neoplasms
Status of External Quality Assessment on Tumor Markers in China.
Neoplasms
Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Neoplasms
Stopping screening, when and how?
Neoplasms
Storm over screening for prostate specific antigen. Give men facts on prostate cancer.
Neoplasms
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Neoplasms
Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.
Neoplasms
Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Neoplasms
Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Neoplasms
Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation.
Neoplasms
Sulfur inhibits the growth of androgen-independent prostate cancer in vivo.
Neoplasms
Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Neoplasms
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Neoplasms
Survival in blacks and whites after treatment for localized prostate cancer.
Neoplasms
Susceptibility Loci associations with prostate cancer risk in northern chinese men.
Neoplasms
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
Neoplasms
Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk.
Neoplasms
Systemic radioligand therapy with (177)Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer.
Neoplasms
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
Neoplasms
Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.
Neoplasms
Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification.
Neoplasms
Targeting kallikrein-related peptidases in prostate cancer.
Neoplasms
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
Neoplasms
Targeting thapsigargin towards tumors.
Neoplasms
Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen.
Neoplasms
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy.
Neoplasms
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Neoplasms
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Neoplasms
The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.
Neoplasms
The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male.
Neoplasms
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
Neoplasms
The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model.
Neoplasms
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
Neoplasms
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
Neoplasms
The association between total prostate specific antigen concentration and prostate specific antigen velocity.
Neoplasms
The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer.
Neoplasms
The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
Neoplasms
The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
Neoplasms
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
Neoplasms
The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Neoplasms
The correlation of stage and pathology of prostate cancer in Japan.
Neoplasms
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
Neoplasms
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
Neoplasms
The effect of antibiotics on elevated serum prostate specific antigen in patients with urinary symptoms and negative digital rectal examination: a pilot study.
Neoplasms
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Neoplasms
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.
Neoplasms
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
Neoplasms
The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels.
Neoplasms
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
Neoplasms
The epidemic of prostate cancer and the medical literature: a causal association?
Neoplasms
The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Neoplasms
The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
Neoplasms
The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Neoplasms
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
Neoplasms
The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate.
Neoplasms
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
Neoplasms
The Impact of Clinical Stage on Prostate Cancer Survival Following Radical Prostatectomy.
Neoplasms
The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.
Neoplasms
The impact of intra-operative cell salvage during open radical prostatectomy.
Neoplasms
The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
Neoplasms
The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure.
Neoplasms
The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
Neoplasms
The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies.
Neoplasms
The independent impact of extended pattern biopsy on prostate cancer stage migration.
Neoplasms
The influence of age, sex and race on salivary kallikrein levels in human mixed saliva.
Neoplasms
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Neoplasms
The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy.
Neoplasms
The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Neoplasms
The malignancy index in plasma samples as a prostate cancer biomarker.
Neoplasms
The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients.
Neoplasms
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
Neoplasms
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Neoplasms
The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies.
Neoplasms
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Neoplasms
The new human kallikrein gene family: implications in carcinogenesis.
Neoplasms
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy.
Neoplasms
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
Neoplasms
The older the better: The characteristic of localized prostate cancer in Chinese men.
Neoplasms
The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram.
Neoplasms
The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Neoplasms
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
Neoplasms
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Neoplasms
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
Neoplasms
The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
Neoplasms
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
Neoplasms
The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Neoplasms
The prognostic value of inducible nitric oxide synthase in local prostate cancer.
Neoplasms
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Neoplasms
The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.
Neoplasms
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Neoplasms
The prostate specific antigen. Its use as a tumor marker for prostate cancer.
Neoplasms
The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Neoplasms
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.
Neoplasms
The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Neoplasms
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
Neoplasms
The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
Neoplasms
The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
Neoplasms
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Neoplasms
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
Neoplasms
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
Neoplasms
The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study.
Neoplasms
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
Neoplasms
The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
Neoplasms
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against.
Neoplasms
The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
Neoplasms
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
Neoplasms
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted.
Neoplasms
The significance of isoechoic prostatic carcinoma.
Neoplasms
The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor.
Neoplasms
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Neoplasms
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.
Neoplasms
The treatment of prostate cancer: how is failure defined and how can it be minimized?
Neoplasms
The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
Neoplasms
The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen.
Neoplasms
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Neoplasms
The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml.
Neoplasms
The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma.
Neoplasms
The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy.
Neoplasms
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
Neoplasms
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Neoplasms
Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.
Neoplasms
Time trends in pathologic features of radical prostatectomy--impact of family history.
Neoplasms
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Neoplasms
Tissue Biomarkers for Prostate Cancer Radiation Therapy.
Neoplasms
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Neoplasms
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Neoplasms
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Neoplasms
Touch preparation cytological evaluation of radical prostatectomy specimens.
Neoplasms
Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Neoplasms
Transformation of prostatic adenocarcinoma to well differentiated neuroendocrine tumor after hormonal treatment.
Neoplasms
Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
Neoplasms
Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Neoplasms
Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Neoplasms
Transperineal prostate biopsy after abdominoperineal resection.
Neoplasms
Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study.
Neoplasms
Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
Neoplasms
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Neoplasms
Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor.
Neoplasms
Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data.
Neoplasms
Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method.
Neoplasms
Tumor marker requests in a general teaching Turkish hospital.
Neoplasms
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
Neoplasms
Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability.
Neoplasms
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Neoplasms
Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors.
Neoplasms
Tumour markers as prognostic aids in prostatic carcinoma.
Neoplasms
Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Neoplasms
Tumour markers in prostatic cancer.
Neoplasms
Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells.
Neoplasms
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen.
Neoplasms
Ultra-sensitive protein detection via Single Molecule Arrays towards early stage cancer monitoring.
Neoplasms
Ultrasensitive Detection of Dual Cancer Biomarkers with Integrated CMOS-Compatible Nanowire Arrays.
Neoplasms
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
Neoplasms
Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers.
Neoplasms
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Neoplasms
Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.
Neoplasms
Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.
Neoplasms
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Neoplasms
Urinary PSA level and relative tumor volume after prostate biopsy.
Neoplasms
Urinary tissue factor levels in neoplastic diseases.
Neoplasms
Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread?
Neoplasms
Use of common seric tumor markers in patients with solid cancers.
Neoplasms
Use of quality indicators to evaluate the care of patients with localized prostate carcinoma.
Neoplasms
Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer.
Neoplasms
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Neoplasms
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Neoplasms
Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples.
Neoplasms
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection.
Neoplasms
Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Neoplasms
Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.
Neoplasms
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
Neoplasms
Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Neoplasms
Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy.
Neoplasms
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.
Neoplasms
Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
Neoplasms
Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy.
Neoplasms
Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.
Neoplasms
Virus encoded circulatory miRNAs for early detection of prostate cancer.
Neoplasms
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.
Neoplasms
Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Neoplasms
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Neoplasms
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Neoplasms
Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience.
Neoplasms
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.
Neoplasms
Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
Neoplasms
Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.
Neoplasms
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Neoplasms
What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy?
Neoplasms
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Neoplasms
Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Neoplasms
Words of wisdom. Re: Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
Neoplasms
Zonal biopsy in the detection of prostate cancer in Japanese men.
Neoplasms
Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer.
Neoplasms
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Neoplasms
[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
Neoplasms
[A case of clear cell adenocarcinoma of the female urethra]
Neoplasms
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
Neoplasms
[A case of prostate cancer presenting as extensive abdominal metastasis].
Neoplasms
[A case of prostate cancer that developed following transurethral resection of the prostate: diagnostic efficiency of diffusion-weighted images on magnetic resonance imaging]
Neoplasms
[A Case Report : Primary Urothelial Carcinoma of the Prostate Producing Interleukin-6 Detected from a Fever].
Neoplasms
[A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential].
Neoplasms
[A preliminar mathematical model for patients with a previous negative prostate biopsy]
Neoplasms
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Neoplasms
[Adenocarcinoma of the prostate]
Neoplasms
[Apoptosis in pathologic prostatic processes]
Neoplasms
[Application of angiotensin II receptor blocker in prostate cancer]
Neoplasms
[Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer]
Neoplasms
[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers]
Neoplasms
[Cancer of the prostate: influence of nutritional factors. A new nutritional approach]
Neoplasms
[Changes in tumor markers following cryosurgery of prostate carcinoma]
Neoplasms
[Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels]
Neoplasms
[Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer]
Neoplasms
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Neoplasms
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
Neoplasms
[Clinical studies of stage D2 prostatic cancer]
Neoplasms
[Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years]
Neoplasms
[Clinical study of tumor marker in prostatic carcinoma--clinical significance of the prostate specific antigen (PA)]
Neoplasms
[Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate]
Neoplasms
[Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations]
Neoplasms
[Comparison of tumor markers versus their relative values to prostatic volume in detecting prostate cancer]
Neoplasms
[Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients].
Neoplasms
[Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer]
Neoplasms
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]
Neoplasms
[Digital rectal examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate cancer in clinical urological practice-detection of impalpable cancer]
Neoplasms
[Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors]
Neoplasms
[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma]
Neoplasms
[Docetaxel for small cell carcinoma of the prostate with a metastatic pelvic tumor : a case report].
Neoplasms
[Early detection and follow-up of prostatic carcinoma. Responsibilities of the general practitioner]
Neoplasms
[Early detection of prostate cancer: a summary of the past 10 years].
Neoplasms
[Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice]
Neoplasms
[Effects of digital rectal examination on serum prostate specific antigen]
Neoplasms
[Establishment of reference intervals of tumor markers in Korean adults]
Neoplasms
[Examination of prostate biopsy among Japanese with less than 4.0 ng/ml prostate specific antigen--usefulness of free/total PSA ratio]
Neoplasms
[Expression of endocrine-paracrine cells in prostatic carcinoma]
Neoplasms
[Giant prostate carcinoma treated effectively with endocrine therapy: case report]
Neoplasms
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
Neoplasms
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
Neoplasms
[Laparoscopic pelvic lymphadenectomy in patients with localized prostate cancer]
Neoplasms
[Lymphatic involvement predominating and revealing prostatic carcinoma]
Neoplasms
[Mass screening for prostate cancer in Nagano]
Neoplasms
[Mucinous adenocarcinoma of the prostatic gland. Histochemical and immunohistochemical studies]
Neoplasms
[National external quality assessment and comparability of assays for tumor markers measurements]
Neoplasms
[Occult cancer in patients with symptomatic benign prostatic hyperplasia]
Neoplasms
[Ophthalmoplegia in a patient with prostate cancer and bone metastases]
Neoplasms
[Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate]
Neoplasms
[Potential of ultrasonography and ultrasonography-guided biopsy in the diagnosis of local recurrence following radical prostatectomy]
Neoplasms
[Preliminary data on our laparoscopy experience in urinary pathology]
Neoplasms
[Prognosis in stage a prostate cancer]
Neoplasms
[Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report]
Neoplasms
[Prostate cancer]
Neoplasms
[Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml]
Neoplasms
[Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate]
Neoplasms
[Prostate specific antigen and diagnosis of prostate cancer]
Neoplasms
[Prostate specific antigen. Clinical applications of ultrasensitive assay]
Neoplasms
[Prostate specific antigen: its proper diagnostic use]
Neoplasms
[Prostate-specific antigen as a tumor marker of prostate carcinoma]
Neoplasms
[Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia]
Neoplasms
[Prostatic carcinoid and neuroendocrine tumors--a case report]
Neoplasms
[Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen]
Neoplasms
[PSA in early detection of prostate cancer and course of disease]
Neoplasms
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
Neoplasms
[Recent improvements and results of radical prostatectomy]
Neoplasms
[Rectal involvement by prostate carcinoma: a report of three cases]
Neoplasms
[Reference values of prostate specific antigen (PSA) in 63926 workers without prostatic symptoms who participated in prostate screening cancer developed by the Ibermutuamur Prevention Society in 2006]
Neoplasms
[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]
Neoplasms
[Selective application of tumor markers PSA]
Neoplasms
[Sense and nonsense of tumor markers in practice]
Neoplasms
[Sensitivity and specificity evaluation of endorectal magnetic resonance imaging and transrectal sonography in the staging of prostate cancer.]
Neoplasms
[Significance of the PSA-concentration for the detection of prostate cancer]
Neoplasms
[Skip metastasis of prostate cancer: diagnosis and treatment]
Neoplasms
[Spermatic cord liposarcoma. Association with prostate cancer. Report of a case and review of literature]
Neoplasms
[Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer]
Neoplasms
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer]
Neoplasms
[The incidence, mortality and risk factors of prostate cancer].
Neoplasms
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Neoplasms
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]
Neoplasms
[The role of PSA in diagnosis of prostate cancer and its recurrence]
Neoplasms
[Transrectal ultrasound examination of the prostate in 100 cases of prostate cancer]
Neoplasms
[Treatment of metastatic prostate cancer: certainty and doubts]
Neoplasms
[TROUSSEAU'S SYNDROME ACCOMPANIED BY ADVANCED PROSTATE CANCER THAT DEVELOPED ISCHEMIC STROKE; A CASE REPORT].
Neoplasms
[Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]
Neoplasms
[Tumor markers of urinary tract carcinoma]
Neoplasms
[Use of prostate specific antigen. A review]
Neoplasms
[Usefulness of free prostate specific antigen in the detection of prostate cancer]
Neoplasms
[Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer]
Neoplasms
[When should bone scanning be carried out in prostatic cancer?]
Neoplasms, Germ Cell and Embryonal
Human tissue kallikreins and testicular cancer.
Neoplasms, Second Primary
The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Neoplastic Cells, Circulating
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Neoplastic Cells, Circulating
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Neoplastic Cells, Circulating
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Neoplastic Cells, Circulating
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Neoplastic Cells, Circulating
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Neoplastic Cells, Circulating
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Neoplastic Cells, Circulating
Prostate cancer and microfluids.
Neoplastic Cells, Circulating
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Neoplastic Cells, Circulating
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Nervous System Diseases
Treatment options for benign prostatic hyperplasia in older men.
Neuroblastoma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Neuroblastoma
Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model.
Neuroendocrine Tumors
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Neuroendocrine Tumors
Pure small cell carcinoma of the prostate.
Neuroendocrine Tumors
Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Neuroinflammatory Diseases
Human Urinary Kallidinogenase Reduces Lipopolysaccharide-Induced Neuroinflammation and Oxidative Stress in BV-2 Cells.
Newcastle Disease
Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.
Non-alcoholic Fatty Liver Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Obesity
Age and Obesity Promote Methylation and Suppression of 5?-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
Obesity
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Obesity
Association of Body Mass Index With Prostate Cancer Biochemical Failure.
Obesity
Association of obesity with prostate specific antigen and prostate specific antigen velocity in healthy young men.
Obesity
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Obesity
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Obesity
Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population.
Obesity
Health risk behaviors and prostate specific antigen awareness among men in California.
Obesity
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.
Obesity
Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy.
Obesity
Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.
Obesity
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Obesity
Obesity and prostate cancer.
Obesity
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
Obesity
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
Obesity
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Obesity
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Obesity
Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
Obesity
Renal functional reserve in obesity hypertension.
Obesity
Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.
Obesity
The inverse relationship between prostate specific antigen (PSA) and obesity
Obesity
The inverse relationship between prostate specific antigen (PSA) and obesity.
Obesity
The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
Obesity
[Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen].
Obesity, Abdominal
Effect of central obesity on prostate specific antigen measured by computerized tomography: related markers and prostate volume.
Oligospermia
Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases.
Osteoarthritis
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
Osteoarthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Osteoporosis
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation.
Otitis Media
A top 5 list for French general practice.
Otitis Media with Effusion
A top 5 list for French general practice.
Ovarian Neoplasms
A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.
Ovarian Neoplasms
A novel protease homolog differentially expressed in breast and ovarian cancer.
Ovarian Neoplasms
Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site.
Ovarian Neoplasms
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Ovarian Neoplasms
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.
Ovarian Neoplasms
Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.
Ovarian Neoplasms
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Ovarian Neoplasms
Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm.
Ovarian Neoplasms
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Ovarian Neoplasms
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Ovarian Neoplasms
Prostate specific antigen (PSA) in breast and ovarian cancer.
Ovarian Neoplasms
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Ovarian Neoplasms
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.
Overweight
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Overweight
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Pancreatic Neoplasms
Combining diagnostic test results to increase accuracy.
Pancreatic Neoplasms
Urinary kallikrein excretion in chronic pancreatic diseases.
Pancreatitis
Expression and characterization of human tissue kallikrein variants.
Pancreatitis
Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.
Pancreatitis
Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.
Pancreatitis
Kallikrein, kininogen and kinins in control of blood pressure.
Pancreatitis
Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.
Pancreatitis
Role of the kallikrein-kinin system in human pancreatitis.
Pancreatitis
Studies on the release of tissue kallikrein in experimental pancreatitis in the pig.
Pancreatitis
Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
Pancreatitis
Urinary kallikrein excretion in chronic pancreatic diseases.
Pancreatitis
[Enzyme liberation and activation of the kallikrein-kinin system in experimental pancreatitis. Studies of portal vein blood, pancreatic lymph and peritoneal effusion]
Pancreatitis, Acute Necrotizing
Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
Pancytopenia
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Paralysis
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Parkinson Disease
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Parotitis
Effect of radioactive iodine therapy on parotid gland function.
Parotitis
New concepts in the treatment of chronic recurrent parotitis.
Parotitis
[Glandular kallikrein in chronic recurrent parotitis]
Parotitis
[Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)]
Pemphigus
Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem).
Periodontal Diseases
Blood flow, collagen components of oral tissue and salivary kallikrein in young to senescent, germfree and conventional rats. A study on the etiologic factors of periodontal disease.
Periodontal Diseases
Salivary kallikrein and kininase activities in periodontal diseases.
Periodontal Diseases
[Role of salivary kallikrein in the pathogenesis of periodontosis]
Periodontal Pocket
[Experimental periodontitis in rats]
Peripheral Arterial Disease
Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.
Pheochromocytoma
Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.
Pituitary Diseases
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Pituitary Neoplasms
Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours.
Pituitary Neoplasms
Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenoma.
Pituitary Neoplasms
Elevated glandular kallikrein in estrogen-induced pituitary tumors.
Pituitary Neoplasms
Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin.
Pituitary Neoplasms
Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Pituitary Neoplasms
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
plasma kallikrein deficiency
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
Pleural Effusion, Malignant
[Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer]
Pneumonia
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Pneumonia
Granzyme K activates protease-activated receptor-1.
Pneumonia
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Polycystic Ovary Syndrome
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Polycystic Ovary Syndrome
Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome.
Polycystic Ovary Syndrome
Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight.
Polycystic Ovary Syndrome
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination.
Polycystic Ovary Syndrome
The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs).
Polycythemia
[Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy]
Pre-Eclampsia
Localisation of tissue kallikrein in the kidney of black African women with early onset pre-eclampsia: a pilot study.
Pre-Eclampsia
Plasma concentrations of tissue kallikrein in normal and preeclamptic pregnancies.
Pre-Eclampsia
Tissue kallikrein activity in pregnancy.
Pre-Eclampsia
Urinary tissue kallikrein excretion in black African women with severe pre-eclampsia.
Proctitis
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Prolactinoma
Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours.
Prolactinoma
Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Prolactinoma
Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Prolactinoma
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Prostatic Diseases
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
Prostatic Diseases
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Prostatic Diseases
Case report. Two contrasting radiological presentations of prostatic adenocarcinoma in the jaws.
Prostatic Diseases
Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Prostatic Diseases
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Prostatic Diseases
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Prostatic Diseases
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Prostatic Diseases
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
Prostatic Diseases
Expression of prostate specific antigen in male breast cancer.
Prostatic Diseases
Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
Prostatic Diseases
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Prostatic Diseases
Kappa statistics in the screening of malignancy of prostate.
Prostatic Diseases
Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts.
Prostatic Diseases
New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease.
Prostatic Diseases
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Prostatic Diseases
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Prostatic Diseases
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
Prostatic Diseases
Prostate-specific antigen density: a new prognostic indicator for prostate cancer.
Prostatic Diseases
Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer.
Prostatic Diseases
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Prostatic Diseases
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients.
Prostatic Diseases
The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys.
Prostatic Diseases
The lady with raised prostate specific antigen: do we need to worry?
Prostatic Diseases
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Prostatic Diseases
[A mass screening of the prostatic diseases and serum prostate specific antigen]
Prostatic Diseases
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]
Prostatic Diseases
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]
Prostatic Diseases
[Influence of age on serum prostate specific antigen concentration]
Prostatic Diseases
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]
Prostatic Diseases
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]
Prostatic Hyperplasia
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prostatic Hyperplasia
A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening.
Prostatic Hyperplasia
A rational approach to benign prostatic hyperplasia evaluation: recent advances.
Prostatic Hyperplasia
A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
Prostatic Hyperplasia
A study of prostane in the treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
Prostatic Hyperplasia
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Prostatic Hyperplasia
An evaluation of prostate specific antigen in prostatic cancer.
Prostatic Hyperplasia
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Prostatic Hyperplasia
Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.
Prostatic Hyperplasia
Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
Prostatic Hyperplasia
Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Prostatic Hyperplasia
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
Prostatic Hyperplasia
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Prostatic Hyperplasia
Bleeding and activation of coagulation during and after transurethral prostatectomy: importance of the acute-phase response and prostate specific antigen?
Prostatic Hyperplasia
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Prostatic Hyperplasia
Changing trends in the management of prostatic disease in a single private practice: a 5-year followup.
Prostatic Hyperplasia
Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men.
Prostatic Hyperplasia
Clinical use of prostate specific antigen in patients with prostate cancer.
Prostatic Hyperplasia
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Prostatic Hyperplasia
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Prostatic Hyperplasia
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Prostatic Hyperplasia
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Prostatic Hyperplasia
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Prostatic Hyperplasia
Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia.
Prostatic Hyperplasia
Determinants of ejaculatory dysfunction in a community-based longitudinal study.
Prostatic Hyperplasia
Determination of transition zone volume by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: agreement with enucleated prostate adenoma weight.
Prostatic Hyperplasia
Development and initial evaluation of a novel urology curriculum for medical students.
Prostatic Hyperplasia
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Prostatic Hyperplasia
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Prostatic Hyperplasia
Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy.
Prostatic Hyperplasia
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Prostatic Hyperplasia
Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Prostatic Hyperplasia
Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia.
Prostatic Hyperplasia
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.
Prostatic Hyperplasia
Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
Prostatic Hyperplasia
Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.
Prostatic Hyperplasia
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
Prostatic Hyperplasia
Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation.
Prostatic Hyperplasia
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Prostatic Hyperplasia
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Prostatic Hyperplasia
Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer.
Prostatic Hyperplasia
Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
Prostatic Hyperplasia
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Prostatic Hyperplasia
Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues.
Prostatic Hyperplasia
First clinical results with Enzymun-Test for free PSA.
Prostatic Hyperplasia
Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Prostatic Hyperplasia
Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.
Prostatic Hyperplasia
GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition.
Prostatic Hyperplasia
Holmium laser enucleation of the prostate--outcomes independent of prostate size?
Prostatic Hyperplasia
Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein.
Prostatic Hyperplasia
IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease?
Prostatic Hyperplasia
Impact of Prostate Specific Antigen and Testosterone Hormone Levels in Patients of Benign Prostatic Hyperplasia in Khartoum State-Sudan.
Prostatic Hyperplasia
Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Prostatic Hyperplasia
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Prostatic Hyperplasia
Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value.
Prostatic Hyperplasia
Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value.
Prostatic Hyperplasia
Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen.
Prostatic Hyperplasia
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Prostatic Hyperplasia
Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Prostatic Hyperplasia
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Prostatic Hyperplasia
Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?
Prostatic Hyperplasia
Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment.
Prostatic Hyperplasia
Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
MOLECULAR MARKERS ASSOCIATED WITH PROSTATE CANCER: 3-NITROTYROSINE AND GENETIC AND PROTEIC EXPRESSION OF MN-SUPEROXIDE DISMUTASA (MN-SOD).
Prostatic Hyperplasia
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Prostatic Hyperplasia
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Prostatic Hyperplasia
Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis.
Prostatic Hyperplasia
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Prostatic Hyperplasia
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Prevention of benign prostatic hyperplasia disease.
Prostatic Hyperplasia
Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Prostate cancer detection in candidates for open prostatectomy.
Prostatic Hyperplasia
Prostate cancer prevention and finasteride.
Prostatic Hyperplasia
Prostate specific antigen and benign prostatic hyperplasia.
Prostatic Hyperplasia
Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia.
Prostatic Hyperplasia
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Prostatic Hyperplasia
Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Prostatic Hyperplasia
Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Prostatic Hyperplasia
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Prostatic Hyperplasia
Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Prostatic Hyperplasia
Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Prostatic Hyperplasia
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Prostatic Hyperplasia
Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Prostatic Hyperplasia
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Prostatic Hyperplasia
Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy.
Prostatic Hyperplasia
Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
Prostatic Hyperplasia
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Prostatic Hyperplasia
Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Prostatic Hyperplasia
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Prostatic Hyperplasia
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Prostatic Hyperplasia
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Prostatic Hyperplasia
Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Prostatic Hyperplasia
Relationship among lymphocytes, free/total prostate specific antigen, lower urinary tract symptoms and prostatic inflammation in benign prostatic hyperplasia patients.
Prostatic Hyperplasia
Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma.
Prostatic Hyperplasia
Relationship between prostate specific antigen, prostate volume and age in the benign prostate.
Prostatic Hyperplasia
Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
Prostatic Hyperplasia
Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Prostatic Hyperplasia
Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Prostatic Hyperplasia
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Prostatic Hyperplasia
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Prostatic Hyperplasia
Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Prostatic Hyperplasia
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Prostatic Hyperplasia
Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
Prostatic Hyperplasia
Serum prostate specific antigen levels during hyperthermia treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Prostatic Hyperplasia
Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml.
Prostatic Hyperplasia
Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia.
Prostatic Hyperplasia
The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Prostatic Hyperplasia
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Prostatic Hyperplasia
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Prostatic Hyperplasia
The effect of finasteride on prostate specific antigen: review of available data.
Prostatic Hyperplasia
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Prostatic Hyperplasia
The effects of ejaculation on serum prostate specific antigen.
Prostatic Hyperplasia
The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels.
Prostatic Hyperplasia
The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride.
Prostatic Hyperplasia
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia.
Prostatic Hyperplasia
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
Prostatic Hyperplasia
The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
Prostatic Hyperplasia
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
Prostatic Hyperplasia
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Prostatic Hyperplasia
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
Prostatic Hyperplasia
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Prostatic Hyperplasia
The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Prostatic Hyperplasia
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
Prostatic Hyperplasia
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Prostatic Hyperplasia
Trends in diagnosis of stage T1a-b prostate cancer.
Prostatic Hyperplasia
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.
Prostatic Hyperplasia
Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men.
Prostatic Hyperplasia
Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group.
Prostatic Hyperplasia
Validity of digital rectal examination in the era of prostate specific antigen.
Prostatic Hyperplasia
Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
Prostatic Hyperplasia
[Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
Prostatic Hyperplasia
[Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen].
Prostatic Hyperplasia
[Benign prostatic hypertrophy with high levels of gamma-seminoprotein (gamma-Sm), prostate specific antigen: report of two cases]
Prostatic Hyperplasia
[Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Prostatic Hyperplasia
[Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer]
Prostatic Hyperplasia
[Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer]
Prostatic Hyperplasia
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer]
Prostatic Hyperplasia
[Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia]
Prostatic Hyperplasia
[Prostate carcinoma: prostate-specific antigen--and then what?]
Prostatic Hyperplasia
[Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay]
Prostatic Hyperplasia
[Prostate-specific antigen. The role in the prostate cancer diagnosis].
Prostatic Hyperplasia
[Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer]
Prostatic Hyperplasia
[Purification and determination of human prostate specific antigen in the serum]
Prostatic Hyperplasia
[Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia]
Prostatic Hyperplasia
[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer]
Prostatic Hyperplasia
[Significance of various examination methods in the management of prostatic cancer]
Prostatic Hyperplasia
[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method]
Prostatic Hyperplasia
[Two cases of mucinous adenocarcinoma of the prostate]
Prostatic Hyperplasia
[Validity of digital rectal examination of prostate specific antigen]
Prostatic Hyperplasia
[Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia]
Prostatic Hyperplasia
[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention]
Prostatic Intraepithelial Neoplasia
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
Prostatic Intraepithelial Neoplasia
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
Prostatic Intraepithelial Neoplasia
Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Prostatic Intraepithelial Neoplasia
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Prostatic Intraepithelial Neoplasia
Chemoprevention of prostate cancer with nutrients and supplements.
Prostatic Intraepithelial Neoplasia
Chemoprevention of prostate cancer: agents and study designs.
Prostatic Intraepithelial Neoplasia
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Prostatic Intraepithelial Neoplasia
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Prostatic Intraepithelial Neoplasia
Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer.
Prostatic Intraepithelial Neoplasia
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Prostatic Intraepithelial Neoplasia
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
Prostatic Intraepithelial Neoplasia
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
Prostatic Intraepithelial Neoplasia
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Prostatic Intraepithelial Neoplasia
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Prostatic Intraepithelial Neoplasia
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Prostatic Intraepithelial Neoplasia
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Prostatic Intraepithelial Neoplasia
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
Prostatic Intraepithelial Neoplasia
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Prostatic Intraepithelial Neoplasia
Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Prostatic Intraepithelial Neoplasia
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Prostatic Intraepithelial Neoplasia
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prostatic Intraepithelial Neoplasia
Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.
Prostatic Intraepithelial Neoplasia
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Prostatic Intraepithelial Neoplasia
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
Prostatic Intraepithelial Neoplasia
Prostatic intraepithelial neoplasia and prostate cancer.
Prostatic Intraepithelial Neoplasia
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
Prostatic Intraepithelial Neoplasia
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer.
Prostatic Intraepithelial Neoplasia
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Prostatic Intraepithelial Neoplasia
Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk.
Prostatic Intraepithelial Neoplasia
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Prostatic Intraepithelial Neoplasia
The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
Prostatic Intraepithelial Neoplasia
The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies.
Prostatic Intraepithelial Neoplasia
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Prostatic Intraepithelial Neoplasia
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
Prostatic Intraepithelial Neoplasia
Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.
Prostatic Neoplasms
"Mix-to-Go" Silver Colloidal Strategy for Prostate Cancer Molecular Profiling and Risk Prediction.
Prostatic Neoplasms
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.
Prostatic Neoplasms
'Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS).
Prostatic Neoplasms
(18)F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
Prostatic Neoplasms
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
Prostatic Neoplasms
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
Prostatic Neoplasms
(99m)Tc-MDP uptake in SPECT/CT by a bladder hernia simulating inguinal metastasis: A case report.
Prostatic Neoplasms
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Prostatic Neoplasms
11C-choline PET/CT predicts survival in prostate cancer patients with PSA?1 NG/ml.
Prostatic Neoplasms
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Prostatic Neoplasms
18F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.
Prostatic Neoplasms
18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
Prostatic Neoplasms
2-Methoxyestradiol, a promising anticancer agent.
Prostatic Neoplasms
25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.
Prostatic Neoplasms
25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy.
Prostatic Neoplasms
25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology.
Prostatic Neoplasms
25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series.
Prostatic Neoplasms
2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
Prostatic Neoplasms
3D label-free prostate specific antigen (PSA) immunosensor based on graphene-gold composites.
Prostatic Neoplasms
3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
Prostatic Neoplasms
4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Prostatic Neoplasms
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
Prostatic Neoplasms
55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor.
Prostatic Neoplasms
5?-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy.
Prostatic Neoplasms
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
Prostatic Neoplasms
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Prostatic Neoplasms
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Prostatic Neoplasms
A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.
Prostatic Neoplasms
A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
Prostatic Neoplasms
A case of Sister Mary Joseph's nodule from prostatic cancer.
Prostatic Neoplasms
A case study: ductal adenocarcinoma of the prostate.
Prostatic Neoplasms
A centralized comparison of radical perineal and retropubic prostatectomy specimens: is there a difference according to the surgical approach?
Prostatic Neoplasms
A chemiluminescent dual-aptasensor capable of simultaneously quantifying prostate specific antigen and vascular endothelial growth factor.
Prostatic Neoplasms
A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.
Prostatic Neoplasms
A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT.
Prostatic Neoplasms
A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
Prostatic Neoplasms
A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models.
Prostatic Neoplasms
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Prostatic Neoplasms
A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995.
Prostatic Neoplasms
A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer.
Prostatic Neoplasms
A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
Prostatic Neoplasms
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prostatic Neoplasms
A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.
Prostatic Neoplasms
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience.
Prostatic Neoplasms
A deep imputation and inference framework for estimating personalized and race-specific causal effects of genomic alterations on PSA.
Prostatic Neoplasms
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
Prostatic Neoplasms
A dual-round signal amplification strategy for colorimetric/photoacoustic/fluorescence triple read-out detection of prostate specific antigen.
Prostatic Neoplasms
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
Prostatic Neoplasms
A Four-kallikrein Panel and ?-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Prostatic Neoplasms
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Prostate Cancer Screening, Rotterdam.
Prostatic Neoplasms
A framework for the identification of men at increased risk for prostate cancer.
Prostatic Neoplasms
A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates.
Prostatic Neoplasms
A guideline to clinical utility of prostate specific antigen.
Prostatic Neoplasms
A label-free fluorescent aptasensor based on HCR and G-quadruplex DNAzymes for the detection of prostate-specific antigen.
Prostatic Neoplasms
A large, benign prostatic cyst presented with an extremely high serum prostate-specific antigen level.
Prostatic Neoplasms
A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.
Prostatic Neoplasms
A long follow-up on prostate specific antigen density and prostate biopsy.
Prostatic Neoplasms
A mechanistic insight into the anti-metastatic role of the prostate specific antigen.
Prostatic Neoplasms
A miniature chip for protein detection based on magnetic relaxation switches.
Prostatic Neoplasms
A molecularly imprinted electrochemical nanobiosensor for prostate specific antigen determination.
Prostatic Neoplasms
A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Prostatic Neoplasms
A Multi-Institutional Prospective Trial in the Veterans Affairs Health System Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
Prostatic Neoplasms
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Prostatic Neoplasms
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
Prostatic Neoplasms
A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting.
Prostatic Neoplasms
A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
Prostatic Neoplasms
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.
Prostatic Neoplasms
A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
Prostatic Neoplasms
A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
Prostatic Neoplasms
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.
Prostatic Neoplasms
A new luciferase reporter gene assay for the detection of androgenic and antiandrogenic effects based on a human prostate specific antigen promoter and PC3/AR human prostate cancer cells.
Prostatic Neoplasms
A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Prostatic Neoplasms
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
Prostatic Neoplasms
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Prostatic Neoplasms
A Non-Enzymatic and Label-Free Fluorescence Bioassay for Ultrasensitive Detection of PSA.
Prostatic Neoplasms
A novel aptamer-functionalized MoS2 nanosheet fluorescent biosensor for sensitive detection of prostate specific antigen.
Prostatic Neoplasms
A novel fluorescent assay based on DNAzyme-assisted detection of prostate specific antigen for signal amplification.
Prostatic Neoplasms
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
Prostatic Neoplasms
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
Prostatic Neoplasms
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
Prostatic Neoplasms
A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Prostatic Neoplasms
A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.
Prostatic Neoplasms
A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
Prostatic Neoplasms
A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers.
Prostatic Neoplasms
A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence after Robot-Assisted Radical Prostatectomy with or without a Small Intestinal Submucosa Bladder Neck Sling.
Prostatic Neoplasms
A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
Prostatic Neoplasms
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
Prostatic Neoplasms
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Prostatic Neoplasms
A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate.
Prostatic Neoplasms
A pilot study of the association of manganese superoxide dismutase and glutathione peroxidase 1 single gene polymorphisms with prostate cancer and serum prostate specific antigen levels.
Prostatic Neoplasms
A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening.
Prostatic Neoplasms
A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml.
Prostatic Neoplasms
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
Prostatic Neoplasms
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
Prostatic Neoplasms
A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
Prostatic Neoplasms
A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms.
Prostatic Neoplasms
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Prostatic Neoplasms
A quantitative analysis of the costs and benefits of prostate cancer screening.
Prostatic Neoplasms
A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol.
Prostatic Neoplasms
A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
Prostatic Neoplasms
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Prostatic Neoplasms
A robust electrochemical immunosensor based on hydroxyl pillar[5]arene@AuNPs@g-C3N4 hybrid nanomaterial for ultrasensitive detection of prostate specific antigen.
Prostatic Neoplasms
A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
Prostatic Neoplasms
A simple and general change-point identifier.
Prostatic Neoplasms
A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.
Prostatic Neoplasms
A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Prostatic Neoplasms
A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
Prostatic Neoplasms
A technique of bladder neck closure combining prostatectomy and intestinal interposition for unsalvageable urethral disease.
Prostatic Neoplasms
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
Prostatic Neoplasms
A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000.
Prostatic Neoplasms
Abdominal Mass After Robotic Assisted Laparoscopic Prostatectomy: Spigelian Type Trocar Hernia.
Prostatic Neoplasms
Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
Prostatic Neoplasms
Abnormal prostatic cells in ejaculates from men with prostatic cancer--a preliminary report.
Prostatic Neoplasms
Abnormal PSA tests--delays in referral.
Prostatic Neoplasms
Accuracy of a new echographic method (RULES, radiofrequency ultrasonic local estimators) in prostate cancer diagnosis.
Prostatic Neoplasms
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer.
Prostatic Neoplasms
Active surveillance for prostate cancer: trials and tribulations.
Prostatic Neoplasms
Activin A Enhances Prostate Cancer Cell Migration via Activation of Androgen Receptor and Is Overexpressed in Metastatic Prostate Cancer.
Prostatic Neoplasms
Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation.
Prostatic Neoplasms
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
Prostatic Neoplasms
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Prostatic Neoplasms
Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core.
Prostatic Neoplasms
African-American men and their reflections and thoughts on prostate cancer.
Prostatic Neoplasms
African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
Prostatic Neoplasms
African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Prostatic Neoplasms
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Prostatic Neoplasms
Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men.
Prostatic Neoplasms
Age-specific Serum Prostate Specific Antigen Ranges Among Apparently Healthy Nigerian Men Without Clinical Evidence of Prostate Cancer.
Prostatic Neoplasms
Aggressive Variants of Castration Resistant Prostate Cancer.
Prostatic Neoplasms
alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.
Prostatic Neoplasms
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.
Prostatic Neoplasms
American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen.
Prostatic Neoplasms
Amperometric biosensors for detection of the prostate cancer marker (PSA).
Prostatic Neoplasms
An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level.
Prostatic Neoplasms
An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene.
Prostatic Neoplasms
An aptamer based resonance light scattering assay of prostate specific antigen.
Prostatic Neoplasms
An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Prostatic Neoplasms
An evaluation of five tests to diagnose prostate cancer.
Prostatic Neoplasms
An evaluation of prostate specific antigen in prostatic cancer.
Prostatic Neoplasms
An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital.
Prostatic Neoplasms
An examination of variations in the uptake of prostate cancer screening within and between the countries of the EU-27.
Prostatic Neoplasms
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Prostatic Neoplasms
An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.
Prostatic Neoplasms
An update of the Gleason grading system.
Prostatic Neoplasms
An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.
Prostatic Neoplasms
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Prostatic Neoplasms
Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
Prostatic Neoplasms
Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit?
Prostatic Neoplasms
Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices.
Prostatic Neoplasms
Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Prostatic Neoplasms
Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Prostatic Neoplasms
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Prostatic Neoplasms
Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.
Prostatic Neoplasms
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
Prostatic Neoplasms
Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
Prostatic Neoplasms
ANNALS EXPRESS: Frequency of KLK3 gene deletions in the general population.
Prostatic Neoplasms
Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
Prostatic Neoplasms
Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Prostatic Neoplasms
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.
Prostatic Neoplasms
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Prostatic Neoplasms
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Prostatic Neoplasms
Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer.
Prostatic Neoplasms
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Prostatic Neoplasms
Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds.
Prostatic Neoplasms
Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer.
Prostatic Neoplasms
Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Prostatic Neoplasms
Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells.
Prostatic Neoplasms
Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review.
Prostatic Neoplasms
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Prostatic Neoplasms
Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.
Prostatic Neoplasms
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Prostatic Neoplasms
Artificial neural network model to predict biochemical failure after radical prostatectomy.
Prostatic Neoplasms
Assay for prostate specific antigen (PSA): problems and possible solutions.
Prostatic Neoplasms
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Prostatic Neoplasms
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Prostatic Neoplasms
Assessing individual risk for prostate cancer.
Prostatic Neoplasms
Assessing prostate cancer growth with mRNA of spermine metabolic enzymes.
Prostatic Neoplasms
Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control.
Prostatic Neoplasms
Assessing uncertainty in microsimulation modelling with application to cancer screening interventions.
Prostatic Neoplasms
Assessment of a new point-of-care system for detection of prostate specific antigen.
Prostatic Neoplasms
Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males.
Prostatic Neoplasms
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Prostatic Neoplasms
Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Prostatic Neoplasms
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Prostatic Neoplasms
Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Prostatic Neoplasms
Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
Prostatic Neoplasms
Association of Body Mass Index With Prostate Cancer Biochemical Failure.
Prostatic Neoplasms
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Prostatic Neoplasms
Association of ferritin with prostate cancer.
Prostatic Neoplasms
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Prostatic Neoplasms
ASSOCIATION OF HEMOSPERMIA WITH PROSTATE CANCER.
Prostatic Neoplasms
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Prostatic Neoplasms
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Prostatic Neoplasms
Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe.
Prostatic Neoplasms
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
Prostatic Neoplasms
Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
Prostatic Neoplasms
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.
Prostatic Neoplasms
Associations between the expressions of MiR-135 and MiR-92a and pathogenesis of prostate cancer and analysis of their clinical significance.
Prostatic Neoplasms
Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study).
Prostatic Neoplasms
Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
Prostatic Neoplasms
Autoantibodies to prostasomes as new markers for prostate cancer.
Prostatic Neoplasms
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
Prostatic Neoplasms
Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins.
Prostatic Neoplasms
Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Prostatic Neoplasms
Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Prostatic Neoplasms
Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
Being on active surveillance: the patient perspective.
Prostatic Neoplasms
Beyond PSA: The Role of Prostate Health Index (phi).
Prostatic Neoplasms
Bias correction to secondary trait analysis with case-control design.
Prostatic Neoplasms
Bioassays based on molecular nanomechanics.
Prostatic Neoplasms
Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer.
Prostatic Neoplasms
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations.
Prostatic Neoplasms
Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.
Prostatic Neoplasms
Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer.
Prostatic Neoplasms
Biomarkers for prostate cancer detection.
Prostatic Neoplasms
Biomarkers for prostate cancer.
Prostatic Neoplasms
Biomarkers identified for prostate cancer patients through genome-scale screening.
Prostatic Neoplasms
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Prostatic Neoplasms
Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
Prostatic Neoplasms
Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
Prostatic Neoplasms
Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Prostatic Neoplasms
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Prostatic Neoplasms
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Prostatic Neoplasms
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013.
Prostatic Neoplasms
Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy.
Prostatic Neoplasms
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.
Prostatic Neoplasms
Brief report: Impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer.
Prostatic Neoplasms
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.
Prostatic Neoplasms
Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea.
Prostatic Neoplasms
Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.
Prostatic Neoplasms
Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?
Prostatic Neoplasms
Can microfocal prostate cancer be regarded as low-risk prostate cancer?
Prostatic Neoplasms
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Prostatic Neoplasms
Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?
Prostatic Neoplasms
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
Prostatic Neoplasms
Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial.
Prostatic Neoplasms
Cancer chemoprevention by pomegranate: laboratory and clinical evidence.
Prostatic Neoplasms
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Prostatic Neoplasms
Cancer screening for the primary care physician.
Prostatic Neoplasms
Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers.
Prostatic Neoplasms
Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Prostatic Neoplasms
Cancer-Cells on Chip for Label-Free Detection of Secreted Molecules.
Prostatic Neoplasms
Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Prostatic Neoplasms
Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL.
Prostatic Neoplasms
Case report of metastatic prostate cancer masquerading as squamous cell carcinoma on the tip of the penis.
Prostatic Neoplasms
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
Prostatic Neoplasms
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
Prostatic Neoplasms
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Prostatic Neoplasms
cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes.
Prostatic Neoplasms
Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.
Prostatic Neoplasms
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Prostatic Neoplasms
Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
Prostatic Neoplasms
Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Prostatic Neoplasms
Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Prostatic Neoplasms
Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience.
Prostatic Neoplasms
Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.
Prostatic Neoplasms
Changes in Serum PSA During Normal Menstrual Cycle.
Prostatic Neoplasms
Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Prostatic Neoplasms
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.
Prostatic Neoplasms
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Prostatic Neoplasms
Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Prostatic Neoplasms
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
Prostatic Neoplasms
Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Prostatic Neoplasms
Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization.
Prostatic Neoplasms
Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS.
Prostatic Neoplasms
Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.
Prostatic Neoplasms
Chemotherapy in the treatment of prostate cancer--is there a role?
Prostatic Neoplasms
Choline PET/CT for prostate cancer: Main clinical applications.
Prostatic Neoplasms
Circulating biomarkers for prostate cancer.
Prostatic Neoplasms
Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection.
Prostatic Neoplasms
Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.
Prostatic Neoplasms
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.
Prostatic Neoplasms
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Prostatic Neoplasms
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Prostatic Neoplasms
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Prostatic Neoplasms
Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
Prostatic Neoplasms
Clarifying the PSA grey zone: The management of patients with a borderline PSA.
Prostatic Neoplasms
Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.
Prostatic Neoplasms
Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians.
Prostatic Neoplasms
Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
Prostatic Neoplasms
Clinical and imaging tools in the early diagnosis of prostate cancer, a review.
Prostatic Neoplasms
Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer.
Prostatic Neoplasms
Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer.
Prostatic Neoplasms
Clinical diagnosis of prostate cancer.
Prostatic Neoplasms
Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Prostatic Neoplasms
Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
Prostatic Neoplasms
Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer.
Prostatic Neoplasms
Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Prostatic Neoplasms
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Prostatic Neoplasms
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Prostatic Neoplasms
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.
Prostatic Neoplasms
Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.
Prostatic Neoplasms
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Prostatic Neoplasms
Clinical significance of prostate specific antigen for early stage prostate cancer detection.
Prostatic Neoplasms
Clinical trials of immunotherapy for advanced prostate cancer.
Prostatic Neoplasms
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
Prostatic Neoplasms
Clinical use of prostate specific antigen in patients with prostate cancer.
Prostatic Neoplasms
Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Prostatic Neoplasms
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Prostatic Neoplasms
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Prostatic Neoplasms
Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
Prostatic Neoplasms
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
Prostatic Neoplasms
Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer.
Prostatic Neoplasms
Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.
Prostatic Neoplasms
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Prostatic Neoplasms
Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer.
Prostatic Neoplasms
Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume.
Prostatic Neoplasms
Clinical value of transrectal ultrasound-guided puncture biopsy combined with serum prostate specific antigen level in prostate cancer.
Prostatic Neoplasms
Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer.
Prostatic Neoplasms
Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml.
Prostatic Neoplasms
Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan.
Prostatic Neoplasms
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.
Prostatic Neoplasms
Co-registration of MRI and ultrasound: accuracy of targeting based on radiology-pathology correlation.
Prostatic Neoplasms
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Prostatic Neoplasms
Colocalization of immunoglobulin binding factor and prostate specific antigen in human prostate gland.
Prostatic Neoplasms
Color Doppler sonography of the prostate.
Prostatic Neoplasms
Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification.
Prostatic Neoplasms
Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling.
Prostatic Neoplasms
Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naïve patients.
Prostatic Neoplasms
Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Prostatic Neoplasms
Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer.
Prostatic Neoplasms
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Prostatic Neoplasms
Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer.
Prostatic Neoplasms
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Prostatic Neoplasms
Common cancers--genetics, origin, prevention, screening: Parts I and II.
Prostatic Neoplasms
Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Prostatic Neoplasms
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Prostatic Neoplasms
Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer.
Prostatic Neoplasms
Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.
Prostatic Neoplasms
Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Prostatic Neoplasms
Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer.
Prostatic Neoplasms
Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Prostatic Neoplasms
Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Prostatic Neoplasms
Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
Prostatic Neoplasms
Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
Prostatic Neoplasms
Comparing Revo-i and da Vinci in Retzius-sparing robot-assisted radical prostatectomy: a preliminary propensity score analysis of outcomes.
Prostatic Neoplasms
Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Prostatic Neoplasms
Comparison of 3 investigational assays for the free form of prostate specific antigen.
Prostatic Neoplasms
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Prostatic Neoplasms
Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.
Prostatic Neoplasms
Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer.
Prostatic Neoplasms
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.
Prostatic Neoplasms
Comparison of different serum prostate specific antigen measures for early prostate cancer detection.
Prostatic Neoplasms
Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
Prostatic Neoplasms
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
Prostatic Neoplasms
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
Prostatic Neoplasms
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Prostatic Neoplasms
Comparison of methods for calculating prostate specific antigen velocity.
Prostatic Neoplasms
Comparison of methods for prediction of prostate cancer in Turkish men with PSA levels of 0-10 ng/mL.
Prostatic Neoplasms
Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Prostatic Neoplasms
Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Prostatic Neoplasms
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Prostatic Neoplasms
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
Prostatic Neoplasms
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
Prostatic Neoplasms
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Prostatic Neoplasms
Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
Prostatic Neoplasms
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Prostatic Neoplasms
Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Prostatic Neoplasms
Comparison of serum uric acid levels between prostate cancer patients and a control group.
Prostatic Neoplasms
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Prostatic Neoplasms
Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Prostatic Neoplasms
Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men.
Prostatic Neoplasms
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Prostatic Neoplasms
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Prostatic Neoplasms
Complementary and alternative therapies in prostate cancer.
Prostatic Neoplasms
Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Prostatic Neoplasms
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Prostatic Neoplasms
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Prostatic Neoplasms
Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range.
Prostatic Neoplasms
Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
Prostatic Neoplasms
Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Prostatic Neoplasms
Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Prostatic Neoplasms
Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination.
Prostatic Neoplasms
Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Prostatic Neoplasms
Contemporary trends in low risk prostate cancer: risk assessment and treatment.
Prostatic Neoplasms
Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.
Prostatic Neoplasms
Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer.
Prostatic Neoplasms
Control of prostate cancer by transrectal HIFU in 227 patients.
Prostatic Neoplasms
Controversies in prostate cancer screening.
Prostatic Neoplasms
Correlation between bone metabolic markers and bone scan in prostatic cancer.
Prostatic Neoplasms
Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Prostatic Neoplasms
Correlation between Prostate Imaging Reporting and Data System Version 2, Prostate-Specific Antigen Levels, and Local Staging in Biopsy-Proven Carcinoma Prostate: A Retrospective Study.
Prostatic Neoplasms
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Prostatic Neoplasms
Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
Prostatic Neoplasms
Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration.
Prostatic Neoplasms
Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.
Prostatic Neoplasms
Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease.
Prostatic Neoplasms
Correlation of serum prostate specific antigen and semi quantitative tissue RT-PCR from prostate cancer samples.
Prostatic Neoplasms
Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Prostatic Neoplasms
Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Prostatic Neoplasms
Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Prostatic Neoplasms
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Prostatic Neoplasms
Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Prostatic Neoplasms
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Prostatic Neoplasms
Could the sextant prostate biopsy be replaced by transurethral resection?
Prostatic Neoplasms
Coumarins from campylotropis hirtella (FRANCH.) SCHINDL. and their inhibitory activity on prostate specific antigen secreted from LNCaP cells.
Prostatic Neoplasms
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Prostatic Neoplasms
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
Prostatic Neoplasms
Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.
Prostatic Neoplasms
Critical-laboratoristic correlation of the diagnostic importance of prostate specific antigen compared with prostatic acid phosphatase and carcinoembryonic antigen in the prostatic cancer.
Prostatic Neoplasms
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).
Prostatic Neoplasms
Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Prostatic Neoplasms
Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results.
Prostatic Neoplasms
Cultural sensitivity and informed decision making about prostate cancer screening.
Prostatic Neoplasms
Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
Prostatic Neoplasms
Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.
Prostatic Neoplasms
Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists.
Prostatic Neoplasms
Current perspectives on the Gleason grading of prostate cancer.
Prostatic Neoplasms
Current treatment of non-metastatic castration-refractory prostate cancer.
Prostatic Neoplasms
Cut off value of time to prostate specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
Prostatic Neoplasms
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Prostatic Neoplasms
Cytokine variations in patients with hormone treated prostate cancer.
Prostatic Neoplasms
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Prostatic Neoplasms
Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.
Prostatic Neoplasms
De novo muscle invasive bladder cancer: is there a change in trend?
Prostatic Neoplasms
Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Prostatic Neoplasms
Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Prostatic Neoplasms
Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families.
Prostatic Neoplasms
Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision.
Prostatic Neoplasms
Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Prostatic Neoplasms
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
Prostatic Neoplasms
Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Prostatic Neoplasms
Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance.
Prostatic Neoplasms
Defining recurrence after radiation for prostate cancer.
Prostatic Neoplasms
Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
Prostatic Neoplasms
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Prostatic Neoplasms
Demographic, Social Support, and Community Differences in Predictors of African-American and White Men Receiving Prostate Cancer Screening in the United States.
Prostatic Neoplasms
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Prostatic Neoplasms
Design of the Prostate Cancer Prevention Trial (PCPT).
Prostatic Neoplasms
Design, synthesis and biological evaluation of thiohydantoin derivatives as novel anti-prostate cancer agents.
Prostatic Neoplasms
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Prostatic Neoplasms
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Prostatic Neoplasms
Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target.
Prostatic Neoplasms
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.
Prostatic Neoplasms
Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor.
Prostatic Neoplasms
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Prostatic Neoplasms
Detection of early stage prostate cancer by using a simple carbon nanotube@paper biosensor.
Prostatic Neoplasms
Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
Prostatic Neoplasms
Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Prostatic Neoplasms
Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein.
Prostatic Neoplasms
Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Prostatic Neoplasms
Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
Prostatic Neoplasms
Detection of Prostate Cancer in an Ethnically Diverse, Disadvantaged Population With Multiple Prostate Specific Antigen Measurements Before Biopsy.
Prostatic Neoplasms
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
Prostatic Neoplasms
Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
Prostatic Neoplasms
Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
Prostatic Neoplasms
Detection of prostate cancer with 11C-methionine positron emission tomography.
Prostatic Neoplasms
Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody.
Prostatic Neoplasms
Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation.
Prostatic Neoplasms
Detection of prostate specific antigen messenger RNA from pelvic lymph node in prostate cancer.
Prostatic Neoplasms
Detection of prostate specific antigen with nanomechanical resonators.
Prostatic Neoplasms
Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography.
Prostatic Neoplasms
Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology.
Prostatic Neoplasms
Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study.
Prostatic Neoplasms
Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.
Prostatic Neoplasms
Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.
Prostatic Neoplasms
Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device.
Prostatic Neoplasms
Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.
Prostatic Neoplasms
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Prostatic Neoplasms
Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum.
Prostatic Neoplasms
Development and external validation of an extended repeat biopsy nomogram.
Prostatic Neoplasms
Development and initial evaluation of a novel urology curriculum for medical students.
Prostatic Neoplasms
Development and validation of health beliefs model scale for prostate cancer screenings (HBM-PCS): Evidence from exploratory and confirmatory factor analyses.
Prostatic Neoplasms
Development of a Listeria monocytogenes based vaccine against prostate cancer.
Prostatic Neoplasms
Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Prostatic Neoplasms
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.
Prostatic Neoplasms
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids.
Prostatic Neoplasms
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
Prostatic Neoplasms
Development of glycan specific lectin based immunoassay for detection of prostate specific antigen.
Prostatic Neoplasms
Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Prostatic Neoplasms
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Prostatic Neoplasms
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Prostatic Neoplasms
Diagnosing prostate cancer - what GPs need to know.
Prostatic Neoplasms
Diagnosis of malignant ascites in prostate cancer by measurement of prostate specific antigen.
Prostatic Neoplasms
Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
Prostatic Neoplasms
Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Prostatic Neoplasms
Diagnosis, management and screening of early localised prostate cancer.
Prostatic Neoplasms
Diagnostic accuracy of [-2]proPSA versus Gleason score and Prostate Health Index versus Gleason score for the determination of aggressive prostate cancer: a systematic review.
Prostatic Neoplasms
Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Prostatic Neoplasms
Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Prostatic Neoplasms
Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Prostatic Neoplasms
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.
Prostatic Neoplasms
Diagnostic potential of serum proteomic patterns in prostate cancer.
Prostatic Neoplasms
Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer.
Prostatic Neoplasms
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Prostatic Neoplasms
Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer.
Prostatic Neoplasms
Diagnostic test accuracy study of
Prostatic Neoplasms
Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.
Prostatic Neoplasms
Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Prostatic Neoplasms
Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL.
Prostatic Neoplasms
Dielectrophoretic label-free immunoassay for rare-analyte quantification in biological samples.
Prostatic Neoplasms
Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
Prostatic Neoplasms
Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.
Prostatic Neoplasms
Dietary phosphorus intake and serum prostate-specific antigen in non-prostate cancer American adults: A secondary analysis of the National Health and Nutrition Examination Survey (NHANES), 2003-2010.
Prostatic Neoplasms
Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA.
Prostatic Neoplasms
Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml.
Prostatic Neoplasms
Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Prostatic Neoplasms
Differential Glycosylation of Cellular Prostate Specific Antigen and the Regulatory Mechanism of Its Secretion.
Prostatic Neoplasms
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Prostatic Neoplasms
Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy.
Prostatic Neoplasms
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less.
Prostatic Neoplasms
Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population.
Prostatic Neoplasms
Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Prostatic Neoplasms
Discovering subpopulation structure with latent class mixed models.
Prostatic Neoplasms
Discovery and validation of urinary biomarkers for prostate cancer.
Prostatic Neoplasms
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.
Prostatic Neoplasms
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Prostatic Neoplasms
Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists.
Prostatic Neoplasms
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level.
Prostatic Neoplasms
Distinct urinary glycoprotein signatures in prostate cancer patients.
Prostatic Neoplasms
Distribution and secretory pathways of prostate specific antigen, alpha1-antichymotrypsin and prostate secretory granules in prostate cancers.
Prostatic Neoplasms
Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Prostatic Neoplasms
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
Prostatic Neoplasms
DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Prostatic Neoplasms
DNA Nanoswitch Barcodes for Multiplexed Biomarker Profiling.
Prostatic Neoplasms
DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.
Prostatic Neoplasms
Do anxiety and distress increase during active surveillance for low risk prostate cancer?
Prostatic Neoplasms
Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer?
Prostatic Neoplasms
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?
Prostatic Neoplasms
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Prostatic Neoplasms
Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
Prostatic Neoplasms
Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Prostatic Neoplasms
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Prostatic Neoplasms
Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
Prostatic Neoplasms
Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20?ng/ml?
Prostatic Neoplasms
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature.
Prostatic Neoplasms
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.
Prostatic Neoplasms
Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?
Prostatic Neoplasms
Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?
Prostatic Neoplasms
Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10 ng/mL?
Prostatic Neoplasms
Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
Prostatic Neoplasms
Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
Prostatic Neoplasms
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Prostatic Neoplasms
Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells.
Prostatic Neoplasms
Downward trend in prostate cancer mortality in Quebec and Canada.
Prostatic Neoplasms
DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.
Prostatic Neoplasms
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
Prostatic Neoplasms
Dual electrochemical genosensor for early diagnosis of prostate cancer through lncRNAs detection.
Prostatic Neoplasms
Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study.
Prostatic Neoplasms
Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Prostatic Neoplasms
Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan.
Prostatic Neoplasms
Early detection of prostate cancer: evaluating the diagnostic performance of prostate specific antigen by comparing with histological technique among africans.
Prostatic Neoplasms
Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen.
Prostatic Neoplasms
Early Diagnosis and Staging.
Prostatic Neoplasms
Early diagnosis and surgical management of prostate cancer.
Prostatic Neoplasms
Early identification of individuals with prostate cancer in negative biopsies.
Prostatic Neoplasms
Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT.
Prostatic Neoplasms
Early onset prostate cancer: predictors of clinical grade.
Prostatic Neoplasms
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.
Prostatic Neoplasms
Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
Prostatic Neoplasms
Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Prostatic Neoplasms
Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
Prostatic Neoplasms
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Prostatic Neoplasms
Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
Prostatic Neoplasms
Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea.
Prostatic Neoplasms
Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong.
Prostatic Neoplasms
Editor's Comment.
Prostatic Neoplasms
Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population.
Prostatic Neoplasms
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
Prostatic Neoplasms
Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population.
Prostatic Neoplasms
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.
Prostatic Neoplasms
Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.
Prostatic Neoplasms
Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen.
Prostatic Neoplasms
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Prostatic Neoplasms
Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
Prostatic Neoplasms
Effectiveness of the Combined Evaluation of KLK3 Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis.
Prostatic Neoplasms
Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients.
Prostatic Neoplasms
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Prostatic Neoplasms
Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells.
Prostatic Neoplasms
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
Prostatic Neoplasms
Effects of the MTHFR C677T Polymorphism on Prostate Specific Antigen and Prostate Cancer.
Prostatic Neoplasms
Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma.
Prostatic Neoplasms
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Prostatic Neoplasms
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Prostatic Neoplasms
Efficacy of brachytherapy combined with endocrine therapy and external beam radiotherapy in the treatment of intermediate and high-risk localized prostate cancer.
Prostatic Neoplasms
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Prostatic Neoplasms
Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Prostatic Neoplasms
Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer.
Prostatic Neoplasms
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study.
Prostatic Neoplasms
Electrical properties of prostatic tissues: I. Single frequency admittivity properties.
Prostatic Neoplasms
Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India.
Prostatic Neoplasms
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Prostatic Neoplasms
Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease.
Prostatic Neoplasms
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.
Prostatic Neoplasms
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
Prostatic Neoplasms
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Prostatic Neoplasms
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Prostatic Neoplasms
Emerging impact of quercetin in the treatment of prostate cancer.
Prostatic Neoplasms
Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis.
Prostatic Neoplasms
Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
Prostatic Neoplasms
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers.
Prostatic Neoplasms
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers.
Prostatic Neoplasms
Energy Dispersive X-Ray Fluorescence Zn/Fe Ratiometric Determination of Zinc Levels in Expressed Prostatic Fluid: A Direct, Non-Invasive and Highly Accurate Screening for Prostate Cancer.
Prostatic Neoplasms
Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer.
Prostatic Neoplasms
Enhancing PSA performance in the diagnosis of prostate cancer.
Prostatic Neoplasms
Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro.
Prostatic Neoplasms
Environmental Exposure to Trace Elements and Prostate Cancer in Three New Zealand Ethnic Groups.
Prostatic Neoplasms
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.
Prostatic Neoplasms
Enzyme-free sandwich-type electrochemical immunosensor for highly sensitive prostate specific antigen based on conjugation of quantum dots and antibody on surface of modified glassy carbon electrode with core-shell magnetic metal-organic frameworks.
Prostatic Neoplasms
Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean.
Prostatic Neoplasms
Epidemiology, Staging and Management of Prostate Cancer.
Prostatic Neoplasms
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.
Prostatic Neoplasms
Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Prostatic Neoplasms
Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells.
Prostatic Neoplasms
Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.
Prostatic Neoplasms
ERSPC, PLCO Studies and Critique of Cochrane Review 2013.
Prostatic Neoplasms
Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study.
Prostatic Neoplasms
Establishment of a Urological Surgery Quality Collaborative.
Prostatic Neoplasms
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
Prostatic Neoplasms
Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy.
Prostatic Neoplasms
Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.
Prostatic Neoplasms
Estimation of Time Trends of Incidence of Prostate Cancer -an Indian Scenario.
Prostatic Neoplasms
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Prostatic Neoplasms
Ethical issues for cancer screening.
Prostatic Neoplasms
Ethical issues for cancer screenings. Five countries--four types of cancer.
Prostatic Neoplasms
Evaluating multiple diagnostic tests with partial verification.
Prostatic Neoplasms
Evaluating the predictiveness of a continuous marker.
Prostatic Neoplasms
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
Prostatic Neoplasms
Evaluation of a new serum testing method for detection of prostate cancer.
Prostatic Neoplasms
Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma.
Prostatic Neoplasms
Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Prostatic Neoplasms
Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening.
Prostatic Neoplasms
Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
Prostatic Neoplasms
Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Prostatic Neoplasms
Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Prostatic Neoplasms
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Prostatic Neoplasms
Evaluation of Prostate Needle Biopsies.
Prostatic Neoplasms
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Prostatic Neoplasms
Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.
Prostatic Neoplasms
Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
Prostatic Neoplasms
Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer.
Prostatic Neoplasms
Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
Prostatic Neoplasms
Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer.
Prostatic Neoplasms
Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Prostatic Neoplasms
Evaluation of the BioSign PSA membrane test for the identification of semen stains in forensic casework.
Prostatic Neoplasms
Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
Prostatic Neoplasms
Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
Prostatic Neoplasms
Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Prostatic Neoplasms
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer.
Prostatic Neoplasms
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Prostatic Neoplasms
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
Prostatic Neoplasms
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
Prostatic Neoplasms
Experiences of Uncertainty in Men With an Elevated PSA.
Prostatic Neoplasms
Exploring Prostate Cancer Literacy and Family Cancer Awareness in College Students: Getting Ahead of the Curve in Cancer Education.
Prostatic Neoplasms
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Prostatic Neoplasms
Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Prostatic Neoplasms
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Prostatic Neoplasms
Expression of p21(waf1/cip1), p27 (kip1), p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer.
Prostatic Neoplasms
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
Prostatic Neoplasms
Expression of the multidrug resistance gene in human prostate cancer.
Prostatic Neoplasms
Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis.
Prostatic Neoplasms
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Prostatic Neoplasms
Extensive serum cytokine analysis in patients with prostate cancer.
Prostatic Neoplasms
Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
Prostatic Neoplasms
Factors affecting prostate cancer screening behaviour in a discrete population of doctors at the university hospital of the west indies, Jamaica.
Prostatic Neoplasms
Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.
Prostatic Neoplasms
Factors influencing prostate cancer screening decisions among African American men.
Prostatic Neoplasms
Factors Predicting Prostate Specific Antigen Failure Following Radical Prostatectomy: Experience with 961 Patients.
Prostatic Neoplasms
Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients.
Prostatic Neoplasms
Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.
Prostatic Neoplasms
Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence.
Prostatic Neoplasms
Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Prostatic Neoplasms
False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Prostatic Neoplasms
Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma.
Prostatic Neoplasms
Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
Prostatic Neoplasms
Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.
Prostatic Neoplasms
Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques.
Prostatic Neoplasms
Feasibility study of an EHR-integrated mobile shared decision making application.
Prostatic Neoplasms
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Prostatic Neoplasms
Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities.
Prostatic Neoplasms
Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Prostatic Neoplasms
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Prostatic Neoplasms
Finasteride-its impact on sexual function and prostate cancer.
Prostatic Neoplasms
Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
Prostatic Neoplasms
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Prostatic Neoplasms
First clinical results with Enzymun-Test for free PSA.
Prostatic Neoplasms
Five-alpha-reductase Inhibitors for prostate cancer prevention.
Prostatic Neoplasms
Fluciclovine, Anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid: A Novel Radiotracer for Meningioma.
Prostatic Neoplasms
Fluorescent immunosensor based on CuS nanoparticles for sensitive detection of cancer biomarker.
Prostatic Neoplasms
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Prostatic Neoplasms
Focal therapy for prostate cancer: opportunities and uncertainties.
Prostatic Neoplasms
Follow-up costs after external radiation for low risk prostate cancer.
Prostatic Neoplasms
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
Prostatic Neoplasms
FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
Prostatic Neoplasms
Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary?
Prostatic Neoplasms
Free / total prostate specific antigen ratio for prostate cancer detection: a prospective blind study.
Prostatic Neoplasms
Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Prostatic Neoplasms
Free and total human glandular kallikrein 2 in patients with prostate cancer.
Prostatic Neoplasms
Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.
Prostatic Neoplasms
Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer.
Prostatic Neoplasms
Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer.
Prostatic Neoplasms
Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Prostatic Neoplasms
Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
Prostatic Neoplasms
Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen.
Prostatic Neoplasms
Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.
Prostatic Neoplasms
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Prostatic Neoplasms
Genetic counseling for prostate cancer risk.
Prostatic Neoplasms
Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer.
Prostatic Neoplasms
Genetic variants in xenobiotic detoxification enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer.
Prostatic Neoplasms
Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
Prostatic Neoplasms
GEOGRAPHIC VARIATION ACROSS VETERANS AFFAIRS MEDICAL CENTERS IN THE TREATMENT OF EARLY STAGE PROSTATE CANCER.
Prostatic Neoplasms
Gleason 6 Prostate Cancer: Translating Biology into Population Health.
Prostatic Neoplasms
Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS.
Prostatic Neoplasms
Glycosylation of prostate specific antigen and its potential diagnostic applications.
Prostatic Neoplasms
Glycotyping of prostate specific antigen.
Prostatic Neoplasms
GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.
Prostatic Neoplasms
GPRC6A regulates prostate cancer progression.
Prostatic Neoplasms
Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report.
Prostatic Neoplasms
Graphene nanocomposites modified electrochemical aptamer sensor for rapid and highly sensitive detection of prostate specific antigen.
Prostatic Neoplasms
GREB1 tissue expression is associated with organ-confined prostate cancer.
Prostatic Neoplasms
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Prostatic Neoplasms
Has ultrasonography a role in screening for prostatic cancer?
Prostatic Neoplasms
Health risk behaviors and prostate specific antigen awareness among men in California.
Prostatic Neoplasms
Healthy living and cancer: evidence from UK Biobank.
Prostatic Neoplasms
Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Prostatic Neoplasms
Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Prostatic Neoplasms
Hereditary prostate cancer: clinical aspects.
Prostatic Neoplasms
Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.
Prostatic Neoplasms
High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Prostatic Neoplasms
High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
Prostatic Neoplasms
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
Prostatic Neoplasms
High Incidence of Predominant Gleason Pattern 4 Localized Prostate Cancer is Associated With Low Serum Testosterone.
Prostatic Neoplasms
High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer.
Prostatic Neoplasms
High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.
Prostatic Neoplasms
High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Prostatic Neoplasms
High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry.
Prostatic Neoplasms
High-Throughput Electrochemical Microfluidic Immunoarray for Multiplexed Detection of Cancer Biomarker Proteins.
Prostatic Neoplasms
High-throughput quantitative analysis of total N-glycans by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Prostatic Neoplasms
Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases.
Prostatic Neoplasms
Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.
Prostatic Neoplasms
Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Prostatic Neoplasms
Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
Prostatic Neoplasms
Hormone therapy of prostatic bone metastases.
Prostatic Neoplasms
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Prostatic Neoplasms
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Prostatic Neoplasms
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Prostatic Neoplasms
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Prostatic Neoplasms
Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Prostatic Neoplasms
Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Prostatic Neoplasms
Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer.
Prostatic Neoplasms
Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Prostatic Neoplasms
Human prostate cancer model: roles of growth factors and extracellular matrices.
Prostatic Neoplasms
Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein.
Prostatic Neoplasms
Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues.
Prostatic Neoplasms
Human tissue kallikreins: a family of new cancer biomarkers.
Prostatic Neoplasms
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.
Prostatic Neoplasms
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Prostatic Neoplasms
Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Prostatic Neoplasms
Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases.
Prostatic Neoplasms
Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
Prostatic Neoplasms
Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
Prostatic Neoplasms
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
Prostatic Neoplasms
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Prostatic Neoplasms
Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
Prostatic Neoplasms
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
Prostatic Neoplasms
Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes.
Prostatic Neoplasms
Image-guided focal therapy for prostate cancer.
Prostatic Neoplasms
Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control.
Prostatic Neoplasms
Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Immune response to sipuleucel-T in prostate cancer.
Prostatic Neoplasms
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Prostatic Neoplasms
Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer.
Prostatic Neoplasms
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.
Prostatic Neoplasms
Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers.
Prostatic Neoplasms
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Prostatic Neoplasms
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Prostatic Neoplasms
Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Prostatic Neoplasms
Impact of capillary conditioning and background electrolyte composition on capillary electrophoresis analysis of prostate specific antigen isoforms.
Prostatic Neoplasms
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
Prostatic Neoplasms
Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening.
Prostatic Neoplasms
Impact of increased number of biopsies on the nature of prostate cancer identified.
Prostatic Neoplasms
Impact of low prostate specific antigen on prostate cancer--a rare case report.
Prostatic Neoplasms
Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database.
Prostatic Neoplasms
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Prostatic Neoplasms
Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry.
Prostatic Neoplasms
Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases.
Prostatic Neoplasms
Impedimetric PSA aptasensor based on the use of a glassy carbon electrode modified with titanium oxide nanoparticles and silk fibroin nanofibers.
Prostatic Neoplasms
Implications of a new element in the early diagnostic pathway for prostate cancer for rural Australians.
Prostatic Neoplasms
Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Prostatic Neoplasms
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).
Prostatic Neoplasms
Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels.
Prostatic Neoplasms
Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy.
Prostatic Neoplasms
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
Prostatic Neoplasms
In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Prostatic Neoplasms
In-bore MRI targeted biopsy.
Prostatic Neoplasms
Inactive free : total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men.
Prostatic Neoplasms
Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography.
Prostatic Neoplasms
Incidental Hydroxyapatite Ocular Implant Uptake on Bone Scan Done for Prostate Cancer Staging: Case Report and Brief Review
Prostatic Neoplasms
Incidental possible diagnosis by 18F-fluorocholine PET/CT of Meckel's diverticulum and potential pitfalls.
Prostatic Neoplasms
Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Prostatic Neoplasms
Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Prostatic Neoplasms
Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Prostatic Neoplasms
Increased peripheral CD4+CD25high Treg in prostate cancer patients is correlated with PSA.
Prostatic Neoplasms
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Prostatic Neoplasms
Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
Prostatic Neoplasms
Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells.
Prostatic Neoplasms
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Prostatic Neoplasms
Increasing incidence of prostate cancer in Taiwan: A study of related factors using a nationwide health and welfare database.
Prostatic Neoplasms
Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Prostatic Neoplasms
Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer.
Prostatic Neoplasms
Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
Prostatic Neoplasms
Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Prostatic Neoplasms
Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.
Prostatic Neoplasms
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Prostatic Neoplasms
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Prostatic Neoplasms
Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
Prostatic Neoplasms
Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection.
Prostatic Neoplasms
Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Prostatic Neoplasms
Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer.
Prostatic Neoplasms
Inhibition of prostate specific antigen expression by genistein in prostate cancer cells.
Prostatic Neoplasms
Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Prostatic Neoplasms
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Prostatic Neoplasms
Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP.
Prostatic Neoplasms
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
Prostatic Neoplasms
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
Prostatic Neoplasms
Initiation of salvage therapy for prostate cancer.
Prostatic Neoplasms
INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.
Prostatic Neoplasms
Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Prostatic Neoplasms
Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Prostatic Neoplasms
Integration of quantitative diffusion kurtosis imaging and prostate specific antigen in differential diagnostic of prostate cancer.
Prostatic Neoplasms
Intensive lifestyle changes may affect the progression of prostate cancer.
Prostatic Neoplasms
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Prostatic Neoplasms
Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Prostatic Neoplasms
Interleukin-6 polymorphism is associated with more aggressive prostate cancer.
Prostatic Neoplasms
Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
Prostatic Neoplasms
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Prostatic Neoplasms
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Prostatic Neoplasms
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Prostatic Neoplasms
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
Prostatic Neoplasms
Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Prostatic Neoplasms
Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer.
Prostatic Neoplasms
Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6year screening interval.
Prostatic Neoplasms
Intracranial metastasis of prostate cancer: report of two cases.
Prostatic Neoplasms
Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Prostatic Neoplasms
Intron retention: a common splicing event within the human kallikrein gene family.
Prostatic Neoplasms
Inverse Relationship between PSA and IL-8 in Prostate Cancer: An Insight into a NF-?B-Mediated Mechanism.
Prostatic Neoplasms
Involvment of IL-1 beta Mediated NF-Kappa B Signalling Payhways to Downregulate Prostate Specific Antigen And Cell Proliferation in LNCaP Prostate Cancer Cells.
Prostatic Neoplasms
Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Prostatic Neoplasms
Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
Prostatic Neoplasms
Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies?
Prostatic Neoplasms
Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution).
Prostatic Neoplasms
Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature.
Prostatic Neoplasms
Is magnetic resonance imaging helpful in detecting significant prostate cancer in patients with haematospermia, normal prostate specific antigen level and digital rectal examination. A single institution, observational, and retrospective study in a United Kingdom hospital.
Prostatic Neoplasms
Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?
Prostatic Neoplasms
Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy?
Prostatic Neoplasms
Is race a positive predictor of cancer on repeat prostate biopsy?
Prostatic Neoplasms
Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Prostatic Neoplasms
Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?
Prostatic Neoplasms
Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?
Prostatic Neoplasms
Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?
Prostatic Neoplasms
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Prostatic Neoplasms
Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era?
Prostatic Neoplasms
Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer.
Prostatic Neoplasms
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Prostatic Neoplasms
Joint latent class models for longitudinal and time-to-event data: A review.
Prostatic Neoplasms
Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
Prostatic Neoplasms
Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.
Prostatic Neoplasms
Kallikreins as biomarkers for prostate cancer.
Prostatic Neoplasms
Kinetic analysis of prostatic volume and prostate specific antigen (PSA) in patients with advanced prostatic cancer treated by castration.
Prostatic Neoplasms
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Prostatic Neoplasms
Knockdown of scavenger receptor class B Type I reduces prostate specific antigen secretion and viability of prostate cancer cells.
Prostatic Neoplasms
Knowledge of prostate cancer screening among native African urban population in Nigeria.
Prostatic Neoplasms
Knowledge, attitudes and practices of Ugandan men regarding prostate cancer.
Prostatic Neoplasms
Labeless immunosensor assay for prostate specific antigen with picogram per milliliter limits of detection based upon an ac impedance protocol.
Prostatic Neoplasms
Laparoscopic pelvic lymph node dissection.
Prostatic Neoplasms
Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen.
Prostatic Neoplasms
Large-scale propagation of recombinant adherent cells that secrete a stable form of human glandular kallikrein, hK2.
Prostatic Neoplasms
Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies.
Prostatic Neoplasms
Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Prostatic Neoplasms
Lead-time in the European Randomised Study of Screening for Prostate Cancer.
Prostatic Neoplasms
Learning to improve safety: false-positive pathology report results in wrongful surgery.
Prostatic Neoplasms
Leptin influences cellular differentiation and progression in prostate cancer.
Prostatic Neoplasms
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Prostatic Neoplasms
Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
Prostatic Neoplasms
Liarozole.
Prostatic Neoplasms
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
Prostatic Neoplasms
Lifestyle and prostate cancer among older African-American and Caucasian men in South Carolina.
Prostatic Neoplasms
Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada.
Prostatic Neoplasms
Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.
Prostatic Neoplasms
Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database.
Prostatic Neoplasms
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
Prostatic Neoplasms
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Prostatic Neoplasms
Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.
Prostatic Neoplasms
LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.
Prostatic Neoplasms
Local-regional prostate cancer.
Prostatic Neoplasms
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Prostatic Neoplasms
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Prostatic Neoplasms
Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
Prostatic Neoplasms
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Prostatic Neoplasms
Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study.
Prostatic Neoplasms
Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Prostatic Neoplasms
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Prostatic Neoplasms
Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment.
Prostatic Neoplasms
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
Prostatic Neoplasms
Low expression of Galpha protein subunits in human prostate cancer.
Prostatic Neoplasms
LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?
Prostatic Neoplasms
Lower urinary tract symptoms and risk of prostate cancer in Japanese men.
Prostatic Neoplasms
Lower use of prostate specific antigen testing by cigarette smokers-Another possible explanation for the unfavorable prostate cancer (PCA) specific prognosis in smokers?
Prostatic Neoplasms
Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.
Prostatic Neoplasms
Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Prostatic Neoplasms
Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
Prostatic Neoplasms
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
Prostatic Neoplasms
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Prostatic Neoplasms
Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
Prostatic Neoplasms
Malignant Ascites Associated with Carcinoma of the Prostate.
Prostatic Neoplasms
Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
Prostatic Neoplasms
Management of hormone resistant prostate cancer.
Prostatic Neoplasms
Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial.
Prostatic Neoplasms
Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy?
Prostatic Neoplasms
Markers for detection of prostate cancer.
Prostatic Neoplasms
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
Prostatic Neoplasms
Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Prostatic Neoplasms
Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen.
Prostatic Neoplasms
Mass screening of prostate cancer in Changchun City of China.
Prostatic Neoplasms
Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.
Prostatic Neoplasms
Mass-tag enhanced immuno-laser desorption/ionization mass spectrometry for sensitive detection of intact protein antigens.
Prostatic Neoplasms
Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy.
Prostatic Neoplasms
Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Prostatic Neoplasms
Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Measurement of prostate specific antigen as screening test for prostate cancer. False positive results cast doubt on conclusion.
Prostatic Neoplasms
Measurement of prostate specific antigen as screening test for prostate cancer. Measurement presents technical difficulties.
Prostatic Neoplasms
Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view.
Prostatic Neoplasms
Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening.
Prostatic Neoplasms
Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Prostatic Neoplasms
Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique.
Prostatic Neoplasms
Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Prostatic Neoplasms
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds.
Prostatic Neoplasms
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Prostatic Neoplasms
Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
Prostatic Neoplasms
Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.
Prostatic Neoplasms
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes.
Prostatic Neoplasms
Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer.
Prostatic Neoplasms
Metastasis on Bone Scan With Low Prostate Specific Antigen (? 20 ng/ml) and Gleason's Score (<8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines?
Prostatic Neoplasms
Metastatic prostate cancer to lung with normal prostate specific antigen levels.
Prostatic Neoplasms
Metastatic prostate cancer: complications and treatment.
Prostatic Neoplasms
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Prostatic Neoplasms
Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer.
Prostatic Neoplasms
Microfluidic integration for automated targeted proteomic assays.
Prostatic Neoplasms
Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Prostatic Neoplasms
Mining laboratory data to describe prostate specific antigen testing and prostate cancer in Johannesburg, South Africa.
Prostatic Neoplasms
miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
Prostatic Neoplasms
Mitochondria, prostate cancer, and biopsy sampling error.
Prostatic Neoplasms
Mn-doped ZnSe d-dots-based ?-methylacyl-CoA racemase probe for human prostate cancer cell imaging.
Prostatic Neoplasms
Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study.
Prostatic Neoplasms
Modeling Disease Progression with Longitudinal Markers.
Prostatic Neoplasms
Modeling the overdetection of screen-identified cancers in population-based cancer screening with the Coxian phase-type Markov process.
Prostatic Neoplasms
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
Prostatic Neoplasms
Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
Prostatic Neoplasms
Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Prostatic Neoplasms
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Prostatic Neoplasms
Molecular markers for prostatic cancer.
Prostatic Neoplasms
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.
Prostatic Neoplasms
Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.
Prostatic Neoplasms
Molecular sampling of prostate cancer: a dilemma for predicting disease progression.
Prostatic Neoplasms
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Prostatic Neoplasms
Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Prostatic Neoplasms
Monitoring percent free PSA in serial specimens: improvement of test specificity, early detection, and identification of occult tumors.
Prostatic Neoplasms
More information on prostate specific antigen and prostate cancer.
Prostatic Neoplasms
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Prostatic Neoplasms
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Prostatic Neoplasms
Mortality reductions produced by sustained prostate cancer screening have been underestimated.
Prostatic Neoplasms
MRI of the skeleton in prostate cancer staging.
Prostatic Neoplasms
MRI/TRUS FUSION guided biopsy as first approach in ambulatory setting: Feasibility and performance of a new fusion device.
Prostatic Neoplasms
Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer.
Prostatic Neoplasms
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Prostatic Neoplasms
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
Prostatic Neoplasms
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Prostatic Neoplasms
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
Prostatic Neoplasms
Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
Prostatic Neoplasms
Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients.
Prostatic Neoplasms
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves But Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.
Prostatic Neoplasms
Multiparametric MRI in the PSA screening era.
Prostatic Neoplasms
Multiple imputation for threshold-crossing data with interval censoring.
Prostatic Neoplasms
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.
Prostatic Neoplasms
Multivariate statistical analysis for pathologist. Part I, The logistic model.
Prostatic Neoplasms
Nanomaterial based aptasensing of prostate specific antigen (PSA): Recent progress and challenges in efficient diagnosis of prostate cancer using biomedicine.
Prostatic Neoplasms
Nanomaterial-based biosensors for detection of prostate specific antigen.
Prostatic Neoplasms
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Prostatic Neoplasms
Natural history of changes in prostate specific antigen in early stage prostate cancer.
Prostatic Neoplasms
Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.
Prostatic Neoplasms
Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Prostatic Neoplasms
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
Prostatic Neoplasms
Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.
Prostatic Neoplasms
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Prostatic Neoplasms
Neoadjuvant Hormone Therapy Before Radical Prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center Trials.
Prostatic Neoplasms
Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma.
Prostatic Neoplasms
Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.
Prostatic Neoplasms
Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.
Prostatic Neoplasms
New biomarkers for diagnosis and prognosis of localized prostate cancer.
Prostatic Neoplasms
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
Prostatic Neoplasms
New circulating biomarkers for prostate cancer.
Prostatic Neoplasms
New serum tests for the diagnosis of prostate cancer.
Prostatic Neoplasms
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Prostatic Neoplasms
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Prostatic Neoplasms
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Prostatic Neoplasms
No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
Prostatic Neoplasms
No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Prostatic Neoplasms
Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL.
Prostatic Neoplasms
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Prostatic Neoplasms
Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study.
Prostatic Neoplasms
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Prostatic Neoplasms
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Prostatic Neoplasms
Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer.
Prostatic Neoplasms
Not all patients pursue prostate biopsy after abnormal prostate specific antigen results.
Prostatic Neoplasms
Novel Biomarkers for Prostate Cancer Detection and Prognosis.
Prostatic Neoplasms
Novel diagnostic biomarkers of prostate cancer: an update.
Prostatic Neoplasms
Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
Prostatic Neoplasms
Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer.
Prostatic Neoplasms
Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks.
Prostatic Neoplasms
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.
Prostatic Neoplasms
Obesity and prostate cancer.
Prostatic Neoplasms
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
Prostatic Neoplasms
Octreotide in advanced prostatic cancer relapsing under hormonal treatment.
Prostatic Neoplasms
Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
Prostatic Neoplasms
One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer.
Prostatic Neoplasms
Operational Characteristics of (11)C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial Treatment.
Prostatic Neoplasms
Opportunistic prostate cancer screening: A population-based analysis.
Prostatic Neoplasms
Optimal use of prostate specific antigen for prostate cancer screening.
Prostatic Neoplasms
Optimising the management of early prostate cancer.
Prostatic Neoplasms
Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Prostatic Neoplasms
Oral chemotherapy in the treatment of hormone-refractory prostate cancer.
Prostatic Neoplasms
Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.
Prostatic Neoplasms
Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
Prostatic Neoplasms
Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Prostatic Neoplasms
Outcome based staging for clinically localized adenocarcinoma of the prostate.
Prostatic Neoplasms
Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy.
Prostatic Neoplasms
Outcome of radical prostatectomy as primary treatment for high-risk prostate cancer patients.
Prostatic Neoplasms
Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
Prostatic Neoplasms
Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Prostatic Neoplasms
Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Prostatic Neoplasms
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
Prostatic Neoplasms
Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results.
Prostatic Neoplasms
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Prostatic Neoplasms
p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines.
Prostatic Neoplasms
Paget's disease of bone in ethnic Thai presented with urologic symptoms and misleading as metastatic prostate cancer: report of a case with a review of the literature.
Prostatic Neoplasms
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
Prostatic Neoplasms
Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Prostatic Neoplasms
Parameter identification of a model for prostate cancer treated by intermittent therapy.
Prostatic Neoplasms
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Prostatic Neoplasms
Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Prostatic Neoplasms
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
Prostatic Neoplasms
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
Prostatic Neoplasms
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Prostatic Neoplasms
Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Prostatic Neoplasms
Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.
Prostatic Neoplasms
Patterns of Local Failure following Radiation Therapy for Prostate Cancer.
Prostatic Neoplasms
PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.
Prostatic Neoplasms
PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
Prostatic Neoplasms
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
Prostatic Neoplasms
PCA3: from basic molecular science to the clinical lab.
Prostatic Neoplasms
Pelvic lymphadenectomy for localized prostate cancer.
Prostatic Neoplasms
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Prostatic Neoplasms
Peptide-nanoparticle hybrid SERS probes for optical detection of protease activity.
Prostatic Neoplasms
Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Prostatic Neoplasms
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Prostatic Neoplasms
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Prostatic Neoplasms
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Prostatic Neoplasms
Percent free PSA as an additional measure in a prostate cancer screen.
Prostatic Neoplasms
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Prostatic Neoplasms
Perceptions of Prostate Cancer Fatalism and Screening Behavior Between United States-Born and Caribbean-Born Black Males.
Prostatic Neoplasms
Performance of Prostate Health Index in Biopsy Naïve Black Men.
Prostatic Neoplasms
Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples.
Prostatic Neoplasms
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
Prostatic Neoplasms
Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Prostatic Neoplasms
Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality.
Prostatic Neoplasms
Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Prostatic Neoplasms
Personalized approach to prostate cancer prognosis.
Prostatic Neoplasms
Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies.
Prostatic Neoplasms
Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
Prostatic Neoplasms
PET-CT for treatment planning in prostate cancer.
Prostatic Neoplasms
PET/CT variants and pitfalls in prostate cancer: What you might see on PET and should never forget.
Prostatic Neoplasms
Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys(145)-Lys(146) internally cleaved forms.
Prostatic Neoplasms
Phage display screening identifies a prostate specific antigen (PSA)-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.
Prostatic Neoplasms
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Prostatic Neoplasms
Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Prostatic Neoplasms
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Prostatic Neoplasms
Phase I study of phenylacetate administered twice daily to patients with cancer.
Prostatic Neoplasms
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
Prostatic Neoplasms
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Prostatic Neoplasms
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Prostatic Neoplasms
PHI in the Early Detection of Prostate Cancer.
Prostatic Neoplasms
Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance.
Prostatic Neoplasms
Piflufolastat F 18: Diagnostic First Approval.
Prostatic Neoplasms
Pitfalls in interpreting prostate specific antigen velocity.
Prostatic Neoplasms
Pitfalls of hormonal injection therapy in prostate cancer.
Prostatic Neoplasms
Pituitary metastasis of prostate cancer presenting as a unilateral third nerve palsy.
Prostatic Neoplasms
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Prostatic Neoplasms
Plasma sialic acid in patients with prostate cancer.
Prostatic Neoplasms
Polyamine deprivation provokes an antalgic effect.
Prostatic Neoplasms
Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
Prostatic Neoplasms
Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Prostatic Neoplasms
Pomegranate and its components as alternative treatment for prostate cancer.
Prostatic Neoplasms
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland.
Prostatic Neoplasms
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Prostatic Neoplasms
Population standards of prostate specific antigen values in men over 40: community based study in Turkey.
Prostatic Neoplasms
Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Prostatic Neoplasms
Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
Prostatic Neoplasms
Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer.
Prostatic Neoplasms
Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis.
Prostatic Neoplasms
Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6.
Prostatic Neoplasms
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
Prostatic Neoplasms
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Prostatic Neoplasms
Potential selection bias in a community-based study of PSA levels in African-American men.
Prostatic Neoplasms
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Prostatic Neoplasms
Powerful Chemiluminescence Probe for Rapid Detection of Prostate Specific Antigen Proteolytic Activity: Forensic Identification of Human Semen.
Prostatic Neoplasms
Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level.
Prostatic Neoplasms
Practice trends in the diagnosis and management of prostate cancer in the United States.
Prostatic Neoplasms
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.
Prostatic Neoplasms
Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10ng/ml.
Prostatic Neoplasms
Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Prostatic Neoplasms
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Prostatic Neoplasms
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
Prostatic Neoplasms
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Prostatic Neoplasms
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy.
Prostatic Neoplasms
Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
Prostatic Neoplasms
Predicting Pelvic Lymph Node Involvement in Current-Era Prostate Cancer.
Prostatic Neoplasms
Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker.
Prostatic Neoplasms
Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
Prostatic Neoplasms
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.
Prostatic Neoplasms
Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
Prostatic Neoplasms
Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
Prostatic Neoplasms
Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.
Prostatic Neoplasms
Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Prostatic Neoplasms
Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Prostatic Neoplasms
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Prostatic Neoplasms
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Prostatic Neoplasms
Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm.
Prostatic Neoplasms
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Prostatic Neoplasms
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Prostatic Neoplasms
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Prostatic Neoplasms
Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Prostatic Neoplasms
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Prostatic Neoplasms
Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
Prostatic Neoplasms
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Prostatic Neoplasms
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Prostatic Neoplasms
Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate.
Prostatic Neoplasms
Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.
Prostatic Neoplasms
Predictive factors of prostate cancer diagnosis with PSA 4.0-10.0 ng/ml in a multi-ethnic Asian population, Malaysia.
Prostatic Neoplasms
Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells.
Prostatic Neoplasms
Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach.
Prostatic Neoplasms
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.
Prostatic Neoplasms
Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Prostatic Neoplasms
Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Prostatic Neoplasms
Predictors of histological disease progression in untreated, localized prostate cancer.
Prostatic Neoplasms
Predictors of prostate cancer after initial negative systematic 12 core biopsy.
Prostatic Neoplasms
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
Prostatic Neoplasms
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Prostatic Neoplasms
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen.
Prostatic Neoplasms
Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice.
Prostatic Neoplasms
Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
Prostatic Neoplasms
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Prostatic Neoplasms
Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.
Prostatic Neoplasms
Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
Prostatic Neoplasms
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Prostatic Neoplasms
Preoperative prostate specific antigen and prostate volume are significant predictors of seminal vesicle invasion in patients with prostate cancer.
Prostatic Neoplasms
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Prostatic Neoplasms
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
Prostatic Neoplasms
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Prostatic Neoplasms
Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Prostatic Neoplasms
Preperitoneal mesh-plug herniorraphy during radical retropubic prostatectomy.
Prostatic Neoplasms
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
Prostatic Neoplasms
Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients.
Prostatic Neoplasms
Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.
Prostatic Neoplasms
Prevalence and associations of general practitioners' ordering of "non-symptomatic" prostate-specific antigen tests: A cross-sectional analysis.
Prostatic Neoplasms
Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination.
Prostatic Neoplasms
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
Prostatic Neoplasms
Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml.
Prostatic Neoplasms
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate.
Prostatic Neoplasms
Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Prostatic Neoplasms
Prevalence of undiagnosed prostate cancer in men with erectile dysfunction.
Prostatic Neoplasms
Prevention of benign prostatic hyperplasia disease.
Prostatic Neoplasms
Primary cryoablation nadir prostate specific antigen and biochemical failure.
Prostatic Neoplasms
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Prostatic Neoplasms
Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Prostatic Neoplasms
Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml.
Prostatic Neoplasms
Problems in the determination of prostate specific antigen.
Prostatic Neoplasms
Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa.
Prostatic Neoplasms
Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels.
Prostatic Neoplasms
Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen.
Prostatic Neoplasms
Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques.
Prostatic Neoplasms
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Prostatic Neoplasms
Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer.
Prostatic Neoplasms
Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy.
Prostatic Neoplasms
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Prostatic Neoplasms
Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.
Prostatic Neoplasms
Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
Prostatic Neoplasms
Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
Prostatic Neoplasms
Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment.
Prostatic Neoplasms
Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Prostatic Neoplasms
Progression of prostate cancer despite undetectable serum prostate specific antigen.
Prostatic Neoplasms
Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer.
Prostatic Neoplasms
Promoting informed decision making about prostate cancer screening.
Prostatic Neoplasms
Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men.
Prostatic Neoplasms
Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.
Prostatic Neoplasms
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Prostatic Neoplasms
Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Prostatic Neoplasms
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
Prostatic Neoplasms
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Prostatic Neoplasms
Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Prostatic Neoplasms
Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair.
Prostatic Neoplasms
Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Prostatic Neoplasms
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Prostatic Neoplasms
Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
Prostatic Neoplasms
Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
Prostatic Neoplasms
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
Prostatic Neoplasms
Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer.
Prostatic Neoplasms
Prospects in radionuclide imaging of prostate cancer.
Prostatic Neoplasms
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Prostatic Neoplasms
Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?
Prostatic Neoplasms
Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5?-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer.
Prostatic Neoplasms
Prostate biopsy in the diagnosis of prostate cancer: current trends and techniques.
Prostatic Neoplasms
Prostate biopsy.
Prostatic Neoplasms
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Prostatic Neoplasms
Prostate cancer and microfluids.
Prostatic Neoplasms
Prostate cancer and prostate specific antigen. A Jamaican perspective.
Prostatic Neoplasms
Prostate cancer and sarcoma: Challenges of synchronous malignancies.
Prostatic Neoplasms
Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
Prostatic Neoplasms
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Prostatic Neoplasms
Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Prostatic Neoplasms
Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population.
Prostatic Neoplasms
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Prostatic Neoplasms
Prostate cancer detection at low prostate specific antigen.
Prostatic Neoplasms
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.
Prostatic Neoplasms
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990.
Prostatic Neoplasms
Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml.
Prostatic Neoplasms
Prostate cancer detection in candidates for open prostatectomy.
Prostatic Neoplasms
Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
Prostatic Neoplasms
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
Prostatic Neoplasms
Prostate cancer detection in veterans with a history of Agent Orange exposure.
Prostatic Neoplasms
Prostate cancer detection is also relevant in low prostate specific antigen ranges.
Prostatic Neoplasms
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostatic Neoplasms
Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.
Prostatic Neoplasms
Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols?
Prostatic Neoplasms
Prostate Cancer Diagnostic Algorithm as a "Road Map" from the First Stratification of the Patient to the Final Treatment Decision.
Prostatic Neoplasms
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Prostatic Neoplasms
Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy.
Prostatic Neoplasms
Prostate cancer in general practice. Results of a five year prospective clinical study in one practice.
Prostatic Neoplasms
Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
Prostatic Neoplasms
Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
Prostatic Neoplasms
Prostate cancer in renal transplant recipients.
Prostatic Neoplasms
Prostate cancer in Saskatchewan Canada, before and during the PSA era.
Prostatic Neoplasms
Prostate cancer in senior adults: over- or undertreated?
Prostatic Neoplasms
Prostate cancer in Victoria in 1993: patterns of reported management.
Prostatic Neoplasms
Prostate cancer incidence and mortality in Navarre (Spain).
Prostatic Neoplasms
Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences.
Prostatic Neoplasms
Prostate cancer incidence and survival in relation to education (United States).
Prostatic Neoplasms
Prostate cancer incidence, mortality, total and free prostate specific antigen.
Prostatic Neoplasms
Prostate cancer management: (1) an update on localised disease.
Prostatic Neoplasms
Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men.
Prostatic Neoplasms
Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.
Prostatic Neoplasms
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Prostatic Neoplasms
Prostate cancer prevention and finasteride.
Prostatic Neoplasms
Prostate cancer radiotherapy dose response: an update of the fox chase experience.
Prostatic Neoplasms
Prostate Cancer Risk Alleles Are Associated with Prostate Cancer Volume and Prostate Size.
Prostatic Neoplasms
Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
Prostatic Neoplasms
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Prostatic Neoplasms
Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago.
Prostatic Neoplasms
Prostate cancer screening before and after abdominoperineal resection: recommendations, biopsy, and therapeutic techniques.
Prostatic Neoplasms
Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.
Prostatic Neoplasms
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Prostatic Neoplasms
Prostate cancer screening perceptions, knowledge and behaviors among African American men: focus group findings.
Prostatic Neoplasms
Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012.
Prostatic Neoplasms
Prostate cancer screening with prostate specific antigen in spinal cord injured men.
Prostatic Neoplasms
Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Prostatic Neoplasms
Prostate cancer screening--a physician survey in Missouri.
Prostatic Neoplasms
Prostate cancer screening.
Prostatic Neoplasms
Prostate Cancer Screening.
Prostatic Neoplasms
Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Prostatic Neoplasms
Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
Prostatic Neoplasms
Prostate cancer update: 2005.
Prostatic Neoplasms
Prostate cancer update: 2006.
Prostatic Neoplasms
Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?
Prostatic Neoplasms
Prostate cancer.
Prostatic Neoplasms
Prostate cancer: A challenge for screening.
Prostatic Neoplasms
Prostate Cancer: An Evolving Paradigm.
Prostatic Neoplasms
Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens.
Prostatic Neoplasms
Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA.
Prostatic Neoplasms
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Prostatic Neoplasms
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
Prostatic Neoplasms
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Prostatic Neoplasms
Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.
Prostatic Neoplasms
Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
Prostatic Neoplasms
Prostate screening--the Singapore experience.
Prostatic Neoplasms
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.
Prostatic Neoplasms
Prostate sparing cystectomy for bladder cancer: A two-center study.
Prostatic Neoplasms
Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle\ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens.
Prostatic Neoplasms
Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Prostatic Neoplasms
Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.
Prostatic Neoplasms
Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Prostatic Neoplasms
Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients.
Prostatic Neoplasms
Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
Prostatic Neoplasms
Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (gamma-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels.
Prostatic Neoplasms
Prostate specific antigen - useful screening tool or potential liability?
Prostatic Neoplasms
Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
Prostatic Neoplasms
Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.
Prostatic Neoplasms
Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University.
Prostatic Neoplasms
Prostate specific antigen and benign prostatic hyperplasia.
Prostatic Neoplasms
Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Prostatic Neoplasms
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica.
Prostatic Neoplasms
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen and other markers for prostate cancer.
Prostatic Neoplasms
Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
Prostatic Neoplasms
Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.
Prostatic Neoplasms
Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
Prostatic Neoplasms
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
Prostatic Neoplasms
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
Prostatic Neoplasms
Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
Prostatic Neoplasms
Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate.
Prostatic Neoplasms
Prostate specific antigen and screening for early prostate cancer.
Prostatic Neoplasms
Prostate Specific Antigen as a Clinical Biomarker for Prostate Cancer: What's the Take Home Message?
Prostatic Neoplasms
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.
Prostatic Neoplasms
Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Prostatic Neoplasms
Prostate specific antigen assay standardization bias could affect clinical decision making.
Prostatic Neoplasms
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Prostatic Neoplasms
Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty.
Prostatic Neoplasms
Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Prostatic Neoplasms
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Prostatic Neoplasms
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer.
Prostatic Neoplasms
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Prostatic Neoplasms
Prostate specific antigen change after administration of nimotuzumab in prostate cancer.
Prostatic Neoplasms
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Prostatic Neoplasms
Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Prostatic Neoplasms
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Prostatic Neoplasms
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Prostatic Neoplasms
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Prostatic Neoplasms
Prostate Specific Antigen Decrease and Prostate Cancer Diagnosis: Recognizing the Fundamental Previous Progresses and Moving Forward.
Prostatic Neoplasms
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Prostatic Neoplasms
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Prostatic Neoplasms
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Prostatic Neoplasms
Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Prostatic Neoplasms
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
Prostatic Neoplasms
Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
Prostatic Neoplasms
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.
Prostatic Neoplasms
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
Prostatic Neoplasms
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies.
Prostatic Neoplasms
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Prostatic Neoplasms
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Prostatic Neoplasms
Prostate specific antigen detected prostate cancer.
Prostatic Neoplasms
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Prostatic Neoplasms
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
Prostatic Neoplasms
Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.
Prostatic Neoplasms
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
Prostatic Neoplasms
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
Prostatic Neoplasms
Prostate specific antigen following radiotherapy for local prostate cancer.
Prostatic Neoplasms
Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Prostatic Neoplasms
Prostate specific antigen for detecting early prostate cancer.
Prostatic Neoplasms
Prostate specific antigen for early detection of prostate cancer: longitudinal study.
Prostatic Neoplasms
Prostate specific antigen for screening for prostate cancer: an appraisal of Thai reports.
Prostatic Neoplasms
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Prostatic Neoplasms
Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.
Prostatic Neoplasms
Prostate specific antigen in as a dynamic model in advanced prostate cancer.
Prostatic Neoplasms
Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Prostatic Neoplasms
Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
Prostatic Neoplasms
Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment.
Prostatic Neoplasms
Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
Prostatic Neoplasms
Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade.
Prostatic Neoplasms
Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer.
Prostatic Neoplasms
Prostate specific antigen in the diagnosis and staging of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostatic Neoplasms
Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Prostatic Neoplasms
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Prostatic Neoplasms
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Prostatic Neoplasms
Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.
Prostatic Neoplasms
Prostate specific antigen isoforms and human glandular kallikrein 2--which offers the best screening performance in a predominantly black population?
Prostatic Neoplasms
Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Prostatic Neoplasms
Prostate specific antigen kinetics in the management of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Prostatic Neoplasms
Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer.
Prostatic Neoplasms
Prostate specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low risk prostate cancer.
Prostatic Neoplasms
Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease.
Prostatic Neoplasms
Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy?
Prostatic Neoplasms
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.
Prostatic Neoplasms
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Prostatic Neoplasms
Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
Prostatic Neoplasms
Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Prostatic Neoplasms
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
Prostatic Neoplasms
Prostate specific antigen only progression of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen patterns in US and European populations: comparison of six diverse cohorts.
Prostatic Neoplasms
Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
Prostatic Neoplasms
Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature.
Prostatic Neoplasms
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Prostatic Neoplasms
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Prostatic Neoplasms
Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians.
Prostatic Neoplasms
Prostate specific antigen testing after radical prostatectomy: can we stop at 20 years?
Prostatic Neoplasms
Prostate specific antigen testing among the elderly--when to stop?
Prostatic Neoplasms
Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
Prostatic Neoplasms
Prostate specific antigen testing for prostate cancer.
Prostatic Neoplasms
Prostate specific antigen testing for the diagnosis of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen testing in men older than 75 years in the United States.
Prostatic Neoplasms
Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study.
Prostatic Neoplasms
Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
Prostatic Neoplasms
Prostate specific antigen variation in patients without clinically evident prostate cancer.
Prostatic Neoplasms
Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.
Prostatic Neoplasms
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Prostatic Neoplasms
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Prostatic Neoplasms
Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Prostatic Neoplasms
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
Prostatic Neoplasms
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
Prostatic Neoplasms
Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia
Prostatic Neoplasms
Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.
Prostatic Neoplasms
Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Prostatic Neoplasms
Prostate specific antigen. Experimental and clinical observations.
Prostatic Neoplasms
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
Prostatic Neoplasms
Prostate specific antigen: a useful screening test?
Prostatic Neoplasms
Prostate specific antigen: biology, biochemistry and available commercial assays.
Prostatic Neoplasms
Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Prostatic Neoplasms
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Prostatic Neoplasms
Prostate specific antigen: the past, present and future.
Prostatic Neoplasms
Prostate tissue and serum markers.
Prostatic Neoplasms
Prostate tumour markers and differentiation grade in prostatic cancer.
Prostatic Neoplasms
Prostate tumour markers as an aid in the staging of prostatic cancer.
Prostatic Neoplasms
Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
Prostatic Neoplasms
Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men.
Prostatic Neoplasms
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.
Prostatic Neoplasms
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Prostatic Neoplasms
Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.
Prostatic Neoplasms
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Prostatic Neoplasms
Prostate-specific antigen testing and prostate cancer screening.
Prostatic Neoplasms
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Prostatic Neoplasms
Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
Prostatic Neoplasms
Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
Prostatic Neoplasms
Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis.
Prostatic Neoplasms
Prostatic cancer: hospital-based prostate specific antigen screening.
Prostatic Neoplasms
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Prostatic Neoplasms
Prostatic zinc and prostate specific antigen: an experimental evaluation of their combined diagnostic value.
Prostatic Neoplasms
Protein Counting in Single Cancer Cells.
Prostatic Neoplasms
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Prostatic Neoplasms
Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer.
Prostatic Neoplasms
Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility.
Prostatic Neoplasms
PSA density (PSAD). Role in patient evaluation and management.
Prostatic Neoplasms
PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
Prostatic Neoplasms
PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.
Prostatic Neoplasms
PSA relapse prostate cancer: the importance of tailored therapy.
Prostatic Neoplasms
PSA screening: a public health dilemma.
Prostatic Neoplasms
PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
Prostatic Neoplasms
PSA testing: are patients aware of what lies ahead?
Prostatic Neoplasms
PSA-based machine learning model improves prostate cancer risk stratification in a screening population.
Prostatic Neoplasms
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
Prostatic Neoplasms
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach.
Prostatic Neoplasms
PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Prostatic Neoplasms
Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer.
Prostatic Neoplasms
Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Prostatic Neoplasms
Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
Prostatic Neoplasms
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Prostatic Neoplasms
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Prostatic Neoplasms
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Prostatic Neoplasms
Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Prostatic Neoplasms
Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Prostatic Neoplasms
Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
Prostatic Neoplasms
Quebec prostate cancer mortality dropped in 1996.
Prostatic Neoplasms
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.
Prostatic Neoplasms
Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.
Prostatic Neoplasms
Racial differences in operating characteristics of prostate cancer screening tests.
Prostatic Neoplasms
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
Prostatic Neoplasms
Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study.
Prostatic Neoplasms
Racial variation in prostate specific antigen in a large cohort of men without prostate cancer.
Prostatic Neoplasms
Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
Prostatic Neoplasms
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Prostatic Neoplasms
Radical perineal prostatectomy: oncological outcome during a 20-year period.
Prostatic Neoplasms
Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.
Prostatic Neoplasms
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
Prostatic Neoplasms
Radical prostatectomy in men less than 50 years old.
Prostatic Neoplasms
Radical prostatectomy nomograms in black American men: accuracy and applicability.
Prostatic Neoplasms
Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer?
Prostatic Neoplasms
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Prostatic Neoplasms
Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
Prostatic Neoplasms
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.
Prostatic Neoplasms
Radiotherapy for a rising PSA following radical prostatectomy.
Prostatic Neoplasms
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Prostatic Neoplasms
Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance.
Prostatic Neoplasms
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Prostatic Neoplasms
Rapid aptasensor capable of simply diagnosing prostate cancer.
Prostatic Neoplasms
Rapid Diagnosis of Prostate Cancer Disease Progression Using Paper Spray Ionization Mass Spectrometry.
Prostatic Neoplasms
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Prostatic Neoplasms
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
Prostatic Neoplasms
Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.
Prostatic Neoplasms
Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
Prostatic Neoplasms
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Prostatic Neoplasms
Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Prostatic Neoplasms
Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
Prostatic Neoplasms
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Prostatic Neoplasms
Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.
Prostatic Neoplasms
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.
Prostatic Neoplasms
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
Prostatic Neoplasms
Re: complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Prostatic Neoplasms
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Prostatic Neoplasms
Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation.
Prostatic Neoplasms
Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer.
Prostatic Neoplasms
Re: Endogenous and Exogenous Testosterone and the Risk of Prostate Cancer and Increased Prostate Specific Antigen (PSA): A Meta-Analysis.
Prostatic Neoplasms
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Prostatic Neoplasms
Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
Prostatic Neoplasms
Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.
Prostatic Neoplasms
Re: no increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Prostatic Neoplasms
Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
Prostatic Neoplasms
Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
Prostatic Neoplasms
Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Prostatic Neoplasms
Re: prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Prostatic Neoplasms
Re: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Prostatic Neoplasms
Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Prostatic Neoplasms
Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
Prostatic Neoplasms
Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
Prostatic Neoplasms
Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Prostatic Neoplasms
Re: radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Prostatic Neoplasms
Re: Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening: E. A. Vertosick, B. Y. Poon and A. J. Vickers J Urol 2014;192:724-729.
Prostatic Neoplasms
Re: reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Prostatic Neoplasms
Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Prostatic Neoplasms
Re: Serum prostate specific antigen as prescreening test for prostate cancer.
Prostatic Neoplasms
Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study.
Prostatic Neoplasms
Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265.
Prostatic Neoplasms
Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
Prostatic Neoplasms
Re: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Prostatic Neoplasms
Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
Prostatic Neoplasms
Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Prostatic Neoplasms
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
Prostatic Neoplasms
Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
Prostatic Neoplasms
Re: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Prostatic Neoplasms
Reactions to Recommendations and Evidence About Prostate Cancer Screening Among White and Black Male Veterans.
Prostatic Neoplasms
Real-time elastography for detecting prostate cancer: preliminary experience.
Prostatic Neoplasms
Real-Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models.
Prostatic Neoplasms
Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer.
Prostatic Neoplasms
Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors.
Prostatic Neoplasms
Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate.
Prostatic Neoplasms
Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
Prostatic Neoplasms
Recent progress in hormonal therapy for advanced prostate cancer.
Prostatic Neoplasms
Recent trends in prostate cancer mortality show a continuous decrease in several countries.
Prostatic Neoplasms
Receptor gene messenger RNA expression in metastatic lesions of prostate cancer.
Prostatic Neoplasms
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness.
Prostatic Neoplasms
Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Prostatic Neoplasms
Recommendations by Canadian urologists and radiation oncologists for the treatment of clinically localized prostate cancer.
Prostatic Neoplasms
Reconnoitring the status of prostate specific antigen and its role in women.
Prostatic Neoplasms
Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Prostatic Neoplasms
Recurrent prostate cancer despite undetectable prostate specific antigen.
Prostatic Neoplasms
Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time.
Prostatic Neoplasms
Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Prostatic Neoplasms
Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Prostatic Neoplasms
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.
Prostatic Neoplasms
Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Prostatic Neoplasms
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
Prostatic Neoplasms
Relationship between prostate specific antigen, prostate volume and age in the benign prostate.
Prostatic Neoplasms
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Prostatic Neoplasms
Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Prostatic Neoplasms
Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
Prostatic Neoplasms
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Prostatic Neoplasms
Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate.
Prostatic Neoplasms
Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.
Prostatic Neoplasms
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.
Prostatic Neoplasms
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Prostatic Neoplasms
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Prostatic Neoplasms
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese.
Prostatic Neoplasms
Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
Prostatic Neoplasms
Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer.
Prostatic Neoplasms
Results of compliance with prostate cancer screening guidelines.
Prostatic Neoplasms
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Prostatic Neoplasms
Reversed association between levels of prostate specific antigen and levels of blood cadmium and urinary cadmium.
Prostatic Neoplasms
Review of clinical manifestations of biochemically-advanced prostate cancer cases.
Prostatic Neoplasms
Rising prostate specific antigen after radical prostatectomy: a case based review.
Prostatic Neoplasms
Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Prostatic Neoplasms
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Prostatic Neoplasms
Risk Prediction for Prostate Cancer Recurrence Through Regularized Estimation with Simultaneous Adjustment for Nonlinear Clinical Effects.
Prostatic Neoplasms
Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
Prostatic Neoplasms
Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
Prostatic Neoplasms
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Prostatic Neoplasms
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.
Prostatic Neoplasms
Robot-Assisted Laparoscopic Radical Prostatectomy 6 Months After Rectal Spacer Hydrogel Injection.
Prostatic Neoplasms
Robotic radical prostatectomy in the community setting--the learning curve and beyond: initial 200 cases.
Prostatic Neoplasms
Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Prostatic Neoplasms
Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
Prostatic Neoplasms
Role of complexed PSA in the early detection of prostate cancer.
Prostatic Neoplasms
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Prostatic Neoplasms
Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.
Prostatic Neoplasms
Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases.
Prostatic Neoplasms
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Prostatic Neoplasms
Role of prostate specific antigen and prostate specific antigen density as biomarkers for medical and surgical treatment response in men with lower urinary tract symptoms: a systematic review and meta-analysis.
Prostatic Neoplasms
Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen.
Prostatic Neoplasms
Routine screening by prostate specific antigen for prostate cancer seems unreasonable.
Prostatic Neoplasms
Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer.
Prostatic Neoplasms
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.
Prostatic Neoplasms
Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes?
Prostatic Neoplasms
Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.
Prostatic Neoplasms
Salvage options for biochemical recurrence after primary therapy for prostate cancer.
Prostatic Neoplasms
Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
Prostatic Neoplasms
Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Prostatic Neoplasms
Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges.
Prostatic Neoplasms
Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling.
Prostatic Neoplasms
Sample preparation of serum to allow capillary electrophoresis analysis of prostate specific antigen isoforms.
Prostatic Neoplasms
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Prostatic Neoplasms
Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.
Prostatic Neoplasms
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
Prostatic Neoplasms
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Prostatic Neoplasms
Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against.
Prostatic Neoplasms
Screening for cancer. Is it useful?
Prostatic Neoplasms
Screening for carcinoma of the prostate: a GP based study.
Prostatic Neoplasms
Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins.
Prostatic Neoplasms
Screening for prostate cancer using multivariate mixed-effects models.
Prostatic Neoplasms
Screening for prostate cancer with PSA testing: current status and future directions.
Prostatic Neoplasms
Screening for prostate cancer--how to manage in 2006?
Prostatic Neoplasms
Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination.
Prostatic Neoplasms
Screening for prostate cancer. Does it make a difference?
Prostatic Neoplasms
Screening for prostate cancer: a survey of New Zealand general practitioners.
Prostatic Neoplasms
Screening for prostate cancer: an update.
Prostatic Neoplasms
Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues.
Prostatic Neoplasms
Screening for prostate cancer: moving forward in the molecular era.
Prostatic Neoplasms
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.
Prostatic Neoplasms
Screening for prostate cancer: the current evidence and guidelines controversy.
Prostatic Neoplasms
Screening for prostate cancer: what do general practitioners think?
Prostatic Neoplasms
Screening strategies: a clinical perspective.
Prostatic Neoplasms
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
Prostatic Neoplasms
SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
Prostatic Neoplasms
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Prostatic Neoplasms
Seminal exosomes - An important biological marker for various disorders and syndrome in human reproduction.
Prostatic Neoplasms
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Prostatic Neoplasms
Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results.
Prostatic Neoplasms
Seminal vesicle biopsy in prostate cancer staging.
Prostatic Neoplasms
Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
Prostatic Neoplasms
Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Prostatic Neoplasms
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Prostatic Neoplasms
Sensors for diagnosis of prostate cancer: Looking beyond the prostate specific antigen.
Prostatic Neoplasms
Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.
Prostatic Neoplasms
Ser-486/491 phosphorylation and inhibition of AMPK? activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Prostatic Neoplasms
Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies.
Prostatic Neoplasms
Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Prostatic Neoplasms
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
Prostatic Neoplasms
Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Prostatic Neoplasms
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Prostatic Neoplasms
Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
Prostatic Neoplasms
Serum ceruloplasmin as a marker in prostate cancer.
Prostatic Neoplasms
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
Prostatic Neoplasms
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Prostatic Neoplasms
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Prostatic Neoplasms
Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
Prostatic Neoplasms
Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Prostatic Neoplasms
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Prostatic Neoplasms
Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Prostatic Neoplasms
Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Prostatic Neoplasms
Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Prostatic Neoplasms
Serum insulin-like growth factor-1 is not a useful marker of prostate cancer.
Prostatic Neoplasms
Serum lactate dehydrogenase in combination with free-to-total serum prostate specific antigen ratio for diagnosis of prostate cancer.
Prostatic Neoplasms
Serum levels of prostate specific antigen in men on hemodialysis.
Prostatic Neoplasms
Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Prostatic Neoplasms
Serum levels of total and free prostate specific antigen in men on hemodialysis.
Prostatic Neoplasms
Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Prostatic Neoplasms
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Prostatic Neoplasms
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Prostatic Neoplasms
Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy.
Prostatic Neoplasms
Serum prostate specific antigen as pre-screening test for prostate cancer.
Prostatic Neoplasms
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
Prostatic Neoplasms
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Prostatic Neoplasms
Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Prostatic Neoplasms
Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
Prostatic Neoplasms
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
Prostatic Neoplasms
Serum Testosterone, 17?-Estradiol and PSA Levels in Subjects with Prostate Disorders.
Prostatic Neoplasms
Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Prostatic Neoplasms
Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml.
Prostatic Neoplasms
Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden.
Prostatic Neoplasms
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Prostatic Neoplasms
Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.
Prostatic Neoplasms
Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer?
Prostatic Neoplasms
Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.
Prostatic Neoplasms
Signal-on electrochemical aptasensors with different target-induced conformations for prostate specific antigen detection.
Prostatic Neoplasms
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Prostatic Neoplasms
Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines.
Prostatic Neoplasms
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients.
Prostatic Neoplasms
Significance of serum free prostate specific antigen in the screening of prostate cancer.
Prostatic Neoplasms
Significance of serum total prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer.
Prostatic Neoplasms
Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone.
Prostatic Neoplasms
Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer.
Prostatic Neoplasms
Silver nanoparticles deposited on graphene oxide for ultrasensitive surface-enhanced Raman scattering immunoassay of cancer biomarker.
Prostatic Neoplasms
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Prostatic Neoplasms
Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Prostatic Neoplasms
Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer.
Prostatic Neoplasms
Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
Prostatic Neoplasms
Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Prostatic Neoplasms
Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.
Prostatic Neoplasms
Single-dose antibiotic prophylaxis in core prostate biopsy: impact of timing and identification of risk factors.
Prostatic Neoplasms
Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China.
Prostatic Neoplasms
Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups.
Prostatic Neoplasms
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Prostatic Neoplasms
Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study.
Prostatic Neoplasms
Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening.
Prostatic Neoplasms
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
Prostatic Neoplasms
Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy.
Prostatic Neoplasms
Soluble N-cadherin in human biological fluids.
Prostatic Neoplasms
Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
Prostatic Neoplasms
Spectrum of prostate cancer in the Singapore General Hospital (1980 to 1985).
Prostatic Neoplasms
Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells.
Prostatic Neoplasms
Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
Prostatic Neoplasms
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures.
Prostatic Neoplasms
Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease.
Prostatic Neoplasms
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions.
Prostatic Neoplasms
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Prostatic Neoplasms
Standardization of PSA determinations.
Prostatic Neoplasms
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
Prostatic Neoplasms
Stat3 enhances transactivation of steroid hormone receptors.
Prostatic Neoplasms
Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer.
Prostatic Neoplasms
Statistical models for longitudinal biomarkers of disease onset.
Prostatic Neoplasms
Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation.
Prostatic Neoplasms
Storm over screening for prostate specific antigen. Give men facts on prostate cancer.
Prostatic Neoplasms
Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Prostatic Neoplasms
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Prostatic Neoplasms
Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
Prostatic Neoplasms
Streamlining immunoassays with immiscible filtrations assisted by surface tension.
Prostatic Neoplasms
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Prostatic Neoplasms
SU-E-T-227: Re-Evaluation of Dose Distribution and Margins for IMRT Prostate Plans.
Prostatic Neoplasms
Sub-zeptomole Detection of Biomarker Proteins Using a Microfluidic Immunoarray with Nanostructured Sensors.
Prostatic Neoplasms
Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Prostatic Neoplasms
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.
Prostatic Neoplasms
Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Prostatic Neoplasms
Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Prostatic Neoplasms
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
Prostatic Neoplasms
Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.
Prostatic Neoplasms
Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer.
Prostatic Neoplasms
Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
Prostatic Neoplasms
Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
Prostatic Neoplasms
Surgical approaches to local failure after definitive therapy.
Prostatic Neoplasms
Surgical management of high risk prostate cancer: the Mayo Clinic experience.
Prostatic Neoplasms
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
Prostatic Neoplasms
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Prostatic Neoplasms
Survey of the rate of PSA testing in general practice.
Prostatic Neoplasms
Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era.
Prostatic Neoplasms
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
Prostatic Neoplasms
Survival of prostate cancer patients in central and northern Denmark, 1998-2009.
Prostatic Neoplasms
Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy.
Prostatic Neoplasms
Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
Prostatic Neoplasms
Systematic sextant biopsies in 651 patients referred for prostate evaluation.
Prostatic Neoplasms
Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.
Prostatic Neoplasms
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.
Prostatic Neoplasms
Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.
Prostatic Neoplasms
Targeting thapsigargin towards tumors.
Prostatic Neoplasms
Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen.
Prostatic Neoplasms
Technological aspects of delivering cryotherapy for prostate cancer.
Prostatic Neoplasms
Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980-2011.
Prostatic Neoplasms
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Prostatic Neoplasms
Testing the variability of PSA expression by different human prostate cancer cell lines by means of a new potentiometric device employing molecularly antibody assembled on graphene surface.
Prostatic Neoplasms
Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells.
Prostatic Neoplasms
Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Prostatic Neoplasms
Testosterone Replacement in Men with Treated and Untreated Prostate Cancer.
Prostatic Neoplasms
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy.
Prostatic Neoplasms
Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
Prostatic Neoplasms
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
Prostatic Neoplasms
Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Prostatic Neoplasms
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Prostatic Neoplasms
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Prostatic Neoplasms
The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.
Prostatic Neoplasms
The 11?-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C19 steroids with 11?HSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis.
Prostatic Neoplasms
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
Prostatic Neoplasms
The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required?
Prostatic Neoplasms
The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
Prostatic Neoplasms
The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
Prostatic Neoplasms
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
Prostatic Neoplasms
The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model.
Prostatic Neoplasms
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
Prostatic Neoplasms
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Prostatic Neoplasms
The application of the RT-PCR method for the staging of the prostate cancer progression.
Prostatic Neoplasms
The arachidonic Acid pathway and its role in prostate cancer development and progression.
Prostatic Neoplasms
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Prostatic Neoplasms
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.
Prostatic Neoplasms
The association between total prostate specific antigen concentration and prostate specific antigen velocity.
Prostatic Neoplasms
The Association of Veterans' PSA Screening Rates with Changes in USPSTF Recommendations.
Prostatic Neoplasms
The Benefit of a Surgical Resection of a Solitary Pulmonary Metastasis of Prostate Cancer after Radical Prostatectomy.
Prostatic Neoplasms
The biologic lower detection limit of six ultrasensitive PSA assays.
Prostatic Neoplasms
The case for adjuvant therapy for prostate cancer.
Prostatic Neoplasms
The central role of prostate specific antigen in diagnosis and progression of prostate cancer.
Prostatic Neoplasms
The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer.
Prostatic Neoplasms
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.
Prostatic Neoplasms
The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
Prostatic Neoplasms
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Prostatic Neoplasms
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Prostatic Neoplasms
The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer.
Prostatic Neoplasms
The complexity of PSA interpretation in clinical practice.
Prostatic Neoplasms
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Prostatic Neoplasms
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
Prostatic Neoplasms
The correlation between the gleason score of the biopsy and that of the prostatectomy patch.
Prostatic Neoplasms
The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients.
Prostatic Neoplasms
The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
Prostatic Neoplasms
The Design and Evaluation of a Computerized and Physical Simulator for Training Clinical Prostate Exams.
Prostatic Neoplasms
The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle.
Prostatic Neoplasms
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
Prostatic Neoplasms
The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.
Prostatic Neoplasms
The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age.
Prostatic Neoplasms
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
Prostatic Neoplasms
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Prostatic Neoplasms
The effect of finasteride on prostate specific antigen: review of available data.
Prostatic Neoplasms
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Prostatic Neoplasms
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
Prostatic Neoplasms
The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Prostatic Neoplasms
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
Prostatic Neoplasms
The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
Prostatic Neoplasms
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.
Prostatic Neoplasms
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
Prostatic Neoplasms
The Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Prostatic Neoplasms
The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.
Prostatic Neoplasms
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Prostatic Neoplasms
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Prostatic Neoplasms
The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
Prostatic Neoplasms
The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies.
Prostatic Neoplasms
The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
Prostatic Neoplasms
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
Prostatic Neoplasms
The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
Prostatic Neoplasms
The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.
Prostatic Neoplasms
The eternal enigma in prostatic biopsy access route.
Prostatic Neoplasms
The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
Prostatic Neoplasms
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
Prostatic Neoplasms
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
Prostatic Neoplasms
The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population.
Prostatic Neoplasms
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Prostatic Neoplasms
The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells.
Prostatic Neoplasms
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Prostatic Neoplasms
The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
Prostatic Neoplasms
The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys.
Prostatic Neoplasms
The impact of inadequate knowledge on patient and spouse experience of prostate cancer.
Prostatic Neoplasms
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
Prostatic Neoplasms
The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
Prostatic Neoplasms
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Prostatic Neoplasms
The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
Prostatic Neoplasms
The impact of prostate cancer knowledge on cancer screening.
Prostatic Neoplasms
The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
Prostatic Neoplasms
The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
Prostatic Neoplasms
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer.
Prostatic Neoplasms
The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.
Prostatic Neoplasms
The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy.
Prostatic Neoplasms
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
Prostatic Neoplasms
The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Prostatic Neoplasms
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.
Prostatic Neoplasms
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Prostatic Neoplasms
The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.
Prostatic Neoplasms
The lady with raised prostate specific antigen: do we need to worry?
Prostatic Neoplasms
The Magnetic Resonance Imaging in Active Surveillance "MRIAS" Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Prostatic Neoplasms
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer.
Prostatic Neoplasms
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Prostatic Neoplasms
The natural history of androgen independent prostate cancer.
Prostatic Neoplasms
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
Prostatic Neoplasms
The nature of prostate cancer detected through prostate specific antigen based screening.
Prostatic Neoplasms
The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies.
Prostatic Neoplasms
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Prostatic Neoplasms
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
Prostatic Neoplasms
The number of tPSA tests continues to rise and variation in testing practices persists: a survey of laboratory services in Ireland 2008-2010.
Prostatic Neoplasms
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
Prostatic Neoplasms
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ?65 years.
Prostatic Neoplasms
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
Prostatic Neoplasms
The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
Prostatic Neoplasms
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
Prostatic Neoplasms
The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Prostatic Neoplasms
The prevalence of prostate cancer screening in Thai elderly.
Prostatic Neoplasms
The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer.
Prostatic Neoplasms
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
Prostatic Neoplasms
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
Prostatic Neoplasms
The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Prostatic Neoplasms
The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate.
Prostatic Neoplasms
The Prostate Cancer gene 3 assay: indications for use in clinical practice.
Prostatic Neoplasms
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Prostatic Neoplasms
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Prostatic Neoplasms
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Prostatic Neoplasms
The prostate specific antigen. Its use as a tumor marker for prostate cancer.
Prostatic Neoplasms
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.
Prostatic Neoplasms
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
Prostatic Neoplasms
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
Prostatic Neoplasms
The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men.
Prostatic Neoplasms
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Prostatic Neoplasms
The relationship between Agent Orange and prostate specific antigen: a comparison of a hotspot and a non-sprayed area in Vietnam.
Prostatic Neoplasms
The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients With Prostate Cancer on Active Surveillance.
Prostatic Neoplasms
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
Prostatic Neoplasms
The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Prostatic Neoplasms
The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
Prostatic Neoplasms
The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection.
Prostatic Neoplasms
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Prostatic Neoplasms
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
Prostatic Neoplasms
The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Prostatic Neoplasms
The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
Prostatic Neoplasms
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
Prostatic Neoplasms
The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
Prostatic Neoplasms
The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Prostatic Neoplasms
The role of digital rectal examination, transrectal ultrasound, and prostate specific antigen for the detection of confined and clinically relevant prostate cancer.
Prostatic Neoplasms
The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml.
Prostatic Neoplasms
The role of external radiotherapy in patients treated with permanent prostate brachytherapy.
Prostatic Neoplasms
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
Prostatic Neoplasms
The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer.
Prostatic Neoplasms
The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
Prostatic Neoplasms
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Prostatic Neoplasms
The role of pelvic lymphadenectomy for prostate cancer--therapeutic?
Prostatic Neoplasms
The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.
Prostatic Neoplasms
The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study.
Prostatic Neoplasms
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
Prostatic Neoplasms
The role of prostate specific antigen in screening and management of clinically localized prostate cancer.
Prostatic Neoplasms
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Prostatic Neoplasms
The role of prostate specific antigen measurement in the detection and management of prostate cancer.
Prostatic Neoplasms
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Prostatic Neoplasms
The role of PSA in detection and management of prostate cancer.
Prostatic Neoplasms
The Role of PSA Monitoring after Holmium Laser Enucleation of the Prostate (HoLEP).
Prostatic Neoplasms
The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer.
Prostatic Neoplasms
The role of the androgen receptor as a driver and mitigator of cellular stress.
Prostatic Neoplasms
The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule.
Prostatic Neoplasms
The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor.
Prostatic Neoplasms
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Prostatic Neoplasms
The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes.
Prostatic Neoplasms
The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Prostatic Neoplasms
The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Prostatic Neoplasms
The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Prostatic Neoplasms
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.
Prostatic Neoplasms
The trends in prostate specific antigen usage amongst United Kingdom urologists--a questionnaire based study.
Prostatic Neoplasms
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence.
Prostatic Neoplasms
The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.
Prostatic Neoplasms
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
Prostatic Neoplasms
The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.
Prostatic Neoplasms
The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice.
Prostatic Neoplasms
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Prostatic Neoplasms
The use of prostate specific antigen density to predict clinically significant prostate cancer.
Prostatic Neoplasms
The use of prostate specific antigen for prostate cancer screening: a managed care perspective.
Prostatic Neoplasms
The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database.
Prostatic Neoplasms
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
Prostatic Neoplasms
The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
Prostatic Neoplasms
The Utility and Limitations of Contrast-Enhanced Ultrasound for the Diagnosis and Treatment of Prostate Cancer.
Prostatic Neoplasms
The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml.
Prostatic Neoplasms
The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Prostatic Neoplasms
The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen.
Prostatic Neoplasms
The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
Prostatic Neoplasms
The value of endorectal MRI in the early diagnosis of prostate cancer.
Prostatic Neoplasms
The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Prostatic Neoplasms
The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer.
Prostatic Neoplasms
The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria.
Prostatic Neoplasms
The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913.
Prostatic Neoplasms
The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view.
Prostatic Neoplasms
The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Prostatic Neoplasms
The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
Prostatic Neoplasms
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
Prostatic Neoplasms
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
Prostatic Neoplasms
The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
Prostatic Neoplasms
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Prostatic Neoplasms
Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
Prostatic Neoplasms
Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer.
Prostatic Neoplasms
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Prostatic Neoplasms
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Prostatic Neoplasms
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Prostatic Neoplasms
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).
Prostatic Neoplasms
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Prostatic Neoplasms
Tin Oxide Nanosheet Assembly for Hydrophobic/Hydrophilic Coating and Cancer Sensing.
Prostatic Neoplasms
Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers.
Prostatic Neoplasms
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway.
Prostatic Neoplasms
Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.
Prostatic Neoplasms
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.
Prostatic Neoplasms
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Prostatic Neoplasms
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments.
Prostatic Neoplasms
Toward the detection of prostate cancer in urine: a critical analysis.
Prostatic Neoplasms
Towards the differential diagnosis of prostate cancer by the pre-treatment of human urine using ionic liquids.
Prostatic Neoplasms
Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Prostatic Neoplasms
Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer.
Prostatic Neoplasms
Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Prostatic Neoplasms
Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role.
Prostatic Neoplasms
Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Prostatic Neoplasms
Transperineal magnetic resonance image guided prostate biopsy.
Prostatic Neoplasms
Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies.
Prostatic Neoplasms
Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study.
Prostatic Neoplasms
Transrectal power Doppler imaging in the detection of prostate cancer.
Prostatic Neoplasms
Transrectal real-time elastography-guided transperineal prostate biopsy as an improved tool for prostate cancer diagnosis.
Prostatic Neoplasms
Transrectal sonography in prostate cancer detection--our 25 years experience of implementation.
Prostatic Neoplasms
Transrectal ultrasound in the diagnosis and staging of local disease after I125 seed implantation for prostate cancer.
Prostatic Neoplasms
Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study.
Prostatic Neoplasms
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Prostatic Neoplasms
Treatment of PSA only recurrence of prostate cancer after prior local therapy.
Prostatic Neoplasms
Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels.
Prostatic Neoplasms
Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Prostatic Neoplasms
Trends in diagnosis of stage T1a-b prostate cancer.
Prostatic Neoplasms
Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993.
Prostatic Neoplasms
Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Prostatic Neoplasms
Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance, Epidemiology and End Results database.
Prostatic Neoplasms
Trends in prostate cancer epidemiology in the year 2000.
Prostatic Neoplasms
Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Prostatic Neoplasms
Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines.
Prostatic Neoplasms
Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice.
Prostatic Neoplasms
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Prostatic Neoplasms
Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data.
Prostatic Neoplasms
Tumor markers in prostate cancer I: blood-based markers.
Prostatic Neoplasms
Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability.
Prostatic Neoplasms
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Prostatic Neoplasms
Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Prostatic Neoplasms
Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Prostatic Neoplasms
Tumour markers in prostatic cancer.
Prostatic Neoplasms
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-?B signalling.
Prostatic Neoplasms
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer.
Prostatic Neoplasms
Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Prostatic Neoplasms
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Prostatic Neoplasms
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
Prostatic Neoplasms
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Prostatic Neoplasms
Undetectable prostate specific antigen in disseminated prostate cancer.
Prostatic Neoplasms
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Prostatic Neoplasms
Unrealistic optimism and the Health Belief Model.
Prostatic Neoplasms
Unresolving / progressive skin lesions in cancer patients: be aware of carcinoma cutis.
Prostatic Neoplasms
Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.
Prostatic Neoplasms
Update on chemoprevention of prostate cancer.
Prostatic Neoplasms
Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.
Prostatic Neoplasms
Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.
Prostatic Neoplasms
Urinary prostate specific antigen: is the clinical use likely?
Prostatic Neoplasms
Urinary PSA in monitoring of patients with prostate cancer.
Prostatic Neoplasms
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.
Prostatic Neoplasms
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
Prostatic Neoplasms
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Prostatic Neoplasms
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
Prostatic Neoplasms
Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
Prostatic Neoplasms
Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Prostatic Neoplasms
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Prostatic Neoplasms
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Prostatic Neoplasms
Use of mpMRI in active surveillance for localized prostate cancer.
Prostatic Neoplasms
Use of pleural fluid prostate specific antigen in the diagnosis of malignant effusion from metastatic prostate cancer.
Prostatic Neoplasms
Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer--a local experience.
Prostatic Neoplasms
Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
Prostatic Neoplasms
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
Prostatic Neoplasms
Use of the prostate specific antigen (P.S.A.) in early detection of prostate cancer in males over the age of 50.
Prostatic Neoplasms
Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
Prostatic Neoplasms
Usefulness of Total PSA Value in Prostate Diseases Diagnosis.
Prostatic Neoplasms
Using molecular markers to predict outcome.
Prostatic Neoplasms
Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection.
Prostatic Neoplasms
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Prostatic Neoplasms
Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.
Prostatic Neoplasms
Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.
Prostatic Neoplasms
Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
Prostatic Neoplasms
Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in arab men.
Prostatic Neoplasms
Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
Prostatic Neoplasms
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Prostatic Neoplasms
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection.
Prostatic Neoplasms
Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
Prostatic Neoplasms
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
Prostatic Neoplasms
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.
Prostatic Neoplasms
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.
Prostatic Neoplasms
Validation of the partin nomogram for prostate cancer in a national sample.
Prostatic Neoplasms
Validity of digital rectal examination in the era of prostate specific antigen.
Prostatic Neoplasms
Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland.
Prostatic Neoplasms
Value of 18F-Choline PET/MRI hybrid technique on the therapeutic approach for patients with prostate cancer treated with prostatectomy and rising prostate specific antigen levels below 1 ng/ml.
Prostatic Neoplasms
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters.
Prostatic Neoplasms
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.
Prostatic Neoplasms
Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy.
Prostatic Neoplasms
Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less.
Prostatic Neoplasms
Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
Prostatic Neoplasms
Values of prostate specific antigen in patients with operable prostate carcinoma.
Prostatic Neoplasms
Variables in predicting survival based on treating "PSA-only" relapse.
Prostatic Neoplasms
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.
Prostatic Neoplasms
Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy.
Prostatic Neoplasms
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Prostatic Neoplasms
Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.
Prostatic Neoplasms
Visual electrochemiluminescence ratiometry on bipolar electrode for bioanalysis.
Prostatic Neoplasms
Visual laser ablation of the prostate: clinical experience in 108 patients.
Prostatic Neoplasms
Visual Loss from a Pituitary Mass: Collision Tumors of Prostatic Metastasis and Suprasellar Meningioma.
Prostatic Neoplasms
Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Prostatic Neoplasms
Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
Prostatic Neoplasms
Weight Management to Reduce Prostate Cancer Risk: A Survey of Men's Needs and Interests.
Prostatic Neoplasms
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Prostatic Neoplasms
When is active surveillance the appropriate treatment for prostate cancer?
Prostatic Neoplasms
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Prostatic Neoplasms
Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
Prostatic Neoplasms
Why men in the United Kingdom still want the prostate specific antigen test.
Prostatic Neoplasms
Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study.
Prostatic Neoplasms
Willingness to pay for mass screening for prostate cancer: a contingent valuation survey.
Prostatic Neoplasms
Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Prostatic Neoplasms
XB130 is overexpressed in prostate cancer and involved in cell growth and invasion.
Prostatic Neoplasms
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Prostatic Neoplasms
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.
Prostatic Neoplasms
[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
Prostatic Neoplasms
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
Prostatic Neoplasms
[A case of primary transitional cell carcinoma of the prostate]
Prostatic Neoplasms
[A Case of Prostate Cancer with High Levels of Prostate-Specific Antigen Undetected by Prostate Biopsy].
Prostatic Neoplasms
[A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer].
Prostatic Neoplasms
[A case of solitary endobronchial metastasis of prostatic cancer]
Prostatic Neoplasms
[A low-fat and high soybean protein diet for patients with elevated serum PSA level: alteration of QOL and serum PSA level after the dietary intervention]
Prostatic Neoplasms
[A pilot study of mass screening program for prostatic cancer by means of prostate specific antigen (PSA) filter paper method]
Prostatic Neoplasms
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
Prostatic Neoplasms
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Prostatic Neoplasms
[Advancement of treatment for prostate cancer]
Prostatic Neoplasms
[Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer]
Prostatic Neoplasms
[Alternative tests to PSA for prostate cancer diagnosis.]
Prostatic Neoplasms
[An experience of individual and early diagnosis of prostate cancer in a Tunisian centre]
Prostatic Neoplasms
[Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease]
Prostatic Neoplasms
[Analysis of the results of percent free prostate specific antigen detection among the men without prostate diseases in Xi'an.]
Prostatic Neoplasms
[Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate]
Prostatic Neoplasms
[Antiandrogen withdrawal syndrome]
Prostatic Neoplasms
[Application of angiotensin II receptor blocker in prostate cancer]
Prostatic Neoplasms
[Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Prostatic Neoplasms
[Biochemical recurrence criteria after radiotherapy (external beam, brachytherapy). Natural history of the disease after radiotherapy].
Prostatic Neoplasms
[Biological markers of cancer. Critical study]
Prostatic Neoplasms
[Biological markers of prostate cancer]
Prostatic Neoplasms
[Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification]
Prostatic Neoplasms
[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers]
Prostatic Neoplasms
[Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy]
Prostatic Neoplasms
[Changes in clinical features of inpatients with prostate cancer in the past 11 years].
Prostatic Neoplasms
[Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer]
Prostatic Neoplasms
[Characteristics of screening-detected prostate cancer on health checkup]
Prostatic Neoplasms
[Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
Prostatic Neoplasms
[Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer]
Prostatic Neoplasms
[Clinical evaluation of chemiluminescence immunoassay PSA (ACS-PSA) for detection of prostate cancer]
Prostatic Neoplasms
[Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA]
Prostatic Neoplasms
[Clinical profiles of prostate cancer in our hospital: association between primary symptoms and clinical stage]
Prostatic Neoplasms
[Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer]
Prostatic Neoplasms
[Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer]
Prostatic Neoplasms
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer]
Prostatic Neoplasms
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
Prostatic Neoplasms
[Clinical studies on the prognostic factors in prostate cancer]
Prostatic Neoplasms
[Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience]
Prostatic Neoplasms
[Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years]
Prostatic Neoplasms
[CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].
Prostatic Neoplasms
[Clinical study on poor PSA response to initial endocrine therapy with MAB or estrogenic drugs for treatment of prostate cancer]
Prostatic Neoplasms
[Clinical study on prostatic cancer detected incidentally by transurethral resection of the prostate]
Prostatic Neoplasms
[Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate]
Prostatic Neoplasms
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"]
Prostatic Neoplasms
[Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma]
Prostatic Neoplasms
[Clinical value of prostate specific antigen screening in early detection of prostate cancer]
Prostatic Neoplasms
[Cloning and expression of androgen response elements of prostate specific antigen promoter]
Prostatic Neoplasms
[Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer]
Prostatic Neoplasms
[Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer]
Prostatic Neoplasms
[Comparison of tumor markers versus their relative values to prostatic volume in detecting prostate cancer]
Prostatic Neoplasms
[Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml]
Prostatic Neoplasms
[Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].
Prostatic Neoplasms
[Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer]
Prostatic Neoplasms
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
Prostatic Neoplasms
[Current aspects of prostate cancer screening].
Prostatic Neoplasms
[Current status and problems of a screening for prostatic cancer in the health facilities in Fukuoka Prefecture]
Prostatic Neoplasms
[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age]
Prostatic Neoplasms
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]
Prostatic Neoplasms
[Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Prostatic Neoplasms
[Diagnosis and follow-up of prostate cancer patients using prostate specific antigen (PSA)]
Prostatic Neoplasms
[Diagnosis and treatment of bladder and prostate cancer in early stages]
Prostatic Neoplasms
[Diagnosis and treatment of early prostate cancer]
Prostatic Neoplasms
[Diagnosis and treatment of localized prostate cancer]
Prostatic Neoplasms
[Diagnosis and treatment of prostatitis: a case report]
Prostatic Neoplasms
[Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography]
Prostatic Neoplasms
[Diagnosis Values of Back Propagation Neural Network Integrating Age, Transrectal Ultrasound Characteristics and Serum PSA for Prostate Cancer].
Prostatic Neoplasms
[Diagnostic and prognostic value of quantitative monitoring of prostate specific antigen in blood serum and urine from patients with prostate cancer after radical prostatectomy]
Prostatic Neoplasms
[Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]
Prostatic Neoplasms
[Diagnostic value of tissue and serum prostate specific antigen in prostate cancer]
Prostatic Neoplasms
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]
Prostatic Neoplasms
[Digital rectal examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate cancer in clinical urological practice-detection of impalpable cancer]
Prostatic Neoplasms
[Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors]
Prostatic Neoplasms
[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma]
Prostatic Neoplasms
[Does PSA density of the transition zone represent a useful parameter in the diagnosis of prostate carcinoma?]
Prostatic Neoplasms
[Early detection and follow-up of prostatic carcinoma. Responsibilities of the general practitioner]
Prostatic Neoplasms
[Early diagnosis and surgical management of prostate cancer]
Prostatic Neoplasms
[Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen]
Prostatic Neoplasms
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]
Prostatic Neoplasms
[Effects of digital rectal examination on serum prostate specific antigen]
Prostatic Neoplasms
[Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
Prostatic Neoplasms
[Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies]
Prostatic Neoplasms
[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]
Prostatic Neoplasms
[Epidemiology of prostate cancer in China: an overview and clinical implication].
Prostatic Neoplasms
[Epigenetic markers of early diagnostics of prostate cancer.]
Prostatic Neoplasms
[Etiology of prostate cancer and significance of screening for early prostate cancer]
Prostatic Neoplasms
[Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection]
Prostatic Neoplasms
[Evaluation of transrectal power-Doppler ultrasonography and effect of contrast-enhancement for detecting prostate cancer]
Prostatic Neoplasms
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]
Prostatic Neoplasms
[Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group]
Prostatic Neoplasms
[Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer]
Prostatic Neoplasms
[General features and strategy in the diagnosis of prostatic carcinoma]
Prostatic Neoplasms
[Giant subcutaneous hematoma with hemorrhagic shock induced by goserelin acetate injection for prostate cancer : report of a case].
Prostatic Neoplasms
[Histological characteristics and clinical significance of Japanese prostate cancer with low levels of prostate specific antigen of 4.0 ng/ml or lower]
Prostatic Neoplasms
[Histopathological characteristics of radical prostatectomy specimen and long-term PSA changes in men with PSA levels of 4.0 ng/ml or less]
Prostatic Neoplasms
[Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy]
Prostatic Neoplasms
[Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma]
Prostatic Neoplasms
[Influence of age on serum prostate specific antigen concentration]
Prostatic Neoplasms
[Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer].
Prostatic Neoplasms
[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study]
Prostatic Neoplasms
[Is it possible to do without bone gammagraphy in the staging of prostatic cancer?]
Prostatic Neoplasms
[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
Prostatic Neoplasms
[Management of High-Risk Prostate Cancer and Left Ectopic Ureter Inserting into Seminal Vesicle with Ipsilateral Hypoplastic Kidney of a Young Patient : A Case Report].
Prostatic Neoplasms
[Mass screening for prostate cancer at Ikeda City in Osaka Prefecture--results of screening with PSA alone between 2003 and 2007]
Prostatic Neoplasms
[Mass screening for prostate cancer in Ikeda City Osaka]
Prostatic Neoplasms
[Mass screening for prostate cancer in Nagano]
Prostatic Neoplasms
[Mass screening for prostate cancer in Tokushima City: the results of 2001]
Prostatic Neoplasms
[Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]
Prostatic Neoplasms
[Mass screening prostate cancer and clinical comparison]
Prostatic Neoplasms
[Measurement of serum PSA by DELFIA PSA kit and its application for mass screening. The Gunma Urological Oncology Study Group]
Prostatic Neoplasms
[Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients]
Prostatic Neoplasms
[Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood]
Prostatic Neoplasms
[Molecular staging of hematogenous microdissemination of prostate cancer cells]
Prostatic Neoplasms
[Multiple myeloma diagnosed during hormonal therapy for prostate cancer: report of two cases].
Prostatic Neoplasms
[Multiple prostatic biopsies in the "gray zone" of the specific prostatic antigen]
Prostatic Neoplasms
[Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels]
Prostatic Neoplasms
[Non- PSA serum markers for the diagnosis of PCa].
Prostatic Neoplasms
[Non-specific granulomatous prostatitis. Relationship and differential diagnosis with prostatic cancer]
Prostatic Neoplasms
[Occult cancer in patients with symptomatic benign prostatic hyperplasia]
Prostatic Neoplasms
[Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels]
Prostatic Neoplasms
[Pathological features of prostate cancer in Chinese cohort detected through mass screening and their relationships with serum prostate specific antigen]
Prostatic Neoplasms
[Pilot study of screening of prostate cancer by the assay of prostate specific antigen in occupational milieu]
Prostatic Neoplasms
[Preclinical models of prostate cancer]
Prostatic Neoplasms
[Predicting prostate cancers using a logistic regression model with transrectal ultrasound characteristics, age and Serum PSA].
Prostatic Neoplasms
[Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score]
Prostatic Neoplasms
[Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer]
Prostatic Neoplasms
[Prognosis and predictive factors in prostate cancer.]
Prostatic Neoplasms
[Prognostic factors for PSA relapse of prostate cancer after endocrine therapy]
Prostatic Neoplasms
[Prognostic factors of prostatic cancer]
Prostatic Neoplasms
[Pros and cons of active surveillance for low-risk prostate cancer].
Prostatic Neoplasms
[Prostate biopsy]
Prostatic Neoplasms
[Prostate cancer and prostate specific antigen screening]
Prostatic Neoplasms
[Prostate cancer in the elderly patient]
Prostatic Neoplasms
[Prostate cancer screening at Tatebayashi City in Gunma prefecture--results of screening with PSA alone between 2003 and 2005]
Prostatic Neoplasms
[Prostate cancer screening using prostate specific antigen (PSA) in Tokatsu Hospital--examination of lost-to-followup cases]
Prostatic Neoplasms
[Prostate cancer test and medical reimbursement]
Prostatic Neoplasms
[Prostate cancer with an unusual course]
Prostatic Neoplasms
[Prostate cancer. Treatment]
Prostatic Neoplasms
[Prostate cancer: Diagnosis and staging]
Prostatic Neoplasms
[Prostate cancer]
Prostatic Neoplasms
[Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml]
Prostatic Neoplasms
[Prostate specific antigen and diagnosis of prostate cancer]
Prostatic Neoplasms
[Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status]
Prostatic Neoplasms
[Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay]
Prostatic Neoplasms
[Prostate specific antigen in serum of the patients with prostatic cancer]
Prostatic Neoplasms
[Prostate specific antigen. Clinical applications of ultrasensitive assay]
Prostatic Neoplasms
[Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer]
Prostatic Neoplasms
[Prostate-specific antigen in the follow-up of conservatively treated prostatic cancer]
Prostatic Neoplasms
[Prostate-specific antigen: the most useful marker for prostate cancer]
Prostatic Neoplasms
[Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer]
Prostatic Neoplasms
[Prostatic carcinoma: current status of diagnostic imaging]
Prostatic Neoplasms
[Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen]
Prostatic Neoplasms
[PSA doubling time and method of calculation]
Prostatic Neoplasms
[PSA kinetics after radiotherapy]
Prostatic Neoplasms
[PSA kinetics after total prostatectomy]
Prostatic Neoplasms
[PSA level of the transitional zone: a new marker especially reliable for the detection of prostatic cancer]
Prostatic Neoplasms
[PSA-based parameters]
Prostatic Neoplasms
[PSATZ (prostate specific antigen adjusted for the transition zone volume)]
Prostatic Neoplasms
[Purification of prostatic acid phosphatase and prostate specific antigen from human seminal plasma]
Prostatic Neoplasms
[Quadrature coils for magnetic resonance spectroscopy in the detection of prostate cancer: Single voxel acquisition does not improve the diagnostic accuracy of multivoxel images.]
Prostatic Neoplasms
[Questionnaire based evaluation of prostate biopsy complication comparing different bioptic schemes]
Prostatic Neoplasms
[Radiotherapy of localized cancer of the prostate: current status and new strategies]
Prostatic Neoplasms
[Real-time elastography in the diagnosis of prostate cancer: personal experience].
Prostatic Neoplasms
[Recent advances in proPSA on early detection in prostate cancer]
Prostatic Neoplasms
[Related biomarkers in the diagnosis of prostate cancer].
Prostatic Neoplasms
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
Prostatic Neoplasms
[Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy]
Prostatic Neoplasms
[Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer].
Prostatic Neoplasms
[Repeated ultrasound-guided transrectal prostate biopsy in patients with negative histologic test]
Prostatic Neoplasms
[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault]
Prostatic Neoplasms
[Retrospective evaluation of PSA density for selection of biopsy candidates with prostate specific antigen in the gray zone]
Prostatic Neoplasms
[Rising Prostate Specific Antigen following treatment with curative intention]
Prostatic Neoplasms
[Robot-Assisted Laparoscopic Prostatectomy for Patient with Hereditary Hemorrhagic Telangiectasia: A Case Report].
Prostatic Neoplasms
[Role of prostate specific antigen in the early diagnosis of prostatic cancer. New criteria based on its blood determination]
Prostatic Neoplasms
[Role of prostate specific antigen, transrectal ultrasonography, and digital rectal examination in the search for clinical prostate cancer]
Prostatic Neoplasms
[Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer].
Prostatic Neoplasms
[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]
Prostatic Neoplasms
[Screening for prostate cancer in Yahata, Kitakyushu]
Prostatic Neoplasms
[Screening for prostate cancer: present status and future perspectives].
Prostatic Neoplasms
[Screening test for prostate cancer]
Prostatic Neoplasms
[Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]
Prostatic Neoplasms
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]
Prostatic Neoplasms
[Serum prostate specific antigen for the early detection of prostate cancer in outpatients of internal medicine]
Prostatic Neoplasms
[Serum prostate-specific antigen in a urological outpatient clinic. Efficacy of age-specific and prostate volume-specific reference range in detection of prostate cancer]
Prostatic Neoplasms
[Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml]
Prostatic Neoplasms
[Significance of PSA-density: analysis in PSA gray zone cases]
Prostatic Neoplasms
[Significance of the PSA-concentration for the detection of prostate cancer]
Prostatic Neoplasms
[Significance of various examination methods in the management of prostatic cancer]
Prostatic Neoplasms
[Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
Prostatic Neoplasms
[Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
Prostatic Neoplasms
[Staging and therapeutic options in local prostatic carcinoma]
Prostatic Neoplasms
[Status of PSA determination for early detection of prostate carcinoma]
Prostatic Neoplasms
[Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer]
Prostatic Neoplasms
[Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer]
Prostatic Neoplasms
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]
Prostatic Neoplasms
[Summary of 'General Rule for Clinical and Pathological Studies on Prostate Cancer (the 3rd Edition)']
Prostatic Neoplasms
[Surgical therapy of locally confined prostate carcinoma]
Prostatic Neoplasms
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer]
Prostatic Neoplasms
[Systematic prostate biopsy before transurethral resection of the prostate]
Prostatic Neoplasms
[The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer]
Prostatic Neoplasms
[The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer]
Prostatic Neoplasms
[The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer]
Prostatic Neoplasms
[The Efficacy of Amrubicin Therapy as a Second Line Treatment in Patients with Small Cell Carcinoma of the Prostate : A Case Report].
Prostatic Neoplasms
[The efficacy of PSA density for the early detection of prostate cancer]
Prostatic Neoplasms
[The focus and prospect of prostate cancer research].
Prostatic Neoplasms
[The incidence, mortality and risk factors of prostate cancer].
Prostatic Neoplasms
[The percentage of free prostate specific antigen used in detecting prostate cancer]
Prostatic Neoplasms
[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy]
Prostatic Neoplasms
[The relationships of PSA, FPSAR, clinical and pathological stage in patients with prostate cancer]
Prostatic Neoplasms
[The result of mass screening of 1997 for prostatic cancer in Isesaki City]
Prostatic Neoplasms
[The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer]
Prostatic Neoplasms
[The role of PSA in diagnosis of prostate cancer and its recurrence]
Prostatic Neoplasms
[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer]
Prostatic Neoplasms
[The significance of early detection for prostate cancer in mass screening]
Prostatic Neoplasms
[The survival analysis of the advanced metastatic castration-resistant prostate cancer.]
Prostatic Neoplasms
[The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer]
Prostatic Neoplasms
[The utility of prostate specific antigen doubling time in repeat biopsy for prostate cancer]
Prostatic Neoplasms
[Therapy by endoscopic laser for prostatic obstruction]
Prostatic Neoplasms
[Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]
Prostatic Neoplasms
[Transrectal ultrasound guided biopsies in 266 patients]
Prostatic Neoplasms
[Transrectal ultrasound-guided systematic 12-core biopsy of the prostate improves prostate cancer detection].
Prostatic Neoplasms
[Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy]
Prostatic Neoplasms
[Treatment of metastatic prostate cancer: certainty and doubts]
Prostatic Neoplasms
[Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]
Prostatic Neoplasms
[Updated treatments of castration-resistant prostate cancer].
Prostatic Neoplasms
[Use of biopsy results to predict capsular perforation and seminal vesicle invasion in prostate cancer]
Prostatic Neoplasms
[Use of prostate specific antigen. A review]
Prostatic Neoplasms
[Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone]
Prostatic Neoplasms
[Usefulness of free prostate specific antigen in the detection of prostate cancer]
Prostatic Neoplasms
[Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer]
Prostatic Neoplasms
[Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer]
Prostatic Neoplasms
[Usefulness of PSA-complex in the diagnosis of prostatic carcinoma]
Prostatic Neoplasms
[Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer]
Prostatic Neoplasms
[Usefulness of ultrasound-guided prostate biopsy in the diagnosis and treatment of localized prostate cancer]
Prostatic Neoplasms
[Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score].
Prostatic Neoplasms
[Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels]
Prostatic Neoplasms
[Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer]
Prostatic Neoplasms
[Validity of digital rectal examination of prostate specific antigen]
Prostatic Neoplasms
[Value of determining prostate specific antigen in follow-up of prostatic cancer]
Prostatic Neoplasms
[Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)]
Prostatic Neoplasms
[Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].
Prostatic Neoplasms
[Value of prostate specific antigen in early diagnosis of prostatic cancer]
Prostatic Neoplasms
[Value of prostate volume, PSAD and F/T in the detection of prostate cancer in males with PSA 4-10 ?g/L].
Prostatic Neoplasms
[Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer]
Prostatic Neoplasms
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]
Prostatic Neoplasms
[Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?]
Prostatic Neoplasms
[Yield of ultrasonography-guided transrectal biopsy in the diagnosis of carcinoma of the prostate]
Prostatic Neoplasms, Castration-Resistant
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Prostatic Neoplasms, Castration-Resistant
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Prostatitis
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
Prostatitis
Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Prostatitis
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Prostatitis
Can expressed prostatic secretions effect prostate biopsy decision of urologist?
Prostatitis
Can mean platelet volume serve as a marker for prostatitis?
Prostatitis
Case report: laparoscopic ureteropyelostomy and distal ureterectomy for management of duplication with ectopia.
Prostatitis
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Prostatitis
Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.
Prostatitis
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Prostatitis
Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study.
Prostatitis
Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia.
Prostatitis
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Prostatitis
Elevation of prostate specific antigen from bacillus Calmette-Guerin-induced granulomatous prostatitis.
Prostatitis
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Prostatitis
Incidence of histological prostatitis and its correlation with PSA density.
Prostatitis
Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value.
Prostatitis
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Prostatitis
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Prostatitis
Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient.
Prostatitis
Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
Prostatitis
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
Prostatitis
Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate.
Prostatitis
Prostate specific antigen and prostatitis. II. PSA production and release kinetics in vitro.
Prostatitis
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Prostatitis
Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis.
Prostatitis
PSA decrease after levofloxacin therapy in patients with histological prostatitis.
Prostatitis
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Prostatitis
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Prostatitis
Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
Prostatitis
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Prostatitis
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Prostatitis
Serum prostate specific antigen levels in non-specific granulomatous prostatitis.
Prostatitis
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Prostatitis
The characterization of nonbacterial prostatitis: search for an etiology.
Prostatitis
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis.
Prostatitis
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
Prostatitis
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
Prostatitis
The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen.
Prostatitis
Total and free serum prostate specific antigen levels during the first month of acute prostatitis.
Prostatitis
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Prostatitis
Treatment of chronic prostatitis lowers serum prostate specific antigen.
Prostatitis
[Chronic prostatitis and PSA values.]
Prostatitis
[Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients].
Prostatitis
[Effects of antibiotic and anti-inflammatory treatment on serum PSA and free PSA levels in patients with chronic prostatitis IIIA]
Proteinuria
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Proteinuria
Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria.
Pseudorabies
A trypsin-like serine protease is involved in pseudorabies virus invasion through the basement membrane barrier of porcine nasal respiratory mucosa.
Psoriasis
Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.
Psoriasis
Bivalent inhibition of human beta-tryptase.
Puberty, Precocious
Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment.
Pyelonephritis
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Pyelonephritis
Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes.
Pyuria
Prostatic Inflammation Detected in Initial Biopsy Specimens and Urinary Pyuria are Predictors of Negative Repeat Prostate Biopsy.
Pyuria
[Granulomatous Prostatitis : Three Cases Report].
Rectal Neoplasms
Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma.
Rectal Neoplasms
[A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer].
Renal Insufficiency
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.
Renal Insufficiency
Effect of magnesium lithospermate B on the renal and urinary kallikrein activities in rats with adenine-induced renal failure.
Renal Insufficiency
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Renal Insufficiency
Tissue kallikrein and kinins in renal disease.
Renal Insufficiency, Chronic
Prostate specific antigen levels in pre-dialysis chronic kidney disease patients.
Reperfusion Injury
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.
Reperfusion Injury
Human urinary kininogenase reduces the endothelial injury by inhibiting Pyk2/MCU pathway.
Reperfusion Injury
Human urine kininogenase attenuates balloon-induced intimal hyperplasia in rabbit carotid artery through transforming growth factor ?1/Smad2/3 signaling pathway.
Reperfusion Injury
Therapeutic modulation of tissue kallikrein expression.
Reperfusion Injury
Tissue Kallikrein Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the B2R-ERK1/2-CREB-Bcl-2 Signaling Pathway in Diabetic Rats.
Retinal Neovascularization
The kallikrein system in retinal damage/protection.
Retinal Neovascularization
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Retinal Perforations
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Rhinitis
Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree.
Rhinitis, Allergic
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis.
Rosacea
Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin.
Rosacea
Endoplasmic reticulum stress: key promoter of rosacea pathogenesis.
Rosacea
Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations in Rosacea and How Individual Treatments May Provide Therapeutic Benefit.
Sarcoidosis
Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography.
Sarcoma, Avian
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.
Sarcoma, Avian
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Schistosomiasis
[Prothrombin and prokallikrein in a patient with hepatosplenic schistosomiasis: effects of heparinization and splenectomy]
Scleroderma, Systemic
Differential expression of tissue kallikrein in the skin of systemic sclerosis.
Scleroderma, Systemic
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.
Scleroderma, Systemic
The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis.
Seminoma
New cancer markers.
Sepsis
Association between pre-biopsy white blood cell count and prostate biopsy - related sepsis.
Sepsis
Granzyme K activates protease-activated receptor-1.
Sepsis
Tissue Kallikrein Exacerbating Sepsis-Induced Endothelial Hyperpermeability is Highly Predictive of Severity and Mortality in Sepsis.
Sexually Transmitted Diseases
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration.
Shock, Cardiogenic
Acute myocardial infarction without cardiogenic shock does not affect serum prostate specific antigen levels: A case control study.
Shock, Septic
A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker.
Sialadenitis
Effect of radioactive iodine therapy on parotid gland function.
Situs Inversus
Incidental Finding of Dextrocardia with Situs Inversus in a 59-Year-Old Man.
Sjogren's Syndrome
Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.
Skin Diseases
Expression and ultrastructural localization of plasmin(ogen) in the terminally differentiated layers of normal human epidermis.
Skin Diseases
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.
Skin Diseases
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Skin Neoplasms
Screening for cancer. Is it useful?
Sleep Apnea, Obstructive
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Sleep Initiation and Maintenance Disorders
A top 5 list for French general practice.
Spinal Cord Injuries
Evaluation of serum and seminal levels of prostate specific antigen in men with spinal cord injury.
Spinal Cord Injuries
Seminal plasma PSA in spinal cord injured men: a preliminary report.
Spinal Diseases
Anorectal application of 5% lidocaine cream reduces pain prior to periprostatic nerve block during transrectal ultrasound guided prostate biopsy: Randomized, prospective controlled study.
Squamous Cell Carcinoma of Head and Neck
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
Starvation
Exocrine and endocrine release of kallikrein after reflex-induced salivary secretion.
Stomach Neoplasms
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Stomach Neoplasms
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Stomach Ulcer
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
Stomach Ulcer
The evaluation of tissue kallikrein in Helicobacter pylori-associated gastric ulcer disease.
Stomach Ulcer
[Bio- and histochemical changes of tissue kallikrein in the rat stomach after water immersion-induced gastric ulcer]
Stomach Ulcer
[Correlation between glandular kallikrein and experimental gastric ulcer in rats]
Stroke
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Stroke
Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis.
Stroke
Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery.
Stroke
Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging.
Stroke
Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke.
Stroke
Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB.
Stroke
Increase in Blood-Brain Barrier Permeability is Modulated by Tissue Kallikrein via Activation of Bradykinin B1 and B2 Receptor-Mediated Signaling.
Stroke
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Stroke
Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: A multicenter case-control study in China.
Stroke
The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.
Stroke
Tissue Kallikrein Activity, Detected by a Novel Method, May Be a Predictor of Recurrent Stroke: A Case-Control Study.
Stroke
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Subarachnoid Hemorrhage
Human tissue kallikrein ameliorates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
[Effects of human tissue kallikrein on cerebral vasospasm: experiment with rabbits]
Subarachnoid Hemorrhage
[Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm]
Synovitis
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
Teratoma
Concurrent primary carcinoid tumor arising within mature teratoma and clear cell renal cell carcinoma in the horseshoe kidney: report of a rare case and review of the literature.
Testicular Neoplasms
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Thromboangiitis Obliterans
Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans.
Thrombocytopenia
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Thromboembolism
Recent progress in hormonal therapy for advanced prostate cancer.
Thrombosis
Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
Thrombosis
High-Throughput Docking and Molecular Dynamics Simulations towards the Identification of Potential Inhibitors against Human Coagulation Factor XIIa.
Thrombosis
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
Thrombosis
The factor VII zymogen structure reveals reregistration of beta strands during activation.
Thymoma
Imaging Comparison between (18) F-FDG-PET/CT and (18) F-Flouroethyl Choline PET/CT in Rare Case of Thymus Carcinoma Exhibiting a Positive Choline Uptake.
tissue kallikrein deficiency
Kallikrein protects against microalbuminuria in experimental type I diabetes.
tissue kallikrein deficiency
Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans.
tissue kallikrein deficiency
Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.
tissue kallikrein deficiency
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
tissue kallikrein deficiency
Tissue kallikrein deficiency, insulin resistance and diabetes in mouse and man.
Tuberculosis
Pauci-symptomatic disseminated tuberculosis revealed by an increase in the specific antigen of the prostate.
Ureteral Calculi
Effect of extracorporeal shock wave lithotripsy on prostate specific antigen.
Ureteral Calculi
Extracorporeal shockwave lithotripsy in patients with distal ureteral calculi does not influence the prostate specific antigen value.
Ureteral Obstruction
Differential effects of ureteral obstruction on rat kininogen gene family.
Ureteral Obstruction
The kininogen gene family in obstructive uropathy.
Urethral Obstruction
Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.
Urethral Stricture
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Urinary Bladder Calculi
Patient selection and counseling before prostatic arterial embolization.
Urinary Bladder Diseases
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Urinary Bladder Neck Obstruction
2-year followup pressure flow studies of prostate photoselective vaporization using local anesthesia with sedation.
Urinary Bladder Neck Obstruction
Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement.
Urinary Bladder Neck Obstruction
Routine estimation of prostate specific antigen prior to clinic attendance in patients with symptoms of bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
Urinary Bladder Neck Obstruction
The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
Urinary Bladder Neck Obstruction
[Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia]
Urinary Bladder Neoplasms
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
Urinary Bladder Neoplasms
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Urinary Bladder Neoplasms
Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Urinary Bladder Neoplasms
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.
Urinary Bladder Neoplasms
Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer.
Urinary Bladder Neoplasms
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Urinary Bladder Neoplasms
Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function.
Urinary Bladder Neoplasms
Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.
Urinary Bladder Neoplasms
Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.
Urinary Bladder, Neurogenic
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Urinary Bladder, Overactive
Deficits in urological knowledge among medical students and primary care providers: potential for impact on urological care.
Urinary Bladder, Overactive
Efficacy of Adding Dutasteride to ?-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30?mL).
Urinary Bladder, Overactive
Urological knowledge among primary health care physicians in Saudi Arabia.
Urinary Incontinence
Quality control of radical prostatectomy: a feasibility study.
Urinary Retention
Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Urinary Retention
Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement.
Urinary Retention
Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Urinary Retention
Giant prostatic hyperplasia and its causes.
Urinary Retention
Holmium laser enucleation of the prostate--outcomes independent of prostate size?
Urinary Retention
Holmium Laser Enucleation vs Bipolar Plasmakinetic Enucleation of a Large Volume Benign Prostatic Hyperplasia: A Randomized Controlled Trial.
Urinary Retention
Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass.
Urinary Retention
Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
Urinary Retention
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Urinary Retention
Simple perineal prostatectomy: lessons learned from a modern series.
Urinary Retention
Simultaneous transurethral resection of prostate and prostate needle biopsy in patients with acute urinary retention and elevated prostate specific antigen levels.
Urinary Retention
Urinary retention and post-void residual urine in men: separating truth from tradition.
Urinary Retention
Validity of PSA, free/total PSA ratio and complexed/total PSA ratio measurements in men with acute urinary retention.
Urinary Retention
[Serum PSA and transition zone index as predictors of acute urinary retention in benign prostate hyperplasia]
Urinary Retention
[The effect of acute urinary retention on serum prostate specific antigen concentration]
Urinary Retention
[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention]
Urinary Tract Infections
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Urinary Tract Infections
Patient selection and counseling before prostatic arterial embolization.
Urinary Tract Infections
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Urinary Tract Infections
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Urinary Tract Infections
Prostate specific antigen in urinary tract infection.
Urinary Tract Infections
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Urologic Diseases
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
Urologic Diseases
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]
Urologic Diseases
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]
Uterine Cervical Neoplasms
Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.
Uterine Cervical Neoplasms
Ethical issues for cancer screening.
Uterine Cervical Neoplasms
Ethical issues for cancer screenings. Five countries--four types of cancer.
Vaccinia
A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in Patients with Prostate Cancer.
Vaccinia
Clinical safety of a viral vector based prostate cancer vaccine strategy.
Vaccinia
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Vascular Ring
Proteinase-activated receptors, targets for kallikrein signaling.
Vascular System Injuries
Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.
Vasospasm, Intracranial
Human tissue kallikrein ameliorates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Vasospasm, Intracranial
[Effects of human tissue kallikrein on cerebral vasospasm: experiment with rabbits]
Vasospasm, Intracranial
[Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm]
Ventricular Dysfunction, Left
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.
Vesico-Ureteral Reflux
Significance of the tissue kallikrein promoter and transforming growth factor-beta1 polymorphisms with renal progression in children with vesicoureteral reflux.
Virus Diseases
Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection.
Wilms Tumor
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.